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General Introduction – setting the scene 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
"The most successful practices have an institutional priority for quality of care, involve all of 
the staff in their initiatives, redesign their delivery system, activate and educate their patients, 
and use electronic health record tools. (...) It is clear that optimal diabetes management 
requires an organized, systematic approach and involvement of a coordinated team of 
dedicated health care professionals working in an environment where quality care is a 
priority." 
Diabetes Care. December 29, 2009; January 2010 Supplement 
Doi information: 10.2337/dc09-S013Diabetes Care January 2009vol. 32 no. Supplement 
1S13-S61 
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Section 1: Chronic Diseases: the challenge for modern health care. 
 
A chronic condition can be defined as a “condition that requires ongoing 
adjustments by the affected person and interactions with the health care system“ 
(website of the Chronic Care Model, www.improvingchroniccare.org). Another, more 
comprehensive definition is put forward by the World Health Organisation:  Chronic 
diseases are “Diseases which have one or more of the following characteristics: they 
are permanent, leave residual disability, are caused by non reversible pathological 
alteration, require special training of the patient for rehabilitation, or may be expected 
to require a long period of supervision, observation or care” (WHO 2003). 
Chronic diseases are assumed to be the major cause of death and disability 
worldwide and they increasingly affect people. Non-communicable diseases such as 
cardiovascular diseases (CVD), diabetes, cancers and respiratory diseases account 
for 59% of the 57 million annual deaths and 46% of the global burden of disease.  In 
developed countries, chronic diseases account for about 75% of total deaths (1; 2). 
Heart attacks and strokes kill about 12 million people every year. In addition, 3.9 
million people die annually from hypertensive and other heart conditions (3). An 
estimated 285 million people are affected by diabetes, the majority by Type 2 
Diabetes, representing 6.4% of the world’s adult population. By 2030 the number of 
people with diabetes will be estimated at 438 million (4). In the United States, 133 
million people, about 50% of the total population suffer from a chronic condition (5).  
Moreover, almost half of all people with chronic illness have multiple conditions (6). 
Since the prevalence of chronic diseases increases with age, increased longevity is a 
major contributor to the rising prevalence of chronic diseases and the aggregate 
costs of care for people with them (7). By 2050, the number of people in the 
European Union aged 65 and above is expected to grow by 70% and the number of 
people aged over 80 by 170%.  Among the developed countries, Europe and Japan 
will experience the most pronounced ageing trends up to 2050 (8).  In Flanders, 
940.367 (about 20%) present with one or more chronic conditions (9), while the 
proportion of people aged 65 and above increased from 14% in 1990 to 18% in 
2008 (10). 
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Chronic illnesses account for the expenditure of over 75% of direct health care 
costs in the United States, according to the Centres for Disease Control and 
Prevention of the U.S.(2) Healthcare expenditures on the single disease diabetes are 
expected to account for 11.6% of the total healthcare expenditure in the world in 
2010 (376 billion USD) and expected to increase at 490 billion USD by 2030.(4) A 
Canadian study showed that about 60% of the costs related to chronic diseases are 
due to premature death, disability and complications (often inducing hospitalization) 
(1).  
 
By some estimates, up to 70% of premature deaths and two-thirds of the 
cases of chronic disability are preventable (11). Prevention of chronic diseases and 
early and aggressive treatment probably can reduce a significant portion of the 
chronic disease burden (1;2;4). As such high quality treatment and follow-up of 
chronic diseases in an ageing population is one of the major challenges in future 
health care. Most health care systems are fundamentally designed to deliver ad hoc 
episodic care to patients with acute illness or acute manifestations of chronic illness. 
However, data for diseases such as diabetes, asthma and congestive heart failure 
clearly indicate that cost savings and quality improvements come from what happens 
over the long term to prevent acute episodes and complications from occurring (12-
16).   An increasing body of evidence indicates that quality improvement of chronic 
care requires a transformation of health care, from a system that is essentially 
reactive - responding mainly when a person is sick - to one that is proactive and 
focused on keeping a person as healthy as possible (17-21).  
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Section 2: Type 2 Diabetes Mellitus (T2DM). 
Severe long-term complications   
Type 2 Diabetes Mellitus (T2DM) is characterized by reduced insulin action (insulin 
resistance) and a relative insulin deficiency (22). Diabetes occurs when pancreatic β-
cell hyper secretion of insulin fails to compensate for insulin resistance. Suboptimal 
treated Type 2 Diabetes Mellitus provokes major long-term complications with 
essentially a vascular origin, either macro-vascular (coronary artery disease, 
peripheral arterial disease, and stroke) or micro-vascular (diabetic nephropathy, 
neuropathy, and retinopathy). The large majority of T2DM presents with insulin 
resistance, which clusters with other Cardio Vascular (CV) risk factors (e.g. 
hypertension, dyslipidaemia, obesity, inflammation, hypercoagulability) and might in 
addition act as an independent CV risk factor. This cluster of risk factors is referred to 
as the plurimetabolic syndrome (PMS). Whereas chronic hyperglycemia leads to 
capillaries (microvascular) complications, PMS induces atherosclerosis and arterial 
(macrovascular) complications (23;24). 
Macrovascular complications 
Diabetes has been associated with coronary heart disease (CHD) since the late 19° 
century: it was recommended to test for glucose in the urine of patients with angina 
pectoris. However the occurrence of CVD in patients with diabetes was considered 
occasional until the end of the 20° century. Nowadays, we know that arterial 
complications cause around 65 to 80% of deaths in people with T2DM (25) compared 
with 30% in the general population. Diabetic patients have a two- to fourfold 
increased risk of CVD compared with non diabetic individuals (26;27). The relative 
risk of death from CHD is 1.5 to 2.5 times higher in diabetic men and more than 4 
times higher in diabetic women compared with age-matched persons without 
diabetes. Several prospective studies in T2DM patients linked chronic hyperglycemia 
with increased CVD and all-cause mortality (28;29) independently of other 
cardiovascular risk factors (30). Haffner et al. observed that T2DM patients without 
coronary disease had a similar risk to contract a heart attack as non diabetic patients 
with known coronary disease (31). A recent Canadian population based study 
comparing  379 000 people with diabetes and over 9 million without the disease  
found that diabetic men and women with CVD were about 15 years younger than 
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those without diabetes in the same risk category (32). Moreover, T2DM abrogates 
sex differences in CV risk (33).  The “European Guidelines on cardiovascular disease 
prevention in clinical practice” consider T2DM patients as subjects at high 
Cardiovascular risk (34).   
Microvascular complications  
Diabetic retinopathy may be the most common microvascular complication of 
diabetes. It is the leading cause of non traumatic blindness in the adult population 
(35). The risk of developing diabetic retinopathy depends on both the duration and 
the severity of hyperglycemia and presence of hypertension (36). Retinopathy may 
start as 7 years before the diagnosis (35). 
Diabetic nephropathy is the leading cause of renal failure. It is defined by proteinuria 
> 500 mg in 24 hours in the setting of diabetes, but this is preceded by lower degrees 
of proteinuria, or “microalbuminuria.” Microalbuminuria is defined as albumin 
excretion of 30-299 mg/24 hours. Without intervention, diabetic patients with 
microalbuminuria typically progress to proteinuria and overt diabetic nephropathy. At 
the time of diagnosis, 7% of patients with Type 2 Diabetes Mellitus may have 
microalbuminuria (37).  
Diabetic neuropathy is defined as “the presence of symptoms and/or signs of 
peripheral nerve dysfunction in people with diabetes after the exclusion of other 
causes” (38). There is no specific treatment of diabetic neuropathy. The primary goal 
of therapy is to control symptoms and prevent degeneration of neuropathy through 
improved glycemic control. Some studies have suggested that optimal glycemia 
control may improve symptoms of peripheral neuropathy (39). 
Diabetic foot is in fact an umbrella term. Due to atherosclerosis of great and small 
vessel walls, diabetic neuropathy, a tendency to delayed wound healing 
and infection or gangrene of the foot is relatively common. It takes place in 15% of all 
patients with diabetes and precedes 84% of all lower leg amputations (40). 
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Evidence Based Treatment 
 
In the Dutch NHG standard of 1993, one of the very few guidelines on the 
treatment of Type 2 Diabetes at that moment, only 2 objectives were put forward:  “to 
control the blood sugar” and “to optimize the body weight” (41). Since 1993, a rapid 
evolution has taken place with regard to the scientific findings in the care for people 
with diabetes. Several landmark studies such as DCCT, UKPDS, Steno-2 and the 
Haffner study have determined the current approach of diabetes to a large extent. 
Indeed, clinical evidence suggests that aggressive, timely, and multi-factorial 
interventions (42) aimed at controlling risk factors such as high blood pressure (43), 
blood lipids (44;45), and glycemia (46;47) can reduce diabetes related complications 
in individuals with T2DM.   
The results of these studies were translated into “evidence-based” guidelines. 
Most of the recommendations differ in a lot of details, but they match regarding the 
core recommendations on the treatment of Type 2 Diabetes:  
- Treatment should be long-term and target-driven with an intensified 
intervention aimed at all validated targets. 
- The cardiovascular preventive treatment of Type 2 Diabetes should start as 
soon as possible after the diagnosis.  
- The treatment should be comprehensive (‘global’) including several drugs and 
education of patients on behaviour and lifestyle changes. 
- Diabetes patients should receive lifelong treatment and follow-up.  Diabetes 
has to be considered as a “chronic condition”. 
- Follow-up should include regular assessment of lifestyle habits (smoking 
status, exercise status and dietary habits), motivational status and treatment 
compliance and bio-clinical parameters (BMI, HbA1c, blood lipids and blood 
pressure) as well as regular screening on the occurrence of eventual 
complications (examination of the eyes, feet and screening on micro-
albuminuria). 
Actually, there is an international consensus about the key role of lifestyle (i.e. no 
smoking, regular physical activity, healthy diet, and weight control) not only in general 
management but also in CV risk prevention of T2DM patients.  
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The decreases in several bio-clinical parameters like HbA1c, blood pressure, 
cholesterol are associated with a reduction in CV risk in T2DM patients. Large CV 
risk reductions are observed with tapering of these parameters towards the normal 
range of the general population. Primary treatment targets can be set for HbA1c at 
7%, for Blood Pressure at 130/80 mm Hg and for LDL-C at 100 mg/dl (70 mg/dl if 
history of CVD). 
Metformin remains the first line drugs for reducing HbA1c, followed by 
sulfonylurea and then insulin. The new DPP4-inhibitors may be an alternative, 
especially in the frail elderly and exenatide can present an intermediary step between 
oral anti-diabetics and insulin therapy. However, the exact place of these new drugs 
still has to be determined. 
Three types of drug-induced inhibitions have proved to be effective in CV risk 
reduction in T2DM patients. Inhibition of the angiotensin pathway (mainly through the 
angiotensin-convertase enzyme inhibition) by ACE-inhibitors or Angiotensin Receptor 
Blockers is generally considered as the first line treatment for diabetic patients with 
hypertension or microalbuminuria. Calcium channel blockers seem a reasonable 
choice for step up treatment, preferable to diuretics.  Direct inhibition of AT-1 
angiotensin receptors by sartans has not been shown to reduce CV risk more than 
ACE-inhibition does.  
The inhibition of cholesterol metabolism (mainly through HMG-CoA reductase 
inhibition; statin therapy) is supported by overwhelming evidence.   
Both the ADA standards and the European guidelines recommend a more 
general use of anti-platelet therapy despite the negative results of a recent meta-
analysis (48). The ADA standards recommend the use of aspirin (75–162 mg/day) in 
all patients with a history of CVD and in patients > 40 years without a history of CVD 
and with at least one additional risk factor. The European guidelines on diabetes 
recommend that aspirin should be given for the same indications and in the same 
dosages to diabetic and non diabetic patients. A recent update of Diabetes UK 
guidelines recommends that people with diabetes who have established 
cardiovascular disease should be offered aspirin treatment and also recommends 
that people with diabetes but without known established cardiovascular disease 
should discuss their individual risk with their healthcare team (49). 
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Interestingly, the ADA standard is the only guideline that explicitly 
recommends a collaborative shared care approach in the management of Type 2 
Diabetes patients. Further on, only the ADA standards and the European guideline 
recommend an individualized management plan. 
Treatment targets according to three leading clinical guidelines: 
 ADA 2009(50) Europe 2007(51) Prodigy UK 2007(52) 
Smoking  Abstinence 
Healthy Diet 
       
Physical exercise 
   Program 
   Intensity 
Weight reduction 
   indication 
   Target 
HbA1c 
   Target 
 
 
 
Glycemia, mg/dl 
   Fasting 
   Postprandial 
Systolic BP, mmHg 
      Target 
Diastolic BP, mmHg 
     Target 
Total-Chol, mg/dl 
      Target 
LDL-C, mg/dl 
     Target 
 
 
 
HDL-C, mg/dl 
     Target 
 
Triglycerides, mg/dl 
      Target 
 
Platelet inhibition 
   ASA 
   Clopidogrel     
 
ACE-inhibition 
 
Cholesterol-inhibition 
  Statin 
  Fibrate, ezetimibe,  
 
T2DM = High CV risk? 
Global Treatment 
Shared care (team)? 
Management plan? 
Education/DSME? 
Yes 
MNT 
 
 
Aerobic/resistance 
150 min/week 
 
Overweight/obesity 
-5%, evtl. surgery 
 
<7 (in general) 
<<7 if possible 
Less stringent if necessary 
 
 
70-130 
<180 
 
<130 
 
<80 
 
- 
 
< 100 (PP) 
<70 (SP) 
-30-40% 
 
 
> 40 
 
 
< 150 
 
 
Yes: in PP¥ and SP¥¥ 
2° line 
 
1° line if HT│ or µalb 
 
 
Yes (algorithm) 
- 
 
No 
Yes 
Yes 
Yes 
Yes 
Yes 
- 
 
 
30-45min> 5days/w 
- 
 
Yes if obesity 
< 25 kg/m³ or -10% 
 
<6.5 if possible 
 
 
 
 
<108 
<135 
 
<130;125 if CVD+KDψ 
 
<80; 75 CVD+KD 
 
<175 
 
<100 (PP) 
<70 (SP) 
 
 
 
>40 (men) 
>46 (women) 
 
> 150 
 
 
Idem as non diabetics 
2° line 
 
1° line if HT│ or µalb 
 
 
Yes 
sometimes 
 
Yes 
Yes 
No 
Yes 
Yes 
Yes 
Healthier diet 
 
  
>30 min >5days/w 
moderate exercise 
 
Yes if overweight 
Aiming at 25 kg/m² 
 
6.5 (population) 
7.5 (intensive) 
 
 
 
- 
- 
 
<140; <130 if KD, EDΦ, SP 
 
<80 
 
<200  
 
<115 
 
 
 
 
- 
 
 
- 
 
 
Yes if CVD event 
? 
 
1° line if HT 
 
 
Yes 
consider if TG>200 
 
No 
Yes 
No 
No 
No 
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Archetype of chronic disease 
Diabetes can be considered as the ‘archetype’ of a chronic condition because of 
several reasons. It is a highly prevalent disease (53) and uncontrolled diabetes will 
lead to serious complications in the long term (53).  As such, the disease has a 
wide impact on the total human being. Usually there are only little or no short term 
complications. The disease deteriorates spontaneously over time and complications 
induce high costs (54). Evidence Based treatment has been described in well-
documented and validated guidelines (55) and has proven to reduce both mortality 
and morbidity (42). Moreover well-designed Quality Improvement Programs in 
diabetes care are assumed to have an acceptable cost-effectiveness ratio (56-62).  
Evidence based diabetes care however is complex (63) and there is consensus in 
the literature that a quality gap exists (64). There is also a growing consensus that 
quality care for people with diabetes requires a coordinated input from different 
disciplines (20;65).  
 In this context, the diabetic epidemic creates new challenges for the health care 
systems which will have to introduce new approaches in order to cope with a disease 
of these dimensions. As such, changes in the approach of diabetes care in pilot 
projects and nation-wide programs are not only an aim in itself, they also could serve 
as a test case for the development of efficient care organization for other chronic 
conditions.  
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Section 3: The Chronic Care model: international model for quality of 
care. 
 
A new model, the ‘Chronic Care Model’ (CCM) (66) has been developed as a 
response to the increasing challenges in chronic care delivery (Fig1). This model 
argues for important changes in the health care system, from a system that is 
essentially reactive - responding mainly when a person is sick - to one that is 
proactive, focused on keeping a person as healthy as possible.  
The model has been developed to overcome four major deficiencies in the actual 
health care system.  These deficiencies are: 
• Lack of guideline based practice by practitioners conditioned for curing acute 
diseases 
• Lack of multidisciplinary teamwork and care coordination 
• Lack of pro-active, organized follow-up  aimed at obtaining the therapeutic 
targets 
• Patients inadequately prepared to contribute to the management of their 
illness 
The model pictures three overlapping universes: 1. The entire community; 2. The 
health care system, including its payment structures; 3. The provider organization, 
whether an integrated delivery system, a small clinic or a loose network of physician 
practices and paramedical disciplines (67). Within these three universes, the CCM 
identifies the essential elements of a health care system that enables high quality 
chronic disease care. These elements are the health system, delivery system design, 
decision support, clinical information systems, self-management support for patients 
and the community. 
(1) Improving the care for chronic diseases demands changes throughout the 
whole system organization. Key elements are leadership, adapted incentives, 
task arrangements and communication. 
(2) Changes to the delivery system design include team changes with task 
delegation to ensure maximum quality of care including critical elements for 
which doctors may not have adequate training or time. 
18 
 
(3) Evidence Based treatment decisions need the availability of validated 
guidelines, which should also be discussed with patients. Other key elements 
are ongoing training, timely reminders and feedback to increase the availability 
of evidence based knowledge at the time that clinical decisions are made. 
Coaching of primary care providers by specialists, especially in the case of 
more complex patients is an important educational modality. 
(4) Clinical information systems can assure access to key data on patients at the 
individual and population level, provide reminders for needed services to plan 
care, can identify groups of patients needing additional care and can monitor 
quality improvement efforts. 
(5) Patients with a chronic disease occupy a central role in its management. 
Effective self-management support promotes a sense of responsibility by 
providing essential information, emotional support, and strategies for living 
with chronic illness. The CCM stresses the importance of a collaborative 
approach where providers and patients are working in a team, defining 
together the problems, setting priorities, establishing goals and treatment 
plans. There is no conclusive evidence about the effectiveness of self-
management programs for the overall  population of chronically ill, but there is 
conclusive evidence in some subgroups of people with diabetes (68). 
(6)  Community programs can support a health system's care for chronically ill 
patients. 
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BOX 1. 
Quality of care can be defined as “the degree to which health services for individuals 
and populations increase the likelihood of desired health outcomes and are consistent with 
current professional knowledge” (69). [Institute of Medicine - Lohr 1990] As such, quality of 
care is closely linked to evidence based medicine.  
Evidence based health care “takes place when decisions that affect the care of patients 
are taken with due weight accorded to all valid, relevant information (70).” Evidence based 
health care deals with policy decisions on groups of patients at the population level and can  
be considered as the result of the combined effect of three factors:  1. the disposable 
evidence; 2. the prevailing values, attitudes and structures; 3. the available financial 
resources. 
 
Figure 1: The Chronic Care Model (reproduced from Wagner. Et al.) 
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Section 4: Implementation science and change management: the missing 
link. 
 
While the Chronic Care Model gives a very comprehensive overview of the 
necessary system changes and quality improvement interventions to assure optimal 
quality of care, it does not explain how to implement it and it does not take into 
account the facilitation methods to assure a successful change from the ‘old system’ 
to the ‘new system’. Many barriers at all levels can hamper the implementation of the 
above defined quality improvement interventions. Overcoming those barriers 
demands specific methods and interventions that are not described in the Chronic 
Care Model. These methods and interventions are the subject of research in the so 
called “Implementation science". Implementation can be defined as « the introduction 
of an innovation in daily routine practice; this requires effective communication 
strategies and the removal of obstacles to change through the use of educational and 
policy techniques which are effective in practice» (71). The medical “innovations” are 
generally outlined in practice guidelines. Several conceptual frameworks on guideline 
implementation and quality improvement have been described in the literature. We 
focus on the “Implementation Model” (Grol et al.) (71) as a methodological framework 
for implementation strategies and change management. The authors confirm that “for 
most changes in health care, a range of factors interact at different levels (patients, 
professionals, interactions among professionals in teams, the organizational context, 
and the economic and political context) to determine whether and to what extent 
change is achieved”. Success or failure of guideline implementation depends on a 
complete range factors that can be subdivided in 6 groups: 
 Characteristics of the guideline: clarity, feasibility, scientific value 
 Characteristics of the health care providers: knowledge, skills, attitudes, 
belief, standards, values, personality traits 
 Characteristics of the patient: knowledge, behaviour, compliance, needs 
 Characteristics of the social context: attitude of the colleagues, cultural and 
social influences, opinion leaders 
 Characteristics of the economic, administrative and organizational context 
 Characteristics of the methods and strategies of dissemination and 
implementation: choice of the method, intensity and prince, source and 
executants. 
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The authors stress the importance to acquire full knowledge of the multiple theories 
that are involved in implementation science and to apply these theories to the ‘local’ 
social, organizational, political and financial context: “For any innovation to be 
implemented successfully, it is necessary to identify the potential interacting 
determining factors. In turn, these factors can be described by and derived from 
different theories that need to be tested for their single or combined influence on 
change. This approach requires understanding the range of available theories and 
their applicability to health care” (72).  
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Section 5: The effectiveness of Quality Improvement Interventions.  
 
Quality improvement interventions have increasingly been tested on their 
effectiveness. In the Cochrane Library, the ‘Effective Practice Organization of Care’ 
(EPOC) dedicates an entire topic of systematic reviews and meta-analyses and 
divided QI interventions in 11 categories (box 2). However, this taxonomy does not 
include all possible interventions (box 3). In 2009, the Cochrane Collaboration 
evaluated the number and quality of reviews of change interventions from 1966 to 
2008 (73).  193 reviews were identified in over 100 journals, including 32 Cochrane 
reviews; most of them published the last 15 years. Corresponding authors of SRs 
were mostly from USA, UK and Canada. Educational meetings, educational 
materials, reminders, audit and feedback and multifaceted strategies were the most 
commonly evaluated interventions. In order to give an overview of the most 
interesting issues about quality improvement, related to the topic of this thesis, we 
conducted a narrative review searching for systematic reviews on quality 
improvement interventions in diabetes care, on the implementation of the Chronic 
Care Model, on Pay for Performance interventions and public reporting. We searched 
in the Cochrane Library, Medline, Embase and the Centre for Review Dissemination 
(CRD) as well as for public reports of the Institute of Medicine (IOM, US), the Agency 
for Healthcare Research and Quality (AHRQ, US), the National Health Service (NHS, 
UK) and the Belgian Health Care Knowledge Centre (KCE).  
 
Systematic Reviews on Quality Improvement 
Single interventions at the professional level 
Shojania et al (2006) assessed the impact on glycemic control of the 11 EPOC QI 
strategies in adults with Type 2 Diabetes and found that most QI strategies produced 
small to modest improvements in glycemic control (reduction of Hba1c values by a 
mean of 0.42% (95% confidence interval [CI], 0.29%-0.54%) over a median of 13 
months of follow-up. Trials with mean baseline HbA1c values of 8.0% or greater 
reported significantly larger effects (0.54% vs. 0.20%, P = .005). Team changes and 
case management showed more robust improvements, especially for interventions in 
which case managers could adjust medications without awaiting physician approval. 
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The review may have been biased by difficulty in classifying complex interventions, 
insufficient numbers of studies, and publication bias. 
Guldberg et al. (2009) reviewed the effect of feedback to general practitioners on 
quality of care for people with Type 2 Diabetes and found that feedback improved the 
care for patients with T2DM, particularly process outcomes. Clinical outcomes like 
lowering of blood pressure, Hba1c and cholesterol levels were seen in only few 
studies (74).  These results are in line with a Cochrane Review that evaluated more 
in general (not disease specific) the effects on professional practice and health care 
outcomes (75). Garg et al. (2005) assessed the effects of computerized-clinical 
decision support systems (CDSSs) on practitioner performance and patient 
outcomes. The authors concluded that many CDSSs improve practitioner 
performance, whereas the effects on patient outcomes were understudied and 
inconsistent when examined (76). More recently (2009), Shojania et al. evaluated the 
effects of on-screen, point of care computer reminders on processes and outcomes 
of care and found that these QI interventions generally achieve small to modest 
improvements in provider behaviour (77). 
Doumit et al. (2007) found that the use of local opinion leaders can successfully 
promote evidence-based practice (78).  Forsetlund et al. (2009) found that 
educational meetings alone or combined with other interventions, can improve 
professional practice and healthcare outcomes for the patients. The effect is most 
likely to be small and similar to other types of continuing medical education, such as 
audit and feedback, and educational outreach visits. Strategies to increase 
attendance at educational meetings may increase the effectiveness of educational 
meetings. Educational meetings alone are not likely to be effective for changing 
complex behaviours (79). 
Single interventions at the patient level 
A recent meta-analysis  (2009) evaluated the effectiveness of individual patient 
education on metabolic control, diabetes knowledge and psychosocial outcomes (80) 
and found a benefit of individual education on glycemic control when compared with 
usual care in a subgroup of those patients with a baseline HbA1c greater than 8% [ -
0.3% (95% CI -0.5 to -0.1, P = 0.007)]. However, overall there did not appear to be a 
significant difference between individual education and usual care. In studies 
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comparing group and individual education, there was an equal impact on HbA1c.  
Additionally, it would seem that education delivered by a team of educators, with 
some degree of reinforcement of that education made at additional points of contact, 
may provide the best opportunity for improvements in patient outcomes (81). A 
Cochrane review assessed the effectiveness of group-based training for self-
management strategies in people with Type 2 Diabetes and found this approach 
effective by improving fasting blood glucose levels, glycated hemoglobin and 
diabetes knowledge and reducing systolic blood pressure levels, body weight and the 
requirement for diabetes medication (82). Another Cochrane review assessed the 
effectiveness of lay-led self-management programmes for people with chronic 
conditions and found that those programmes may lead to small, short-term 
improvements in participants' self-efficacy, self-rated health, cognitive symptom 
management, and frequency of aerobic exercise. There is currently no evidence to 
suggest that such programmes improve psychological health, symptoms or health-
related quality of life, or that they significantly alter healthcare use (83). 
Balas et al. (2004) assessed the effects of computerized information interventions in 
diabetes care at the patient level; more precisely computerized prompting of diabetes 
care, utilization of home glucose records in computer-assisted insulin dose 
adjustment, and computer-assisted diabetes patient education. The authors 
concluded that these interventions could improve measures of diabetic care. The 
results however were not consistent among the studies or outcomes (84). 
Multifaceted and/or multilevel interventions 
The Chronic Care Model 
 Reviews that evaluate the effectiveness of the Chronic Care Model are rather 
consistent in their conclusions: 
Tsai et al. (2005) found that interventions that contain at least 1 CCM element for 
asthma, congestive heart failure (CHF), depression, and diabetes improved clinical 
outcomes and processes of care (85). Coleman et al. (2009) examined the evidence 
of the CCM's effectiveness by reviewing articles published since 2000 that used one 
of five key CCM papers as a reference. They concluded that accumulated evidence 
supports the CCM as an integrated framework to guide practice redesign and that 
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redesigning care using the CCM leads to improved patient care and better health 
outcomes (86). 
The NHS reviewed in 2005 560 systematic reviews, randomized trials and other 
studies (87). They concluded that initiatives to improve the care of people with long-
term conditions can enhance satisfaction with care, quality of life, and in some cases, 
use of health services. They found sufficient evidence to support following initiatives: 
• Broad chronic care management models 
• Integrated community and hospital care 
• Greater reliance on primary care 
• Identifying people at greatest risk of complications and hospitalization 
• Involving people with long-term conditions in decision-making 
• Providing accessible structured information for people with long-term 
conditions and their families 
• Self-management education 
• Self-monitoring and referral systems 
• Electronic monitoring and telemonitoring 
• Using nurse-led strategies, where appropriate 
A Systematic review of the Chronic Care Model in chronic obstructive pulmonary 
disease prevention and management found that patients with chronic obstructive 
pulmonary disease who received  
interventions with 2 or more CCM components had lower rates of hospitalizations 
and emergency/unscheduled visits and a shorter length of stay compared with 
control groups (88). A meta-analysis on the effectiveness of Chronic Care Model-
oriented interventions to improve quality of diabetes care found 69 studies (43 
randomized controlled trials and 26 controlled before-after studies) with a mean 
reduction of 0.46% (95% CI 0.38, 0.54) in HbA1c, mean reduction of 2.2 (95% CI 0.9, 
3.5) mmHg in systolic blood pressure, mean reduction of 1.3 (95% CI 0.6, 2.1) mmHg 
in diastolic blood pressure and mean reduction of 9 (95% CI 2, 16) mg/dl in total 
cholesterol. For specific CCM components, interventions that addressed delivery 
system design reported the largest improvements in patient outcomes, followed by 
those employing a self-management support component. Interventions involving 
decision support or clinical information systems reported relatively smaller effect 
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sizes. 
The authors concluded that interventions featuring CCM components for diabetes 
care produced small-to-moderate improvements in a range of patient intermediate 
outcomes (89).  
Quality Improvement collaborative:  
A systematic review on quality improvement collaborative concluded that the effects 
of quality improvement collaborative on quality of care are uncertain; they may at 
best have only a moderate effect on outcomes (90). 
Shared Care and interdisciplinary collaboration: 
Smith et al. (2007) evaluated the effectiveness of shared care across the interface 
between primary and specialty care in chronic disease management. The authors 
found insufficient evidence to demonstrate significant benefits from shared care apart 
from improved prescribing but admit that methodological shortcomings of the studies 
may have biased the review (91). A Dutch review evaluated the effect of sharing and 
allocation of diabetes care concluded that sharing and allocation of diabetes care 
leads to significant reduction in HbA1c and improves the process of care (92). 
A recent meta-analysis evaluating the effectiveness of interactive communication 
between collaborating primary care physicians and specialists on outcomes relating 
to patients in ambulatory diabetes care found that  interactive communication 
resulted in moderate, statistically significant improvements in HbA1c (-0.64, 95% CI -
0.93 to -0.34)(93). 
Tailored interventions: 
In a systematic review on tailored interventions, Shaw et al. (2005) found that 
interventions tailored to prospectively identify barriers may improve care and patient 
outcomes (94). One review evaluated the effectiveness of health care interventions 
at improving health outcomes and/or reducing diabetes health disparities among 
racial/ethnic minorities with diabetes. Forty-two studies met inclusion criteria. The 
review concluded that on average, these health care interventions improved the 
quality of care for racial/ethnic minorities, found evidence supporting the use of 
interventions that target patients (primarily through culturally tailored programs), 
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providers (especially through one-on-one feedback and education) AND health 
systems (particularly with nurse case managers and nurse clinicians) (95). 
Pay for Performance (P4P) and Public Disclosure of health data 
Several countries have introduced pay for performance programs for the last years. 
Under these programmes a portion of payment is dependent on performance 
assessed against one or more defined measures (65). Italy, Spain, The Netherlands 
and New Zealand are beginning to reward performance in primary care (96). The UK 
remains in the vanguard of such schemes, with the Quality and Outcomes Frame-
work (QOF) introducing a P4P system in 2004. General Practices could obtain points 
by achieving targets for a whole range of quality indicators. HbA1c is one of the 
indicators. The points serve as a basis to obtain supplementary payments but are 
also used by the general practices to advertise.  This ‘Quality and Outcomes’ 
framework probably induced an improvement of the quality of diabetes care.  All 
analyses of the results from the QOF suggest that the program induced a modest 
positive effect on the quality of care delivered in primary care settings (97). The 
overall level of achievement of diabetes targets e.g. increased over 4 years, lower-
performing practices have shown the greatest improvements, and regional variations 
in care were reduced (98). There has been a substantial increase in the proportion of 
all diabetic subjects achieving outcome targets.  A more profound analysis of the 
data confirm the benefits of this Pay for Performance system in the UK, but also 
indicate that practice performance already improved before the introduction of the 
QOF, especially for cardiovascular health outcomes. Some indicators also warn for 
unintended consequences like a decrease in the continuity of care (99). Other more 
recent studies from the UK and other countries have examined the impact of P4P 
programs on the quality of diabetes care and suggest significant improvement in 
comprehensive diabetes care at the physician practice site level (100) and in the 
intermediate outcomes of diabetes care (101).  
In the United States, over 100 private and federal Medicare reward and incentive 
programmes have been launched. The report “Rewarding provider performance: 
aligning incentives in Medicare.” (Institute of Medicine, IOM-2007) has evaluated the 
literature on P4P and found only fewer than 20 studies, yielding mixed conclusions 
on overall impact. Some studies have shown a positive effect on the quality of care, 
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but others have not demonstrated this relationship. In general, the effect of most of 
these programs has not been examined sufficiently (65).  Nevertheless, the report 
pleads for the introduction of a P4P system in Medicare: “The systematic and 
deliberate use of payment incentives that recognize and reward high levels of quality 
and quality improvement can serve as a powerful stimulus to drive institutional and 
provider behaviour toward better quality.” 
 
More recent reviews confirm the mixed evidence regarding the impacts of P4P 
programs (102-104). Some programmes have a large positive effect on the quality 
indicators but most programs only induce a moderate effect. Until now, negative 
results were hardly found and unintended consequences seem limited. Though 
recognizing the probable added value of these programs to shape high performance 
delivery systems, some authors also warn for unintended consequences and pitfalls 
pleading for more evidence to understand what works under what circumstances 
(105). 
The IOM- report also stresses the importance of public disclosure of data: “Beyond 
merely collecting data on provider performance, Centres for Medicare and 
Medicaid Services (CMS) should make such data publicly available so that 
consumers will have the opportunity to fully characterize the performance of 
providers when making health care decisions. Public disclosure of information, with 
necessary patient protections, can also stimulate higher levels of quality by showing 
providers how their performance compares with that of their peers.”  
However, evidence in this domain also remains scarce, particularly about individual 
providers and practices (106). The available evidence suggests that publicly 
releasing performance data stimulates quality improvement activity at the hospital 
level. The effect of public reporting on effectiveness, safety, and patient-
centeredness remains uncertain.  Some studies have shown limited consumer 
movement following some public reports (107). There is also some evidence that 
making hospital quality reports public provides an independent stimulus to quality 
improvement efforts, above and beyond the effect seen with private reports (108-
110). The beneficial impact of public reporting was evaluated as rather small but real, 
positive effects mediated through both likely mechanisms by which public reporting 
may improve quality—consumer recognition of performance differences and provider 
29 
 
efforts to improve—have been found. On the other hand, some evidence showed that 
providers may attempt to avoid sick patients or manipulate the documentation of 
patients’ clinical status (111). 
 
Furthermore, public reporting probably could be a part of a larger pay for 
performance program as a study evaluating changes in adherence to quality 
measures at 613 hospitals that voluntarily reported information about the quality of 
care found modestly greater improvements in quality of care in hospitals that 
engaged in both public reporting and pay for performance than did hospitals engaged 
only in public reporting (112). 
Quality Improvement Trials for people with diabetes  
In order to benchmark the over-time improvement of the primary outcomes (HbA1c, 
LDL-Cholesterol and Systolic Blood Pressure) in both intervention groups of the 
Leuven Diabetes Project, we conducted a narrative review of original trials 
implementing quality improvement interventions in primary diabetes care. We made a 
search in Medline and Embase.  
We found 68 original studies with 45 RCT’s (addendum at the end of this chapter).  
59 reported on continuous outcomes, 9 only reported on dichotomous outcomes 
(addendum). We found thirteen clinician-centred interventions, three organizational 
interventions, 28 patient-centred interventions and 24 multi-level interventions. We 
did not find any study regarding the effect of peer support on patient outcomes. To 
our knowledge, one study on this issue is ongoing (113). One of the included studies 
has not been published yet in a journal, but is extracted from a PhD-thesis: “Disease 
management for patients with Type 2 Diabetes: towards patient empowerment” 
(Laura Welschen, 2008, Vrije Universiteit Amsterdam).  
54 studies included data on both the mean baseline value and the mean change over 
time of HbA1C. 9 studies included data on the baseline proportion of patients 
reaching a target (8 with HbA1C-target of 7% and 1 with a target of 7.5%). Only 24 
studies included data on Cholesterol values (mostly Total Cholesterol) and 8 studies 
included data on the proportion of patients reaching predefined Total Cholesterol 
targets (5) or LDL-targets (3). 30 studies included data on Systolic Blood Pressure 
values and 6 on the proportion of patients reaching a predefined SBP target.  
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25 studies (16 RCTs, 4 NRCTs) showed significant differences between the 
intervention and the control group for at least one of three endpoints. The mean 
baseline value of HbA1c, LDL-C, Total Cholesterol and Systolic Blood Pressure in 
the included studies was respectively 8.3%±1.3, 118± 17 mg/dl, 207±20 mg/dl and 
142±8 mm hg.  The mean change over time was respectively -0.5%±0.6%,   -11±8 
mg/dl, -15±10 mg/dl and -4±4 mm Hg. Regarding HbA1c, most (N= 41) studies 
started with baseline values <8.5%. Most of these studies showed only show small 
HbA1c improvements (< 0.5%). Only 1 study showed an improvement of -1.5%, but 
this improvement was not significant better than the improvement in its control group. 
Almost all studies with a more than moderate clinical effect (improvement > 0.5%) 
started with baseline values > 8.5%. On the other hand, 3 of the included studies 
started with very high baseline HbA1C-values (HbA1c > 11%) and showed only 
modest improvement. Only one of them showed a significant improvement compared 
to the control group.    The mean HbA1c improvement in studies with baseline values 
≤ 7.5% was -0.1±0.3% (N=15) versus a mean improvement of -0.7±0.7% in studies 
with baseline values > 7.5%. We found a highly significant correlation between the 
mean baseline Hba1c values and the change over time (correlation coefficient -
0.664, p<001; N=55). We also found a highly significant correlation between the 
change over time of SBP and baseline values (correlation coefficient = -0, 59, 
p=0.001, N=30). 
Summary of the evidence 
 
This narrative review of trials and systematic reviews on quality improvement 
confirmed the viewpoint of Shojania et al. that many quality improvement 
interventions in diabetes care only showed small improvements in patient outcomes. 
Clinically important improvements are mostly found in studies with high baseline 
values. The most robust improvements have been noticed by team changes, self-
management support and multifaceted improvement programs implementing the 
Chronic Care model. Pay for Performance, eventually with additional public 
disclosure of performance data is a promising initiative to improve the quality of 
chronic care.  
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BOX 2: EPOC Taxonomy Used to Classify Quality Improvement Strategies (reprinted from 
Shojania et al.) (25) 
Audit and Feedback. Summary of clinical performance of health care delivered by an individual 
clinician or clinic over a specified period, which is then transmitted back to the clinician (eg,the 
percentage of a clinician’s patients who have achieved a target glycosylated hemoglobin [HbA1c] 
level, or who have undergone a dilated-eye examination with a specified frequency). 
Case Management. Any system for coordinating diagnosis, treatment, or ongoing patient 
management (eg, arrangement for referrals, follow-up of test results) by a person or multidisciplinary 
team in collaboration with or supplementary to the 
primary care clinician. 
Team Changes. Changes to the structure or organization of the primary health care team, defined as 
present if any of the following applied: 
• Adding a team member or “shared care,” eg, routine visits with personnel other than the primary 
physician (including physician or nurse specialists in diabetic care, pharmacists, nutritionists, 
podiatrists). 
• Use of multidisciplinary teams, ie, active participation of professionals from more than 1 discipline 
(eg, medicine, nursing, pharmacy, nutrition) in the primary, ongoing management of patients. 
• Expansion or revision of professional roles (eg, nurse or pharmacist plays more active role in patient 
monitoring or adjusting medication regimens). 
Electronic Patient Registry. General electronic medical record system or electronic tracking system 
for patients with diabetes.  
Clinician Education. Interventions designed to promote increased understanding of principles guiding 
clinical care or awareness of specific recommendations for a target condition or patient population. 
Subcategories of clinician education included conferences or workshops, distribution of educational 
materials, and educational outreach visits. 
Clinician Reminders. Paper-based or electronic system intended to prompt a health professional to 
recall  patient-specific information (eg, most recent HbA1c value) or to perform a specific task (eg, 
perform a foot examination). If accompanied by a recommendation, the strategy would be 
subclassified as decision 
support. 
Facilitated Relay of Clinical Information to Clinicians. Clinical information collected from patients 
and transmitted to clinicians by means other than the existing medical record. Conventional means of 
correspondence between clinicians were excluded. For example, if the results of routine visits with a 
pharmacist were sent in a letter to the primary care physician, the use of routine visits with a 
pharmacist would count as a “team” change, but the intervention would not also be counted as 
“facilitated relay.” If, however, the pharmacist issues structured diaries for patients to record self-
monitored glucose values, which are then brought in person to office visits to review with the primary 
physician, then the intervention would count as 
“facilitated relay.” Other examples include electronic or Webbased tools through which patients 
provide self-care data and which clinicians review,23-25 as well as point-of-care testing supplying 
clinicians with immediate HbA1c values.26 
Patient Education. Interventions designed to promote increased understanding of a target condition 
or to teach specific prevention or treatment strategies, or specific in-person patient education (eg, 
individual or group sessions with diabetes nurse educator; distribution of printed or electronic 
educational materials). Interventions with patient education were included only if they also included at 
least 1 other strategy related 
to clinician or organizational change. 
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Promotion of Self-Management. Provision of equipment (eg, home glucometers) or access to 
resources (eg, system for electronically transmitting home glucose measurements and receiving 
insulin dose changes based on those data) to promote self-management. Interventions promoting 
patient self-management were included only if they also included at least 1 other strategy related to 
clinician or organizational change. 
Patient Reminder Systems. Any effort (eg, postcards or telephone calls) to remind patients about 
upcoming appointments or important aspects of self-care. Interventions with patient reminders were 
included only if they also included at least 1 other strategy related to clinician or organizational 
change. 
Continuous Quality Improvement. Interventions explicitly identified as using the techniques of 
continuous quality improvement, total quality management, or plan-do-study-act, or any iterative 
process for assessing quality problems, developing solutions to those problems, testing their impacts, 
and then reassessing the need for further action. 
 
Box3. Other relevant terminology 
Quality improvement collaborative: defined as fulfilling the following five criteria: (1) a specific topic 
is addressed, there is major variation between current and best practice; (2) clinical and quality 
improvement experts provide ideas and support for improvement; (3) there is cooperation between 
interdisciplinary teams on multiple sites; (4) a model for improvement sets targets and measures 
change; (5) and the collaborative process involves a series of structured activities within a set 
timeframe.(90)  
Shared care: the joint participation of primary care physicians and specialty care physicians in the 
planned delivery of care, informed by an enhanced information exchange over and above routine 
discharge and referral notices. It has the potential to improve quality and coordination of care delivery 
across the primary-specialty care interface. 
Pay for Performance: payment is dependent on performance assessed against one or more defined 
measures. 
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Section 6. Background of data collection: the Leuven Diabetes Project 
 
The data for this PhD project were collected from the Leuven Diabetes Project (LDP), 
a large federal state funded Quality Improvement Program in Belgium and a pilot 
project to examine the usefulness and feasibility of a nation-wide implementation of 
quality improvement initiatives in the care of chronic diseases.  
The project was constructed on the two before mentioned theoretical frameworks. 
The quality improvement interventions were based on the Chronic Care Model. 
These interventions however were part of a larger implementation plan. This plan 
was based on the methodological framework described in the implementation model.  
The trial was conducted from January 2005 until December 2006 and included 120 
primary care physicians and 2495 predominantly Caucasian patients with Type 2 
Diabetes Mellitus. These physicians work in a semi-rural setting with 357.000 
inhabitants surrounding the University Hospitals of Leuven. The objective of the LDP 
was to improve patients’ outcomes through support measures for general 
practitioners and patients. The LDP was a cluster-randomized trial with before/after 
measurements, two intervention arms and an implementation period of 18 months. 
The first intervention arm received a Usual Quality Improvement Program (UQIP-
program), which was a set of interventions addressing the principal barriers to quality 
improvement: the diffusion of an evidence-based treatment protocol, annual 
benchmarking, postgraduate education, case-coaching for GPs and the possibility to 
refer for patient education. The second arm received an Advanced Quality 
Improvement Program (AQIP-program) that included supplementary initiatives 
focusing on intensified patient follow-up, protocol based shared care and special 
attention to patient behavioural changes.   
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Section 7. Aim and Research Questions 
 
General objective of the PhD project. 
The general research objective of this PhD Project is to assess the quality of care for 
patients with Type 2 Diabetes, to evaluate the effectiveness of quality improvement 
measures in the Belgian health care setting, and to place this in the context of the 
challenges for chronic care re-organization.  
Diabetes in this thesis will be considered as a high cardiovascular risk equivalent. 
Therefore, quality of care will primarily be measured by “patients’ intermediary 
outcomes”, which are defined as all parameters at patient level affecting the co-
morbidity risk of diabetes: lifestyle attitudes (smoking status, physical exercise, diet 
and food patterns), biological and biochemical parameters (Body Mass Index, lipid 
values, blood pressure and HbA1c for glycemic control) and drugs directly affecting 
cardiovascular disease (statins, ACE-inhibitors, anti-platelet therapy). The primary 
outcomes throughout the project are HbA1c, Systolic Blood Pressure and LDL-C. 
Secondarily, process parameters (statin therapy, insulin therapy, indicators for the 
screening of complications) will be taken into account to measure the evolution of 
quality of diabetes care. 
 
Research question per chapter 
I Research 
Question 
What is the quality of diabetes are as measured by patients’ 
intermediate outcomes in a Belgian health care setting? 
Method Cross-sectional study analyzing quantitative data that were collected 
at baseline of the “Leuven Diabetes Project evaluating the ‘usual’ 
care in a Belgian region without any experimental intervention or 
guideline implementation.  
 II 
 
Research 
Questions 
(1) Can improved quality of care be achieved with a basic support 
program for GPs and patients (UQIP), 
(2) Can an intensified support of GPs and patients in the AQIP arm 
paying special attention to shared care, patient compliance and 
adherence to lifestyle changes further improve outcomes in T2DM 
patients achieved by the UQIP? 
Method Cluster randomized trial with two intervention arms, a basic 
intervention arm (UQIP) and an intensive intervention arm (AQIP) 
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 III Research 
Questions 
(1) What is the five year (2002 – 2007) evolution of the quality of 
diabetes care in a region that was the setting of an experimental 
Quality Improvement Program (LDP) for a part of the diabetes 
population during the last two years of this registration period?  
(2) Is the evolution of the quality of care for patients clustered around 
GPs who participated in the LDP significant different from the 
evolution of parameters of patients clustered around GPs who did not 
participate? 
 Method Analysis of insurance claims data of people with Type 2 Diabetes 
taking glucose lowering medication and living in the region of Leuven.  
‘Diabetes Care’ will be evaluated both by analyzing available 
intermediate outcomes (HbA1c, LDL-C, HDL-C and Triglycerides) 
and process parameters. 
 IV Research 
Questions 
(1) What changes did GPs participating to an 18 month Quality 
Improvement Program actually perceive?  
(2) What are the barriers and facilitators to high-quality diabetes care 
as they were experienced by participating GPs. 
Method Qualitative Study that was nested in the controlled trial of the LDP by 
interviewing GPs who participated in the 18-month Quality 
Improvement Program.   
V Research 
Question 
What is the added value of a composite metric based on HbA1c, LDL-
C and SBP in the daily monitoring of General Practices?  
Method Development of a composite indicator and validation of this indicator 
by testing it on the cohort population of the ‘Leuven Diabetes Project’. 
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Addendum: Quality improvement interventions in primary care 
Study Country & 
setting 
Study 
design 
Sig, ∆ Follow-up 
(mo) 
type Level Intervention N (IG) A1c- 
BL 
∆T A1c 
∆C A1c 
LDL-
BL 
∆TLDL 
∆CLDL 
TC-BL ∆TTC 
∆CTC 
SBP- 
BL 
∆TSBP 
∆CSBP 
Hetlevik(114) Norway, 29 
centres and 53 
(24 + 29) 
doctors 
RCT  No  S C Computer based clinical 
decision support 
499 8,2 -0,3 
-0,1 
    153 -1 
-1,2 
Kinmonth 
1998(115) 
England, 41 GP 
practices (21 IG) 
RCT No 12 S C Training in patient centered 
care 
250       144 0 
-2 
Meigs, 
2003(116) 
Massachusetts, 
USA 
RCT no 12 S C Web-based decision 
support tool 
 8,4 -0,2 
-0,3 
127 -15 
-4 
  138 +1 
+3 
Van 
Bruggen(117), 
2008 
Netherlands,30 
GP practices 
RCT No 12 MF C Structured care, clinician 
education, performance 
feedback: MF 
822 
 
7,0  -0,1 
0 
  205 -8 
-4 
146 0 
-1 
Phillips(118) Atlanta, USA, 
345 internal 
residents 
(generalists in 
training) 
RCT  Yes  36 MF C Computerized reminders, 
feedback, clinician 
education 
1063 8,0 -0,54 
-0,38 
122 -19 
-3 
  138 -3 
-1 
Cleveringa(119), 
2007 
Netherlands, 
113 PC 
practices 
Before / 
after 
NA 24 MF ML Practice reorganization 
(task delegation to nurse), 
computerized decision 
support 
7893 
 
7,0 -0,2 
 
  201 -15 149 -6 
Mackey(120) Texas, USA, 
university PC 
practice 
Before / 
after 
NA 12 MF ML CCM: multifaceted (delivery 
system redesign, provider 
education, practice nurse), 
self-evaluation 
44 7,7 -0,3 123 -25   126 +5 
Reed 2001(121) United Arab 
Emirates, 
primary care 
Controlled 
before/after 
no  MF ML Diabetes clinics created 
with guidelines, patient 
education, appointments, 
clinician education and 
access  to  specialist care 
109       129 -2 
+1 
Vargas(122) Los Angeles, 
USA 
Controlled 
before/after 
No 12 M ML CCM: collaborative learning 
sessions to implement 
CCM 
613 7,9 -0,5 
-0,24 
111    138 -2,4 
-0,4 
Balamurugan 
(123) 
Arkansas, USA Controlled 
before/after
, 
participants 
vs, 
nonparticip
? 12 MF ML Diabetes Self-management 
Education in continuous 
quality improvement 
process: 12 hours course 
201 8,0 -0,45 
 
    141 -4 
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ants) 
Grant(124) Massachusets, 
USA, 4 primary 
care clinics 
Non RCT  No 20 MF ML Software diabetes 
registries and population 
management 
898 7,9 -0,3 
-0,1 
106 -11 
-1 
  133 -3 
-1 
Lim 2002(125) Singapore, 
Primary Care 
Non RCT NA 6 MF ML Disease management: 
case management with 
PCP, case manager, 
podiatrist, dietitian, patient 
education, provider 
reminders 
63 9,8 -2,0     142 -8 
Hirsch(126) Washinton, 
USA, Academic 
family practice 
Non RCT  Yes 14 MF ML Reminders, diabetes 
management protocol 
review, clinician education, 
feedback, case 
management, coaching 
65 7,6 -0,1 
-0,7 
  203  135 -1 
Olivarius(127) Danmark, 311 
practices, 474 
GPs (243 +231) 
Non RCT  Yes 72 MF ML Structured personal care: 
individualized goal setting, 
prompting of doctors, 
guidelines, feedback and 
clinician education 
649 10,2 -1,7 
-0,5 
  240 -8 
-4 
150 -5 
-7 
Groeneveld(128) The 
Netherlands, 15  
(8 +7) 
GPractices 
RCT   MF ML Diabetes education (nurse, 
dietician), call/recall system 
every 3 months or more 
91 ? ?   240 -4 
0 
137 -2 
+4 
O’Connor(129) Minneapolis, 
USA, 12 PC 
practices 
RCT No 18 MF ML Seven step QI process: 
clinician education, teams 
(nurse, staff, physician), 
meetings 
428 8,1 -0,1 
+0,1 
 
133  -16 
+4 
  136 -1 
0 
O’Hare(130), 
2008 
UK, south Asian 
pop, 21 PC, 
practices 
RCT No 24 MF ML Enhanced care: practice 
nurse, link workers, 
community nurse, language 
868 
 
8,2 +0,04 
-0,15 
  182 -17 
+1 
 
139 -5 
0 
 
Smith 2004(131) Dublin, Ireland, 
38 GPractices, 
50 GPs 
RCT no 18 
months 
MF ML Structured shared care: 
clinician education, 
diabetes specialized nurse, 
guidelines, review by 
specialist, record cards, 
referral system 
96 6,9 +0,1 
0 
  205 -4 
-4 
 
162 -4 
0 
Wagner 
2001(66) 
Primary care 
practices, HMO, 
USA 
RCT No 24 MF ML Chronic Care clinics for 
groups of 8 patients 
278 7,5 +0,4 
-0,1 
  215 -13 
0 
  
O’Hare(132) UK, south asian 
ethnicity 6 (3 +3) 
practices 
RCT Yes 12 MF ML Enhanced diabetes care: 
asian link workers, practice 
nurse, diabetes specialist 
165 7,8 -0,2 
0 
  213 -19 
-14 
146 -7 
-5 
38 
 
nurse, protocols with 
treatment targets 
Peterson(133), 
2008 
Minnesota,USA, 
24 PC practices, 
238 providers 
RCT Yes 24  MF ML CCM with diabetes registry, 
clinician reminders, 
proactive planning 
3970 
 
7,25 + 0,01 
-0,03 
104  - 4 
0  
  133 - 1,3 
+0,2 
Piatt(134) Pittsburg, USA, 
11 PC practices 
RCT yes 12 MF ML CCM: community 
partnerships, self-
management support, 
process redesign, clinician 
education, diabetes 
educator, feedback, 
30 7,6 -0,6 
-0,6 
154 
 
-11 
-9 
  143 -1 
0 
Rothman 
2005(135) 
Tennesse, USA, 
primarcy care 
RCT yes 12 MF ML Pharmacy-led sisease 
management program, 
educational sesions, EB 
algorithms, pro-active 
management 
99 11 -2,5 
-0,8 
 
  213 -27 
-15 
140 -4 
-5 
Varrroud-
Vial(136) 
France, 57 GPs RCT yes 12 MF ML Diabetes management: 
clinician education, 
decision support tools 
(booklet) 
192 7,5 -0,3 
-0,8 
132 -7 
+10 
 
215 -9 
+1 
 
141 -4 
-2 
Majumdar(137) Canada, rural 
patients 
Controlled 
trial (region 
based) 
no 6 S O 6 monthly visit of specialist 
team 
200 7,2 ?   188  130 ? 
Branger, 
1998(138) 
The Netherlands RCT No  S O Electronic communication 
systems between primary 
and secondary care 
 7,0 -,02       
Litaker(139) USA RCT yes 12 S O Practice nurse 79 8,4 -0,63 
-0,48 
  212 -11 
-1 
  
Clifford 
2002(140) 
    S P Pharmacist monitored 
patients 
 8,4 -0,2 
+0,2 
      
Coast-
Senior(141) 
USA, VA before/ 
after 
  S P Educational intervention to 
improve adherence to 
treatment 
recommendations in Type 
2DM patients: Face to 
Face, pharmacist led 
23 11,1 -2,2       
Miller 2003(142) PC clinic, Atlanta 
USA 
Non RCT no 24 S P Rapid A1 measurement 317 8,5 -0,2 
-0,3 
      
Van Welschen 
(in submission), 
thesis 
The  
Netherlands, 
General 
Practices 
Non RCT no 12 S P cognitive behaviour therapy 
(CBT) in addition to 
managed care, and a 
control group that will 
receive managed care only. 
76 6,8 0 
-0.1 
89 -8 170 -12 
-4 
145 -1 
+2 
39 
 
The CBT consists of three 
to six individual sessions of 
30 minutes to increase the 
patient's motivation, by 
using principles of MI 
(motivational interviewing), 
and ability to change their 
lifestyle, by using PST 
(problem solving 
treatment). 
Gilliland 
2002(143) 
USA, native 
people, 
community 
Non RCT yes 12 S P Culturally appropriated 
education: 
FF: family and friends 
O&O: on in one 
71 
32 
39 
 
8,3 
9,2 
 
+0,5 
+0,2 
   
199 
218 
 
-22 
-20 
  
Cooper 
2003(144) 
Liverpool, UK RCT No 12 S P “Diabetes Look After  
Yourself” course, self-
management given by 
specialist diabetes nurses 
53 7,9 0 
-0,2 
      
Davies 
2008(145) 
UK, primary care 
(DESMOND) 
RCT no 12 S P A structured group 
education programme for 
six hours delivered in the 
community by two trained 
healthcare professional 
educators compared with 
usual care. 
387 7,9 -1.5 
-0.3 
128 -29 
+6 
209 -37 
0 
140 -6 
0 
Goudswaard 
2004(146) 
The Netherlands RCT No 18 S P Education and self-
management 
28 8,2 -0,4 
+0,2 
      
Krier199(147) USA, setting 
unknown 
RCT no  S P Quarterly visits by the 
diabetes educator 
21 9,6 -0,4       
Piette 2001(148) USA, VA 
patients 
RCT No 12 S P Automated Telephone 
Disease Management: 
patient calls with 
information and then 
telephone follow-up by 
nurse 
272 8,2 -0,1 
-0,2 
      
Piette, 
2000(149) 
USA, county 
health system 
RCT No 12 S P Automated Telephone 
Disease Management: 
patient calls with 
information and then 
telephone follow-up by 
nurse 
280 8,8 -0,6 
-0,3 
      
Pouwer(150) Amsterdam, 
outpatients,unive
RCT no 12 S P Psychological monitoring 
and counseling by psy if 
191 7,8 -0,1 
0 
      
40 
 
rsity clinic judged necessary 
Ridgeway 
1999(151) 
USA, community 
(ROMEO) 
RCT no 12 S P Nurse and dietitian led 
education on diet an 
exercise 
28 12,3 -0,8 
-0,1 
133 -3 
-9 
259 -40 
-50 
  
Samuel-Hodge 
2009(152) 
USA, Afro-
Americans 
RCT no 8 S P Church-based educational 
intervention 
117 7,8 -0,4 
0 
      
Aubert 
1998(153) 
USA RCT yes 12 S P nurse case management 
diabetes program 
that included close follow-
up, continuous 
reinforcement of meal 
planning and exercise, and 
systematic treatment 
adjustments 
71 9,0 -1,7 126 -6 211 -12  +1,9 
Brown 
2002(154) 
USA RCT yes 12 S P Culturally competent 
Diabetes self-management 
Group education 
128 11,8 -0,9 
-0,7 
 
  211 -21 
-4 
  
Brown 
2005(155) 
USA RCT yes  S P Culturally competent 
Diabetes self-management 
Group education 
114 11,5 -1 
-0,3 
      
Deakin 
2006(156) 
UK, primary care RCT yes 14 S P Group based education 
and self-management on 
nutrition, weight, exercise, 
complications, goal setting 
and self-monitoring 
157 7,7 -0,6 
-0,7 
104 0 
0 
197 -12 
-8 
148 -7 
-3 
Denver 
2003(157) 
PC RCT yes 6 S P Nurse-led clinic 
Patient education 
120 8,2 0 
0 
  189 -4 
0 
161 -20 
-13 
Hee-Sung 
2007(158) 
 
Korea RCT yes  MF P web-based education, use 
of cellular phone by nurse 
25 8,1 -1,1 
-0,8 
      
McMahon(159) Massachusetts, 
USA, VA-
practice, poorly 
controlled 
patients 
RCT Yes 12 MF P Web-based care 
management: patients 
receive notebook, 
glucometers and BP 
monitor 
52 10 -1,6 
-0,4 
141 -6 
-1 
  141 ? 
Oh 2003(160) Korea RCT yes 3 S P Patient Telephone  calls to 
monitor BG, diet, exercise 
and medication 
adjustments 
20 8,9 -1,2 
+0,8 
 
      
Sadur 1999(161) USA, Health 
maintenance 
(Kaiser 
Permanente) 
RCT yes 6 MF P Multidisciplinary outpatient 
care management by 
nurse, psychologist, 
dietitian and pharmacist in 
82 9,5 -1,3 
-1,1 
      
41 
 
cluster visits (10-18 
patients) 
Sarkadi 
2004(162) 
Sweden RCT yes 24 MF P experience-based group 
educational programme, 
pharmacist-led, also nurse 
(self-management on 
lifestyle and self-
monitoring) 
39 6,5 -0,4 
-0,5 
      
Shea 2007(163) New York RCT yes 12 MF P 1. Videoconferencing 
2. Remote glucose 
monitoring 
3. Electronic access to 
own clinical data 
4. Web-based education 
670 7,4 -0,4 
-0,2 
106 -10 
-8 
183 -12 
-10 
142 -5 
-4 
Trento 
2004(164) 
Italy RCT Yes 60 S P  112 7,4 -0,1 
-1,8 
  225 -13 
+4 
  
Trento 
2008(165) 
Italy RCT yes 24 S P Group care by nurse, 
pedagogist and dietitian 
25 8,0 -0,4   197 -4 145 -9 
 
Izquierdo 
2003(166) 
USA, New York, 
VA 
RT, nurse 
education 
vs. 
telemedicin
e education 
no  S P Nurse education (control), 
vs. telemedicine education 
(intervention) 
24 8.7 -0,9 
-0,1 
110 -14 
-9 
    
Smith 2008(167) USA Mayo Clinic RT no 29 S C Specialty telemedicine 
advice to GP 
358 7.3 -0.6 104 -12   130 -1 
Holbrook 
2009(168) 
Toronto, Canada RT yes 6 S C Electronic decision support 
and reminders 
253 7.0 -0.2 93 +1   135 -4 
O’Connor 
2009(169) 
Minneapolis, 
USA 
RT no 12 S C Simulated physician 
learning with expert input 
604 7.3 +0.2 105 -4     
O’Connor 
2009(170) 
Minneapolis, 
USA 
RT no 12 S ML Customized feedback to 
patients and providers 
656 7.5 -0.1 129 -24     
 
∆ = change over time ; ∆T = change over time in the intervention group 
∆C = difference in change over time between the intervention and the control group (if applicable) 
BL = baseline ; Mo = months ;  Sig.∆ = significant difference with control group for primary outcomes 
Type of intervention: MF = Multifaceted ; S =single intervention 
IG = Intervention Group 
P4Q = Pay for Quality/ P4P = Pay for performance 
Total and LDLC units have been recalculated in mg/dl if mentioned in mmol/l 
Level: P = Patient ; C= clinician (GP,PCP) ; O= Organizational ; ML = Multilevel (at least 2 of the three levels)  
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Study Country Study design Sig, ∆ 
with 
control 
group for 
primary 
outcome
s? 
Perio
d 
mont
hs 
Kind 
Int 
Level intervention N (IG) HbA1 
Targe
t (%) 
% AT 
BL   
HbA1
c 
∆ Chol 
Target 
(mg/dl) 
%AT  
BL 
Chol 
  
∆ 
(S)BP 
Target 
(mm Hg) 
%AT 
BL 
(S)BP 
∆ 
Ornstein2007
(171) 
USA, 66 
practices, 
372 
providers 
Before / after ? 18 MF C Audit, 
feedback, 
practice site 
visits, network 
meetings 
(PPR-net) 
24250 7 :47 +4 LDL 
100 
39 +13 130/80 53 +6 
Coleman 
2007(172) 
Chicago Before/after NA 12 S C P4P 1166 7 32 -6       
Vaghela(98), 
2009 
UK, 98% 
of all 
English 
PC 
practices 
Longitudinal 
observationa
l 
 48 P4P C P4Q 1,000,00
0 
7,5 59 +8 TC: 
193 
73 +11 145/85  71 +9 
Ornstein2004 USA,multi-
center, 20 
practices, 
44 
physicians 
RCT No 24 MF C Practice 
guidelines, 
feedback, 
practice visits, 
network 
meetings 
45571 7 49 +5 LDL: 
100 
45 +12 140/90 64 +8 
Ilag(173) Michigan, 
USA, 9 
practices 
RCT No  24 S C Annual 
assessment 
with feedback 
103 7 34 -6 LDL 
100 
52 -4 135 66 -6 
Renders 
2001 
The 
Netherlan
ds, 
General 
Practice 
Non 
randomized 
controlled 
trial 
No 42 MF ML Clinician 
education, 
audit and 
feedback, 
relay of data 
312 7 41 +4 TC 
200 
21 +7 140 31 +12 
Valk(174) Netherlan
ds, 22 
GPs 
Observation
al 
NA 60 MF ML Medical record 
system, 
clinical 
practice 
guidelines, 
physician 
379 7 54 -
12 
TC 
200 
15 +8    
43 
 
education, 
audit, 
feedback, 
recall system 
Valk(174) USA, 50 
GPs 
Observation
al 
NA 60 MF ML Medical record 
system, 
clinical 
practice 
guidelines, 
physician 
education, 
audit, 
feedback, 
educational 
outreach 
visits, 
multidisciplinar
y teams, 
patient SME 
2119 7 32 -
15 
TC 
200 
23 +17    
Ubink-
Veltmaat 
(175) 
The 
Netherlan
ds, 32 
(+21 +8) 
practices 
Observation
al study, 
controlled 
NA 36 MF ML Structured 
shared care 
intervention: 
diabetes 
register, 
structured 
recall, 
generalist-
specialist 
communicatio
n, feedback, 
reminders and 
patient  
education 
1244 7 43 -1 TC: 
193 
28 +12 150/85 :40 +12 
 
 
IG = intervention group; N above = patients ; below = practices: %AT = % of patients at target ; ∆ = change over time in % of patients at target 
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Abstract 
Objective: To picture the profile of Type 2 diabetic patients in Belgium and to study the 
quality of care in primary care setting, with regard to multi-factorial approach of the disease. 
Methods: Observational study of all known T2DM-patients registered by 120 volunteer 
general practitioners. Quality of care was evaluated by the achievement of three major 
treatment targets: HbA1c <7%; Systolic Blood Pressure ≤130 mmHg; LDL-Cholesterol 
<100mg/dl (ADA 2003). Multivariate analysis was performed.  
Results: 2495 T2DM-patients were included with a mean age of 68±12 years and 51% being 
women. One fifth of patients had microvascular complications and 27% had macrovascular 
complications. Sixty eight percent received oral anti-diabetic drugs and 19% were on insulin. 
Satisfactory glycemic control (HbA1c<7%) was achieved in 54% of the patients, with 
however glucose control deteriorating with disease progression despite more intensive 
hypoglycemic treatment. Systolic blood pressure targets were reached in 50%. Statin use 
was present in 39% and LDL levels <100mg/dl were reached in 42%. 59% of insulin treated 
patients were followed up in shared care with specialized diabetes centres. These patients 
obtained lower values for HbA1c (7.5±1.2% vs. 7.8±1.5%, p=0.038) and LDL-C (90±34 vs. 
111±37, p<0.001) compared to insulin-treated patients only followed up in primary care.  
Conclusion: Overall metabolic control in Type 2 Diabetes patients in primary care in 
Belgium was acceptable for glucose control, but major room for improvement exists 
especially for statin use and blood pressure control. Clinical inertia is present and the 
presence of more structured care in specialized diabetes centres, focusing on therapeutic 
guidelines, may explain the better overall metabolic control in patients followed up in shared 
care with these centres. 
Keywords: Diabetes, Type 2; Primary Care; Cardiovascular Disease; Quality of Care; Cross-
Sectional Studies  
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Introduction 
Type 2 Diabetes Mellitus is a major threat to global public health with micro- 
and macrovascular complications being highly prevalent. Approximately 2.9 million 
deaths per year worldwide are attributable to diabetes (1), part of while could be 
prevented by lifestyle measures and pharmacological therapy (2). A second problem 
is the steep increase in numbers of patients with diabetes. By 2025, more than 10% 
of the adult population will be affected by the disease, reaching over 300 million 
individuals worldwide (3). This will lead to major challenges for health care 
management. The most recent international guidelines recommend an intensive and 
global follow-up of all Type 2 Diabetes patients once the disease has been 
diagnosed (4;5). In order to cope with a disease of these dimensions, health care 
systems will have to introduce new approaches, such as shared care treatment 
protocols and adapted organizational structures and especially, the involvement of 
general practitioners, preferentially assisted by specialized nurses or diabetes 
educators. Nevertheless, despite the necessity of an explicit task division and job 
sharing between the General Practitioner and the endocrinologist (6), no evidence 
based consensus so far exists (7).   
Furthermore, in many countries, like Belgium, France or Germany, the 
traditional primary health care system is poorly adapted to coping with this upcoming 
chronic disease epidemic (8;9). GPs mostly work in solo-practices (10), without 
additional staff, rather demand driven, without a chronic care tradition based on 
diabetes patient registries or organized diabetes consultations. Shared care at 
primary care level is loosely organized since GPs cannot rely on structured 
assistance of dieticians or diabetes nurse educators in their practice. Moreover, in 
some countries such as Belgium, patients have to make considerable financial 
contributions for out-practice dietetic services and materials needed for self 
monitoring. In Belgium, the GP has no gatekeeper function and thus all patients 
theoretically can make an appeal to an endocrinologist for their diabetes treatment. In 
addition, the Belgian law allows some patients, those treated by multiple daily insulin 
injections, to contractually adhere to such a centre enabling the possibility of an 
intensive management by a multidisciplinary diabetes team including diabetes nurse-
educators and dieticians, led by the endocrinologists. Patients adhering to this 
system do receive reimbursement of diabetes education and self monitoring 
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materials. Structured recall systems invite them to the centre and multidisciplinary 
embedding in the hospital is present, with access to specialized advice, e.g. 
cardiology, podiatry and nephrology. A quality-monitoring system (IKED) which has 
been in place for 10 years has contributed to the optimal organization of care for this 
subset of patients (11).   
 
The present study evaluated the ‘usual’ care in a Belgian region without any 
intervention or guideline implementation and allows evaluating the main patient 
outcomes in a health care system characterized by a loosely organized primary care 
with however a task division between primary care and diabetes centres. Most 
patients are primarily treated by the GP, whereas a minority of patients, those on 
multiple daily insulin injections is treated in shared care with diabetes centres. In the 
present study, attention was not only focused on glycated hemoglobin (HbA1c), often 
used as the gold standard of metabolic control. Several other outcome and process 
measures that give an integrated view of diabetes care were assessed, especially 
blood pressure and lipid profile levels and actions to control them, which are 
important determinants of cardiovascular mortality and morbidity (12).  
Patients and Methods 
Study description and data collection 
Data were collected in a cross-sectional design at baseline of a clustered randomized 
intervention, the Leuven Diabetes Project (LDP). The study was performed in a 
region of 357,000 inhabitants that surrounds the medical university hospital of 
Leuven. This particular region was chosen because of its semi-rural, semi-urbanized 
character. All primary care physicians of the region were invited to participate in the 
LDP. A fixed fee of 60 Euro was issued per registered patient. In order to prevent 
selection bias, physicians agreed to register all their known type-2 DM patients 
including those who were adhering to specialized diabetes centres. Diabetes was 
diagnosed according to ADA guidelines (13). Patients with diabetes were identified 
using electronic searching in computerized records and laboratory lists of patients 
with increased glycemia or registered HbA1c. Patient data were collected on a paper 
sheet from January to July 2005 and the completeness of data capture was double-
checked by a data monitor. In order to obtain the requested data, physicians 
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performed an in-depth anamnesis and a complete examination including a blood 
analysis at patient’s first visit during the registration period. Blood Pressure measures 
were taken by the GPs either at the office or at patients’ home. GPs received detailed 
written instructions with the WHO/ISH criteria for correct blood pressure 
measurement and received a short training course at the beginning of the project. 
Patient data sheets included several sociological, biomedical and medication 
parameters. Laboratory data were registered by GPs referring to their usual 
laboratory, thus involving seven laboratories. However, 97% of the HbA1c analyses 
were performed in three laboratories, using the same HPLC-technique (Menarini HA-
81.60™, Menarini Diagnostics, Florence, Italy) with reference values between 4 and 
6%. Three laboratories used other DCCT standardized analyzers (1 HLC-723 
GHbG7, Tosoh Bioscience Corporation, Tokyo, Japan; 1 VARIANT TM II TURBO 
Hemoglobin Testing System, Bio-RadLaboratories, Hercules, USA; 1 ADAMS™A1c, 
HA-8160, Arkray inc., Kyoto, Japan) again with reference values between 4 and 6%. 
Only one laboratory, reflecting measurements for 12 patients presented with 
reference values between 4 and 6.6% (Menarini HA-81.40, Menarini Diagnostics). 
For the involved patients, the presence of shared care with contractual adherence to 
a diabetes centre was registered. The presence of CVD (14) was pre-defined as a 
reported history of heart attack, cerebrovascular disease, and history of angina, PAD 
or coronary, cerebral or peripheral vascular intervention in the personal history.  The 
LDP-study has been approved by the ethical committee of the Catholic University of 
Leuven (project number ML 2719) 
Outcomes and statistical analysis 
The study focused primarily on three patient outcomes: HbA1c for glycemic control, 
Systolic Blood Pressure (SBP) for blood pressure profile and Low Density 
Lipoprotein-Cholesterol (LDL-C) for lipid profile. Mean values as well as the 
proportion of patients reaching the ADA-targets were evaluated [HbA1c <7%; SBD ≤ 
130 mm Hg; LDL-C <100mg/dl]. Secondly, treatment with essential cardiovascular 
drugs like statin and anti-platelet therapy was evaluated. Finally, the relationship 
between diabetes duration, glucose lowering therapy and outcomes was examined.  
Exploratory means and standard deviations were reported for continuous variables. 
Proportions were reported for categorical variables. The clustered nature of the study 
(all patients around their physicians) was accounted for in multilevel analyses, with 
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random physician effect. These models allow for variability between physicians as 
well as variability between patients (within physicians). For continuous outcome 
variables, linear mixed models were fitted using restricted maximum likelihood 
estimation. Dichotomous and ordinal outcomes were analyzed using logistic and 
proportional odds mixed models, respectively. Model estimation was then based on 
maximum likelihood, with Gaussian quadrature with 200 quadrature points for the 
approximation of the likelihood.  Analyses were performed using SAS statistical 
software package, with the procedure MIXED for the linear models and NLMIXED for 
the others. All tests are based on the 5% level of significance. 
 Concerning the three main parameters (HbA1c, LDL-C an SBP), multiple regression 
models were used to study the joint association between the outcomes and all 
predictors, with additional correction for patients’ age, gender, diabetes duration, 
BMI, history of CVD, hypoglycemic treatment, patient’s motivation, presence or 
absence of depression, shared care with a diabetes centre and for GP’s workload, 
gender, use of electronic medical file and practice type (solo/duo/group). 
The models compare patients on insulin treated by the GP with patients taking no 
antidiabetic drugs and patients with OADs, also treated by the GP. Insulin treated 
patients adhering to a diabetes centre were separately compared with patients on 
insulin treated by the GP. 
Since not all variables were available for all patients, case-wise deletion was used. 
However, since all analyses are likelihood based, valid inferences can still be 
obtained under the assumption of random missingness, i.e., the fact that a variable is 
missing for a patient is unrelated to the outcome that would have been measured for 
that patient.  
Results 
Within a three-month inclusion period 120 physicians (32%) agreed to participate. 
Mean physician’s age was 44±10 years with 45% female doctors. 38% of the 
physicians worked solo, 32% worked in a duo and 30% in a group practice (3 or 
more physicians). Mean number of patient contacts per week was 95±29 per 
physician corresponding to a practice population of 760 patients. Nearly all 
physicians (91%) used a computerized record. Present study included 2495 patients 
with a mean number of 21 patients per physician and a range from 2 to 73. The 
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estimated practice prevalence of Type 2 Diabetes patients is 2.8%. As table 1 
indicates, we deal with an older population with only 9% of the patients younger than 
50 years, 40% older than 72 years and 14% older than 80 years.  Overweight and 
obesity were highly prevalent with 82% having a BMI > 25 and 43% >30 kg/m².  
Mean fasting glycemia and HbA1c were 139±47 mg/dl and 7.15±1.3%, respectively. 
Mean blood pressure was 136/79 ± 16/10 mm Hg with 73% of patients under 
antihypertensive drug treatment. Mean total cholesterol, LDL- and HDL-cholesterol 
was 192±40 and 108±34 and 54±16 mg/dl, respectively. Statins were prescribed in 
only 39% of the total population.  
Diabetes complications were highly prevalent: 27% of the patients had macro-
vascular disease : myocardial infarction 11%, angina pectoris 14%, stroke 7%, PAD 
7%, with 15% of the population having received a cardiovascular intervention. One 
fifth of the patients had micro-vascular complications: nephropathy 12%, retinopathy 
10%, neuropathy 10% and diabetes foot problems 4%. 
Most patients were treated with OADs, being metformin, sulfonylurea or 
thiazolidinediones. Thirteen percent were on lifestyle interventions only, taking no 
antidiabetic drugs. Nineteen percent (N = 482) received insulin treatment most of 
which (12%, N= 285) were treated in shared care with contractual adherence to a 
diabetes centre receiving two or more daily injections (table 1 & 2).  
As shown in figure 1, a clear correlation was seen between diabetes duration and 
intensification of therapy. Less than 10% of the patients with disease duration less 
than 5 years received insulin vs. 46% of those with duration of more than ten years. 
This disease evolution is typically accompanied by a deterioration of glycemic 
control, as expressed by HbA1c levels, and an increase of cardiovascular 
complications (Table 1 and 3).  
Data reveal some clinical inertia as 17% of the patients on OADs had HbA1c-levels ≥ 
8% and even 10% (N=169) had levels ≥ 8.5%. In the latter group, diabetes duration 
was significantly higher than in those patients with HbA1c< 8.5% (6.7 years vs. 6.1 
years, p<0.0001 using a Poisson mixed model). In addition, insulin treated patients 
adhering to diabetes centre had better glycemic control than those primarily treated 
by the GP (table 2). 
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Subgroup analysis according to the type of hypoglycemic treatment regimen, showed 
that more intensive glucose-lowering treatment (insulin > 0ADs > no drugs) was 
associated with achieving more targets (Table 1). LDL-C and DBP levels were lower 
whereas statin and aspirin use was more prevalent (Table 2). Of interest, when 
analyzing insulin-treated patients according to the site where diabetes was primarily 
managed (GP vs. diabetes centre), the effect on achieving targets was correlated to 
the site rather than to insulin-treatment itself being present (Table 2). These results 
were confirmed by a multiple regression model (Table 3): HbA1c clearly deteriorated 
with duration and complexity of disease. In insulin treated patients, HbA1c and LDL-
C were lowest in patients followed up in specialized diabetes centres.  
Discussion 
The present study reports the status of care in patients with Type 2 Diabetes, 
generally treated in a primary care setting in Belgium and is reflective of the situation 
of global Type 2 Diabetes care in many industrialized countries, with good health 
care facilities, but with loosely organized primary care and the absence of strict care 
management.  The achievement of targets was very diverse, with HbA1c classically 
being one of the hardest to control. Also in our study, only half of the patients 
reached the goal of HbA1c<7%, a result comparable  and even slightly better than 
those in previous  studies in other countries: United States (50% reaching the ADA-
target in the NHANES (15) study) ; Canada (Mean HbA1c 7.3 with 51% reaching the 
ADA-target) ; Australia (52% reaching the ADA target (16)) ; Germany (Mean HbA1c 
7.1% and 6.9% in two different studies (17;18)) ;  Italy (Mean Hba1c 7.2% with 52% 
reaching the ADA-target (19)) and Ireland (Mean HbA1c 7.1%) (20). This result may 
be the consequence of the Belgian system, where more complex patients have 
access to a reimbursement system for self monitoring materials and education in 
specialized diabetes centres. Still, also in our population, we recognize clearly the 
deterioration of glycemic control and need for additional hypoglycemic interventions 
with progressing duration of the disease. Indeed, HbA1c levels were worse in the 
insulin treated patients, reflecting increasing complexity of the disease. However, 
when these patients were followed in shared care with a specialized diabetes centre, 
the levels of HbA1c were lower than when the GP took care of the patient without 
help of the specialist, indicating a beneficial effect. This beneficial effect of shared 
care was also noticeable on the other parameters, such as LDL-cholesterol, being 
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lower in patients attending not only GP clinics, but also the specialized diabetes 
clinics in the centres.  
Some study limitations have to be mentioned. First, all primary care physicians 
participated in the study on a voluntary basis, reflecting the performance of a 
selected and motivated cohort of physicians operating in a well-defined area. They 
present other characteristics than the general physician population: more female, 
younger, more group practices, higher computerization level. This selection bias 
could express an overestimation of the global quality of diabetes care in primary care 
and an underestimation of the practice diabetes prevalence. Second, in terms of 
characteristics of the patient population, only a limited number of different races and 
socio-economically deprived subpopulations live in the studied area. As a result, the 
data presented in this paper could again be more favourable compared to data of the 
overall population. A third limitation of practice-based research refers to the reliability 
of medical data gathering. In this large field study some of the data were not double-
checked, e.g. laboratory data were collected from different laboratories and no 
external control was performed on blood pressure measurement. The absence of 
patient registries is an important weakness in the Belgian health care system with 
consequences on the present study. Despite considerable efforts to include as many 
patients with diabetes as possible, control with a laboratory based data monitor 
shows that only about 80% of the patients with diabetes have been included in the 
study again resulting in an underestimation of the diabetes prevalence.  
Our data also reflect the progressive nature of the disease and the clinical inertia in 
intensifying hypoglycemic treatments, as too many uncontrolled patients on OADs 
are not moved to insulin therapy timely. Insulin therapy onset is often feared by 
patients and considered as a landmark event in the personal history, an event that 
patients prefer to postpone as much as possible (21). In addition to the classical 
barriers to initiating insulin in patients with Type 2 Diabetes, initiation of insulin in the 
setting of Belgium is particularly counteracted by the dichotomy between primary 
care and endocrinologists, installed by the reimbursement system, limiting 
reimbursement of diabetes education and self home blood glucose monitoring 
materials to specialized diabetes centres. This skewed reimbursement prevents 
many GPs from timely initiating insulin, in an already insulin-hostile population (22). 
Of interest is the difference in HbA1c levels in insulin-treated patients with main 
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follow-up mainly in primary care and patients primarily followed in specialist diabetes 
centres. In the latter patients, not only the age adjusted HbA1c values were lower. 
Patients also were more at target for other essential metabolic targets like LDL-C and 
for the intake of guardian drugs such as statin therapy. This can be the reflection of a 
greater focus on the single disease of diabetes by the endocrinologists and thus a 
better adherence to guidelines. We believe however that the existence of an 
integrated and structured care, with planned visits, structured programs and the 
presence of staff members including diabetes educators is a crucial contributor to the 
better level of care. Many studies indicate that the introduction of structured care and 
diabetes nurse educators clearly improves the quality of diabetes care and overall 
metabolic control (23-28) 
These questions are particularly important and yet controversial for the diabetes care 
in patients with old age. In our study, more than 40% of the population was older than 
70 years and 14% was even older than 80 years. Elderly people represent a 
heterogeneous subpopulation with a continuum of patients from those in very good 
shape (despite diabetes) to very ill, frail and disabled patients (29) presenting with 
co-morbidity and geriatric syndromes like cognitive impairment, functional disability, 
chronic pain, falls,… Those patients are ideally treated in the primary care because 
of their functional disability. The prevalence of Mild Cognitive Impairment e.g. can be 
estimated at 15% in the general population over 75 years. The prevalence of 
cognitive impairment may be higher in the diabetes population (30) and is associated 
with the severity and duration of hyperglycemia and with hypertension (30-32). This 
finding could be an extra stimulus to sharpen diabetes control (33) but the syndrome 
interferes with therapy compliance (34-36) and thus influences diabetes related 
outcomes. Moreover, elderly patients are particularly sensitive to the adverse effects 
of drugs and polypharmacy like hypoglycemia and falls, putting constraints on the 
classic diabetes treatment. As such, strict adherence to guidelines for younger 
patients could be deleterious for the frail elderly (37) who are in need for specific 
geriatric guidelines (38). As these guidelines accentuate, treatment should be 
holistic, targeting all important aspects of the geriatric patients with priorities in the 
treatment scheme. (39) Thus, diabetes related targets should be individually adapted 
to the frail patients with special attention to avoidance of side effects (33).  Especially 
hypoglycemia is an important topic in the elderly with recent studies (40) clearly 
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indicating that hypoglycemia may be a contributing factor to morbidity and mortality in 
older patients. Therefore the use of new drugs that are able to reduce glycemia 
without hypoglycemia should be considered in these patients (41).  
Globally, our results suggest that patients with Type 2 Diabetes, exposed to shared 
care between GPs and specialized care obtain better results in glycemia, blood 
pressure, lipid and pharmacological treatment targets. International literature often 
compares primary vs. specialized care. Most of the studies show that specialized 
care obtains better results than primary care either for process or for intermediary 
outcome variables without necessarily finding an impact on mortality (42). These 
studies however tend to oppose the two care levels and may compare patient groups 
that are not comparable. Our study shows the complementarities between the two 
care levels which means that the end stage patients necessitating the most complex 
treatment are primarily managed by specialized care in shared care with the GP, 
while the majority of patients are treated at primary care level. However, this study 
also shows that quality of care could be improved in those patients primarily treated 
by the GPs. Structured care is yet lacking in many countries with a majority of single 
handed practices. At present, no guidance is given to the organization of diabetes 
follow-up in primary care. Therefore, it will be of interest to investigate whether a 
better integration of the different care levels and the introduction in the GP setting of 
the more structured, consensus and guideline-based approach present in diabetes 
centres will be able to improve the quality of care for patients with Type 2 Diabetes 
with respect to achieving outcome and process parameters.   
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Table 1. Patient characteristics and quality of care according to the hypoglycemic treatment 
regimen.  
    
Parameter/target All  No 
drugs 
OAD Insulin p 
N 2495  314 1699 482  
Mean age (years) 68 ±12  66±13 68±11 69±12 0.0003 
Mean diabetes duration 
(years) 
7.2±7.0  3.1±4.0 6.1±5.4 13.8±9.1 <0.0001 
Female gender 51%  50% 50% 56% 0.0488 
HbA1c < 7% 54%  76% 56% 33% <0.0001 
SBP ≤ 130 mm Hg 50%  46% 50% 50% NS 
LDL-C < 100 mg/dl 42%  30% 40% 57% <0.0001 
HbA1c (%) 7.1±1.3.  6.8±1.2 7.1±1.2 7.6±1.4 <0.0001 
SBP (mm Hg) 136±16  137±16 136±16 135±16 NS 
DBP (mm Hg) 79±10  81±12 80±10 77±9 <0.0001 
LDL-C (mg/dl) 108 ±34  118±36 109±32 98±36 <0.0001 
BMI 29.6 ±5.3  29.6±4.9 29.5±5.1 30.1±5.9 NS 
Statin 39%  37% 37% 50% <0.0001 
Aspirin/clopidogrel 40%  31% 37% 57% <0.0001 
History of CVD 27%  25% 24% 43% <0.0001 
       
 
Table 2. Patient outcome parameters and CV risk lowering treatments in insulin-treated patients 
by setting of care.  
Parameter/target Insulin GP Insulin-
centre 
p 
N 197 285  
Mean age 73±12 66±12 <0.001 
Mean diabetes duration 13.4±8.6 14.1±9.1 NS 
Female gender 59% 54% NS 
HbA1c < 7% 31% 35% NS 
SBP ≤ 130 mm Hg 49% 50% NS 
LDL-C < 100 mg/dl 43% 67% <0.001 
HbA1c (%) 7.8±1.5 7.5±1.2 0.038 
SBP (mm Hg) 135±16 135±16 NS 
DBP (mm Hg) 77.4±8.5 77.6±8.6 NS 
LDL-C (mg/dl) 111±37 90±34 <0.001 
Statin 33% 66% <0.001 
Aspirin/clopidogrel 51% 60% NS 
History of CVD 40% 45% NS 
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Table 3: Multiple regression analyses of HbA1c, SBP and LDL-C. 
 
 HbA1c (%) 
N=1602 
SBP (mm Hg) 
N= 1622 
LDL (mg/dl) 
N= 1442 
Effect Estimate 
(SE) 
p Estimate 
(SE) 
p Estimate 
(SE) 
p 
Diabetes duration/year 
increase 
0.020 
(0.005) 
<0.0001 −0.04  (0.07 
) 
0.5259 −0.24  (0.6 ) 0.1182 
Insulin-GP vs. OADs 0.740 
(0.117) 
<0.0001 -1.82   (1.60 
) 
0.2557 6.6      (3.7) 0.07 
OADs vs. no drugs 0.204 
(0.092) 
0.02644 −1.31  (1.24 
) 
0.2896 −7.5    (2.7) 0.0059 
Insulin GP vs. Insulin centre −0.445 
(0.139) 
<0.001 2.07 (1.90) 0.2755 21.5 (4.3) <0.0001 
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Figure 1: Association between diabetes duration and hypoglycemic treatment group. 
 
 
 
Legend: Note that with increasing diabetes duration, hypoglycemic treatment becomes more intense. 
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Chapter 2:  Start Improving the Quality of Care for Patients with 
Type 2 Diabetes through a General Practice Support Program: a 
Cluster Randomized Trial.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
G. Goderis, L. Borgermans, R. Grol, C. Van Den Broeke, B. Boland, G. Verbeke, A. 
Carbonez, C. Mathieu, J. Heyrman. Start improving the quality of care for people with 
Type 2 Diabetes through a general practice support program: a cluster randomized 
trial. Diabetes Res.Clin.Pract. 2010;88:56-64. 
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ABSTRACT 
Aims: To evaluate the effectiveness of a two-arm Quality Improvement Program (QIP) in 
support of General Practice with limited tradition in chronic care on Type 2 Diabetes 
patient outcomes.   
Methods: During 18 months, we performed a cluster randomized trial with randomization 
of General Practitioners (GP). The Usual QIP (UQIP: 53 GPs, 918 patients) merged 
standard interventions including evidence-based treatment protocol, annual 
benchmarking, postgraduate education, case-coaching for GPs and patient education.  
The Advanced QIP (AQIP: 67 GPs, 1577 patients) introduced additional interventions 
focusing on intensified follow-up, shared care and patient behavioural changes.  Main 
outcomes were HbA1c, Systolic Blood Pressure (SBP), and Low Density Lipoprotein 
Cholesterol (LDL-C), analyzed by Generalized Estimating Equations and linear mixed 
models. 
Results: In UQIP, endpoints improved significantly after intervention: HbA1c -
0.4%, CI95%[-0.4;-0. 3]; SBP -3 mmHg, CI95%[-4; -1]; LDL-C -13 mg/dl, CI95%[-
15; -11].  In AQIP, there were no significant better improvements in outcomes: 
HbA1c -0.4%, CI95%[-0.4;-0.3]; SBP -4 mmHg, CI95%[-5; -2]; LDL-C -14 mg / dl, 
CI95%[-15; -11]. 
Conclusions: A multifaceted program merging standard interventions in support of 
General Practice induced substantial improvements in the quality of diabetes care. 
Intensified follow-up in AQIP with focus on shared care and patient behaviour changes 
did not yield additional benefit. 
Key words: Type 2 Diabetes Mellitus, Quality of Healthcare, Primary Care, 
Implementation Program 
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Introduction 
Type 2 Diabetes Mellitus (T2DM) leads to severe micro- and macrovascular 
complications, resulting in increased morbidity, but particularly in a two- to six-fold 
increased cardiovascular risk (1;2).  Clinical evidence suggests that aggressive, 
timely, and multi-factorial interventions (3) aimed at controlling risk factors such as 
high blood pressure(4), blood lipids (5;6), and glycemia (7;8) can reduce T2DM 
complications.  General Practice plays a key role in the management of this 
disease, but the field suffers from clinical inertia.  This inertia is characterized by 
insufficient adherence to guidelines aimed at reducing measures of glycemia and 
cardiovascular risk factors to target values (9). Additional barriers to clinical 
improvement are the absence of integrated mechanisms between primary and 
secondary care, and insufficient patient involvement during treatment (10).   
High quality Type 2 Diabetes care is a complex matter.  All over the world, 
Quality Improvement Programs (QIPs) have been used to improve diabetes care 
(11-14).  Many intervention programs do not succeed, or yield only small 
improvements (15-17).  Multifaceted interventions are more likely to exert positive 
effects than single interventions (18). Nevertheless, the variety in QIP design and 
associated outcomes undermines clear conclusions about optimal program 
models, or how intensively the physician and patient population should be 
followed (19).   
Before introducing a nation-wide QIP based on the principles of the Chronic 
Care Model, the Belgian government ordered a cluster randomized trial in the 
primary care setting. The mainly demand driven organization of care in Belgium 
makes the situation comparable to settings in the USA, France, Italy or Canada 
(10).  We compared the effects of “Advanced Quality Improvement Program” 
(AQIP) with “Usual Quality Improvement Program” (UQIP) on measured 
outcomes of care success in T2DM patients.  As they are valuable predictors of 
morbidity and mortality, we chose the following measures of care success: 
glycated hemoglobin (HbA1c), Systolic Blood Pressure (SBP), and LDL-
Cholesterol (LDL-C).  Using a set of standard interventions merged into a 
multifaceted general practice support program, UQIP implemented a treatment 
protocol whereby GPs aimed for evidence-based target values in patients. These 
target values were set according to the standards of the American Diabetes 
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Association (ADA), and are defined as: HbA1c of 7%, SBP of 130 mm Hg, and an 
LDL-C of 100 mg / dl.  On top of UQIP, AQIP implemented a more elaborate and 
cost-intensive program with 3 supplementary focuses: 1) intensified, three-
monthly follow-up of the GPs; 2) active stimulation to share care, and 3) additional 
facilitation of patient behaviour changes, such as lifestyle habits and treatment 
compliance. 
Subjects, Materials and Methods 
Study design 
The Belgian National Institute for Health and Disability Insurance (NIHDI) 
sponsored this project, in an effort to examine the usefulness and feasibility of a 
nation-wide implementation.  To this end, NIHDI stipulated there be recruitment of 
at least 33% of available physicians in the region.  Similar to other complex 
intervention evaluations (20), we organized an open pragmatic before / after 
study, with randomization of General Practices in two intervention arms, AQIP 
and UQIP. Patients were clustered around their General Practitioner.  This cluster 
design was necessary because randomization was performed on a practice level, 
the intervention mainly happened on the physician level, but a large part of the 
data was analyzed at the patient level. Patient data were gathered prospectively 
by volunteer GPs who worked in regions surrounding the University Hospital 
Gasthuisberg in Leuven.  All 336 GPs invited to participate were asked to register 
all their known T2DM patients.  After the initial recruitment phase, a researcher 
blinded to the study design used computer-generated numbers to randomly 
assign GPs. Randomization was stratified by practice size in single working GPs, 
duo practices and group practices with three or more GPs.   
Despite the imposed sample size, we performed a power calculation (21). 
With a significance level of 0.05 and assumed Intra Cluster Coefficient of 0.1, we 
calculated that 114 clusters with a cluster size of 20 gave 80% power to detect 
between AQIP and UQIP a 10% in the absolute difference in the proportion of 
patients achieving a 10% improvement in the primary biochemical endpoints.  
All patients were blinded to the study design, but physicians were not, as they 
were involved in the execution of the programs.  Baseline data were designated 
T0, and collected from January to July 2005.  For the development of data in 
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paper charts, we asked GPs to perform a complete examination, including a blood 
analysis, on the first visit of T0.  Endpoint data were designated T1, and collected 
from May to November 2006.  T2DM diagnosis was defined in accordance with 
the 2003 ADA criteria (22). The project was approved by the local ethics 
committee and registered as # NTR1369, with publication of the study protocol 
(23). 
Interventions with physicians and patients 
The intervention period was January 2005 to November 2006.  As explained in 
the study protocol, GPs of both arms received the same basic support program of 
interventions (UQIP) that was based on the Chronic Care Model and theoretical 
frameworks for change management (see also addendum) (24-26). These 
interventions represent standard requirements for what is considered quality 
diabetes care (27).  The aim of UQIP was to implement the Evidence Based 
guidelines recommending a global, target-driven and intensified treatment of Type 
2 Diabetes. The interventions of UQIP were available for all participating GPs and 
patients. However, UQIP was proposed as a service: GPs and patients of the 
UQIP arm were free to choose their level of participation in all these offered 
services. Physicians received €60 for each included patient and an evidence-
based treatment protocol based on ADA-guidelines and elaborated in consensus 
with local GPs and endocrinologists. According to this protocol, GPs received the 
main responsibility for the follow-up of their patients. The protocol recommended 
regular follow-up of the patients with attention to all important parameters 
(biological risk factors and early signs of complications) and recommended global 
treatment that should be intensified whenever the targets were not reached. 
Targets were set at 7% for HbA1c, 130 mm Hg for SBP and 100 mg/dl for LDL-C. 
UQIP offered two postgraduate educational sessions. The first explained the 
Evidence-based treatment protocol in detail. The second explained the principles 
of insulin treatment of T2DM patients in general practice. All GPs could appeal on 
case-coaching by an endocrinologist by phone or by email if they encountered 
problems to treat their patients. Printed benchmarking feedback on HbA1c, Blood 
Lipids, Blood Pressure, BMI, statin and aspirin prescription was provided at the 
beginning of the study and one year later.  
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At patient level, we facilitated patient education via an Interdisciplinary 
Diabetes Care Team (IDCT) that could be counselled upon referral by the GP.  
This team included a nurse educator, a dietician and a general internist with 
interest in diabetes.  The program focused on disease insight, nutrition, physical 
exercise and medical treatment compliance. Patients with insulin therapy were 
educated how to self-manage insulin therapy.  The educational initiatives were 
free of charge for all included patients. 
  
For the AQIP arm, we introduced additional interventions on top of the UQIP. 
At GP-level, AQIP provided a three-monthly, intensified follow-up, actively 
stimulated patient referral to the educational initiatives and paid special attention 
to patient-centred communication. All GPs of the AQIP arm received a detailed 
Shared Care Protocol defining the responsibilities of all partners combined with 
intensified specific postgraduate education, three-monthly benchmarking and 
three-monthly feedback on each individual included patient. Regular reminders 
actively encouraged GPs to refer all their patients not reaching the targets. Other 
reminders encouraged GPs to collaborate with existing community campaigns on 
smoking cessation and physical activity. For those purposes, all GPs of the AQIP 
arm received 4 extra emails, 2 written letters and 3 extra phone calls.  Two 
supplementary postgraduate sessions and peer discussions on patient-centred 
counselling and management of lifestyle habits explained the principles and 
practice of   the Transtheoretical Model of Change (TTM) (28). Finally, GPs were 
invited by telephone to participate in the joint meetings with IDCT and 
endocrinologists when case discussions concerned one of their patients.    
For patients of the AQIP-arm, the IDCT was moreover reinforced with a health 
psychologist and a diabetes educator who delivered diabetes education at the 
patients’ home.  Referral to the health psychologist was recommended for all 
patients with difficulties to maintain healthy lifestyle habits. The counselling 
techniques included extended motivational interviewing based on the Trans 
Theoretical Model of change. 
Finally, AQIP also offered the possibility of organized group educational 
sessions for patients and family members.  These group sessions were organized 
by the project team and presented by the IDCT in collaboration with the GPs. 
Specifically, we organized the distribution of printed educational brochures, 
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pedometers and Home Blood Glucose Material (HBGM), which are not typically 
reimbursed in Belgium for patients on Oral Antidiabetic Drugs, or followed up 
solely by primary care.  
The preparation and organization of the project were implemented by a team 
that included two senior researchers (one GP and one endocrinologist), two junior 
researchers (one GP and one nurse educator) and one ‘program manager’. The 
program manager played a key role in the implementation of both UQIP and 
AQIP. She managed all logistics needed to implement the aforementioned 
interventions and organized the communication with and between GPs, 
endocrinologists and the IDCT. She particularly paid attention to motivate the 
participating GPs and to answer all their questions related to the project. 
Benchmarking feedback and statistical analyses were performed by a 
professional statistical unit led by a senior researcher in statistics. Both teams 
worked in close collaboration. 
Endpoints and statistical analysis  
Differences in physician characteristics were tested using a t-test for 
continuous and a χ2-test for dichotomous outcomes. Primary endpoints were 
defined as improvements in HbA1c, SBP and LDL-C measures, and secondary 
endpoints were defined as improvements in HDL-C, Total Cholesterol, Diastolic 
Blood Pressure (DBP), weight, smoking status, statin and anti-platelet therapy 
efficacy measures.  Endpoints were analyzed according to the intention-to-treat 
principle.  Means were reported for continuous variables, and proportions were 
reported for dichotomous variables.  To compare patient characteristics between 
AQIP and UQIP, the Generalized Estimating Equations (GEE) approach of Liang 
and Zeger (29) was used, taking into account the clustered nature of data within 
physicians (SAS, version 9).  For binary variables, we used the exponential 
inverse transformation to obtain the 95% confidence interval for the odds ratio.  
Since not all variables were available for all patients, case-wise deletion was 
used. 
Subgroup analyses using linear mixed models with random patient effect 
compared the change of primary endpoints and the initiation of insulin, blood 
pressure lowering, and statin therapies, according to various cut-off values 
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corresponding to international accepted thresholds for control of the disease 
(table 3).  Dichotomous outcomes were analyzed with logistic mixed models.  
Further on, linear mixed models with subject-specific intercepts and slopes tested 
whether subject-specific changes were related to the initial level of the outcomes. 
This complex statistical analysis was performed because it allows for eliminating 
the ‘regression to the mean effect’ in significance testing on the observed 
changes. HbA1c values were transformed logarithmically to meet the parametric 
assumptions of the statistical models.  
Cost estimation 
To calculate the investment cost of services administered in both UQIP and 
AQIP, we gathered detailed data about staff salaries, payments to practices, 
postgraduate education fees, and logistics throughout the study.  
Results  
Physician profile, participant flow, and program participation 
A total of 142 physicians from 90 practices agreed to participate and were 
randomized (Figure 1).  Within the first 30 days, 22 physicians dropped out (UQIP 
= 18, AQIP = 4, p < 0.001).  Thus, only 120 physicians (36% of those available, 
67 AQIP vs. 53 UQIP) registered baseline data.  During the study there was 
negligible drop-out (AQIP = 0 and UQIP = 2, NS).  We observed small differences 
in physicians’ characteristics for age (AQIP 46 vs. UQIP 43 years), the mean 
number of patient contacts (AQIP 97 vs. UQIP 92 per week), the proportion of 
female physicians (AQIP 40% vs. UQIP 51%) and the proportion of physicians 
working in solo practices (AQIP 37% vs. UQIP 40%) and duo practices (AQIP 
36% vs. UQIP 26%). Mean follow-up was 18 months with a range from 12 to 23 
months. 
Physician attendance at common educational meetings was 76% in AQIP and 
70% in UQIP (p = 0.173).  AQIP physicians referred significantly more patients to 
the IDCT than UQIP physicians (AQIP: 223 (14.4%) vs. UQIP: 86 (9.6%), p = 
0.03) with in total 178 (7.1%) referred patients to the dietician, 145 (5.8%) to the 
educator and 108 (4.3%) to the general internist. The proportion of GPs who 
monthly referred to the diabetes educator increased during the project from 5% in 
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the first month (January 2005) to 16% in July 2006.” Patients referred to the IDCT 
showed higher baseline HbA1c values than patients who were not referred 
(7.8±1.6% vs. 7.1±1.2%, p< 0.0001). At the end of the intervention, 596 patients 
(27% of the total population, 26% AQIP and 29% UQIP, p=0.12) did not reach the 
HbA1c target and have not been referred to the IDCT. 
The use of additional interventions in the AQIP-arm was as follows. Physician 
attendance at extra postgraduate sessions specific to AQIP was 49%. The 
‘travelling’ educator was consulted by 40 patients (2.5%) and the health 
psychologist by 18 patients (1.1%).  Seven group educational meetings were 
organized, with 310 participants referred by 14 physicians, 126 patients received 
printed educational brochures, 201 received pedometers and 107 received 
HBGM.    
Patient outcomes 
The study included 2495 patients (AQIP 1577, UQIP 918), representing 80% 
of the patients with diabetes according to a control with a laboratory based data 
monitor. There were no significant differences between baseline patient 
characteristics of the two intervention arms (Table 1) with only about half of 
patients reaching individual outcome targets (Figure 2). In AQIP, the proportion of 
patients achieving a 10% improvement in the value of HbA1c, LDL-C or SBP was 
63%, CI95% [60-66]. As shown in table 2, all three primary endpoints improved 
significantly after the intervention.  HbA1c was reduced 0.4%, CI95%[-0.4;-0.3], 
SBP 4 mmHg, CI95%[-5; -2], LDL-C 14 mg / dl, CI95%[-15; -11]. However, there 
were no significant differences in outcomes between AQIP and UQIP.  In UQIP, 
the proportion of patients achieving a 10% improvement in the value of HbA1c, 
LDL-C or SBP was also 63%, CI95%[59-67]. HbA1c reduced by 0.4%, CI95%[-
0.4;-0. 3], SBP by 3 mmHg, CI95%[-4; -1], LDL-C by 13 mg/dl, CI95%[-15; -11].  
Only anti-platelet therapy use and evidence of physical exercise were significantly 
higher in AQIP (table 2).   
Table 3 shows the change of primary endpoints as well as associated 
treatment changes, according to different baseline values.  Data are presented for 
all patients because no significant differences were found between AQIP and 
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UQIP.  For all three endpoints, patients not in good control at baseline showed 
significant higher change compared to patients that were in control at baseline 
and higher initial values were associated with increased treatment intensification.  
For example, the mean change in HbA1c is -1.6%±1.28% for those patients with 
initial levels >8%. Initiation of insulin therapy in this subgroup amounts to 18% of 
the patients not receiving insulin therapy at baseline.  In patients with initial 
HbA1c-levels between 7% and 8%, the mean change is -0.4% ± 0.80% with 
insulin initiation of 6%. We did not observe any change in the mean HbA1c-level 
of patients who were in control at baseline and insulin was initiated in only 1.5% of 
this subgroup. 
The correlation between the patient-specific intercepts (baseline values) and 
slopes of each primary endpoint was statistically significant (p < 0.001), with the 
following correlation coefficients:  log (HbA1c) = -0.514; SBP = -0.447; LDL-C = -
0.331.  These results show that the changes in outcome were significantly 
associated with their initial values. Thus improvement was more commonly 
observed in the patients with the worst initial conditions. 
Costs 
The annual investment cost of UQIP was €226156 or €164 ($210) per patient.  
Of this cost, 61% was spent on staff salaries, 28% on payment to practices, 10% 
on equipments and logistics, and 1% on postgraduate education.  The annual 
investment cost of the AQIP amounted to €481990 ($616706) or €204 ($261) per 
patient.  Of this cost, 70% was spent to staff salaries, 21% on payment to 
practices, 7% to equipments and logistics and 3% on postgraduate education. 
Discussion 
Previous research has shown that shared care improves both the delivery of 
diabetes care (30) and patient outcomes (31), whereas increased treatment 
adherence, weight loss and regular physical activity have a beneficial effect on 
the control of glycemia, blood pressure and blood lipids (32-34). The present 
study investigated whether improved patient outcomes could be achieved with a 
basic support program (UQIP), and whether intensified support of GPs and 
patients in the AQIP arm paying special attention to shared care, patient 
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compliance and adherence to lifestyle change would further improve outcomes in 
T2DM patients achieved by the UQIP.  
Both programs were implemented in a ‘traditional’ Western European primary 
care setting that is mainly focused on reactive, demand driven care with Fee-for-
Service payment (35). Most GPs work in solo practices or small duo practices 
without additional logistic or nursing staff. Diabetes patient registries, planned 
diabetes consultations and practice quality evaluation are not available in primary 
care. Shared care is loosely organized since GPs cannot rely on structured 
assistance of dieticians or diabetes educators in their practice. Moreover there is 
no formal shared care collaboration between primary and specialist care.  This 
situation is not specific to Belgium. Many other countries like France, Italy, 
Austria, Canada and some settings in the USA face a similar situation. Therefore, 
our results may be applicable to those health care settings. 
The baseline data of this study showed that there is room for improvement in 
the major treatment targets and confirmed the problem of clinical inertia (36).  
After 18 months of intervention, all primary and most secondary endpoints 
improved in both intervention arms. Notable is the enhanced prescription of 
guardian drugs like statin and anti-platelet therapy. Moreover, as table 3 shows, 
intensification of insulin, blood pressure and statin treatment was significantly 
higher in patients who were not in good control at baseline and was associated 
with better improvement of respectively HbA1c, SBP and LDL-C. These findings 
demonstrate the effect of the intervention on adherence to the guidelines 
recommending target-driven and global cardiovascular treatment on top of 
glycemic control (37-39). 
However, additional incentives in AQIP did not result in major improvements 
over UQIP.  We only observed a significant additional impact on two secondary 
endpoints (physical exercise and anti-platelet treatment), with no additional impact 
on primary endpoints.  
One of the interventions to facilitate patient behaviour change was a training 
course on the Trans Theoretical Model of change.  Despite a lack of consistent 
evidence for its efficacy (40-42), the TTM provides a widely accepted framework 
for health care providers to develop lifestyle interventions focused on the stage of 
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readiness to change (43). We hypothesized that the combined action of this 
training with additional patient empowerment tools and intensified patient referral 
to the IDCT could induce substantial changes in patient behaviour, and additional 
improvements in the primary outcomes.  We indeed observed a higher referral 
rate to the IDCT in the AQIP arm compared to the UQIP arm, but we did not 
observe any differences in primary outcome improvements between the two 
intervention arms. Previous research has shown that patient education and 
interdisciplinary diabetes care teams have a positive effect on patient outcomes, 
especially on HbA1c (16;44). These observations are somewhat contradictory to 
our findings. However, the differences in referral rates to the IDCT between UQIP 
and AQIP and the use of additional empowerment tools may not have been large 
enough to induce a significant effect on the primary outcomes. A second possible 
explanation is that the effect of the additional interventions on the primary 
outcomes may have been compensated by other interventions in UQIP 
stimulating the GPs to assure a stricter medical follow-up by own means. This 
hypothesis particularly questions the exact positioning of interdisciplinary diabetes 
care teams as a part of a multifaceted QIP in General Practice. Further detailed 
analysis on the effect of the IDCT referral on patient outcomes is needed to clarify 
this issue and will be reported in a separate article.  
The relative low referral rates of patients to the IDCT (AQIP 14.4% vs. UQIP 
9.6%) are in part the reflection of the treatment protocol that recommended GPs 
to refer patients whenever the treatment targets were not reached despite own 
efforts. GPs adhered at least partly to this recommendation since they mostly 
referred patients with higher HbA1c-levels. However, 27% of the included 
population, not reaching the HbA1c target at the end of the study, should have 
been referred to the IDCT, but were not. In a nested qualitative study, we 
interviewed 20 participating GPs and the results of this study will be separately 
discussed.  When confronted to their referral behaviour, most GPs mentioned that 
some patients refused to be referred to the IDCT while some GPs admitted not 
being convinced about the added value of patient education by educators or 
dieticians. Moreover as shown by the increasing GP referral rates during the 
project, behaviour change takes time as new attitudes must be consolidated into 
routine practice. These findings confirm the difficulties of implementing new and 
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innovative interventions in an existing health care system. Besides, interventions 
that merely focus on GPs are mostly inadequate if not accompanied by 
interventions that focus on patients’ behaviour. Thus, further research is needed 
to define all barriers and facilitators to shared care between patients, GPs and 
diabetes educators in primary care. 
Regarding the beneficial effect of UQIP alone, it is not possible to draw a 
formal conclusion, because a pure randomized control group without any 
intervention was not included in this study.  We deemed it impossible to introduce 
such a control group, because physicians perceived registering data on paper 
charts as an important additional workload, and expected a benefit or at least an 
active support for doing this.  However, the results of our trial are in line with the 
increasing evidence for the efficacy of those ‘standard’ interventions on clinical 
inertia (15;45), that can be considered as standard requirements for high quality 
care (46-48).   
However, in a post-hoc analysis, we compared the change of the primary 
outcomes between a random sample of the intervention population and a 
matched subgroup of patients with T2DM from the «INTEGO» Registry Network 
(IRN).  In this network, we organize a rigorous follow-up of bio-clinical data out of 
56 sentinel practices (80 physicians) spread throughout Belgium (49). It is 
designed to reflect nation-wide trends in General Practice. Matching was 
performed on age, sex, diabetes duration and baseline HbA1c-level. We 
succeeded in matching 587 intervention patients (300 AQIP, 287 UQIP) with 507 
patients of the IRN.  Baseline values of the matched IRN subgroup were not 
statistically different from those of the intervention group for age, female gender, 
diabetes duration, HbA1c, SBP and LDL-C.  Still, compared to the matched IRN 
subgroups, the change in both intervention arms was significantly better for 
HbA1c (UQIP -0.4% vs. IRN -0.1%, p < 0.001) and LDL-C (UQIP -16 mg / dl vs. 
IRN -8 mg / dl, p = 0.021), but not for SBP (UQIP -3 mmHg vs. IRN -3 mm Hg, 
p=0.55). These data indicate that UQIP yield a beneficial effect on two of the 
three primary endpoints.  We also estimated the risk reduction in the combined 
ten-year risk of Coronary Heart Disease (CHD) and stroke.  We introduced the 
values for HbA1c, blood pressure and blood lipids, from both the UQIP arm and 
the matched IRN subgroup in the UKPDS risk engine spreadsheet, a validated 
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risk estimation model (50;51).  The estimated baseline risk was 29.0% (UQIP) 
and 29.8% (IRN). The Relative Risk Reduction in favour of the UQIP was 
estimated at 13% (CI95% [5-20]), the “Number needed to treat” at 26 (CI95% = 
[16-63]). 
There were several weaknesses of the present study.  First, important efforts 
were required to motivate GPs for the project, resulting in a global enhancement 
of diabetes awareness throughout the region.  Secondly, despite the motivation of 
the GPs, we observed a significant difference in initial drop-out rate between the 
UQIP and AQIP-assigned GPs, which may indicate that being assigned to AQIP 
motivated more physicians to pay closer attention to T2DM care.  However, 
probably the most motivated GPs remained in the UQIP arm, with possible effects 
on the final outcomes.  Thirdly, some of the additional, interventions of the AQIP 
arm were only used by a small number of participants. This is particularly true for 
the health psychologist counselling, which was only used by 18 patients. 
In conclusion, UQIP positively motivated a large cohort of GPs to take a 
central responsibility in diabetes care and compiled a basic set of interventions in 
support of General Practice: the offer of a clear treatment protocol supported by 
tailored postgraduate education for GPs, case-coaching by an endocrinologist, 
annual benchmarking feedback and the opportunity of referring patients for 
diabetes education free of charge.  These five basic interventions, merged to a 
multifaceted program substantially improved overall quality of care and the major 
diabetes related patient outcomes. The average investment costs of UQIP 
amounted to €164 ($210) per patient, a rather modest amount compared to the 
total annual diabetes-related medical costs estimated at €1207 (52). Additional 
interventions in three areas - a more intense, three monthly follow-up of GPs, 
actively stimulated shared with an interdisciplinary diabetes care team care and 
additional facilitation of patient behaviour changes - did not add substantial 
benefit, despite an incremental annual cost of €40 per patient.  
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Table 1.  Patient data at baseline (T0)  
 AQIP 
N=1577 
UQIP 
N=918 
 
 Mean ± SD 
% [CI95%] 
Mean ± SD 
% [CI95%] 
p* 
Age (yrs) 68 ± 12 68 ± 12 0.536 
Diabetes duration (yrs) 7.2 ± 6.9 7.2 ± 7.3 0.929 
% female 51% [51-57] 53% [49-58] 0.443 
HbA1c (%) 7.1 ± 1.3 7.2 ± 1.3 0.7803 
SBP (mm Hg) 136 ± 15 137 ± 18 0.3622 
DBP (mm Hg) 80 ± 9 80 ± 9 0.8135 
T-C   (mg / dl) 191 ± 40 194 ± 41 0.1151 
LDL-C (mg / dl) 107 ± 33 111 ± 34 0.0648 
HDL-C (mg / dl) 54 ± 16 53 ± 15 0.5936 
BMI (kg / m2) 29·6 ± 5.2 29·6 ± 5.3 0.9515 
Smoking (%) 14 [11-16] 16 [13-20] 0.1828 
Regular Exercise (%)† 53 [48-57] 53  [47-58] 0.9835 
Aspirin / Clopidogrel (%) 41 [37-45] 36 [31-41] 0.1335 
Statin treatment (%) 41 [37-45] 38 [33-42] 0.2361 
 
UQIP= Usual Quality Improvement Program (53 physicians, 32 practices, 918 patients) 
AQIP = Advanced Quality Improvement Program (67 physicians, 42 practices, 1577 patients) 
*
 p < 0.05 for the baseline difference between the  UQIP and AQIP, tested with a GEE model.  Effects 
were adjusted for the clustering of patients within practices. 
†Regular Physical Exercise: light to moderate exercise adapted to the patient’s situation (e.g. walking, 
exercises at home) for least 3 times a week during 20 minutes. 
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Table 2.  Changes in clinical and biochemical parameters by end of study in UQIP and AQIP 
arms (T1) 
 AQIP 
N=1577 
 UQIP 
N=918 
 
Continuous 
outcomes 
Mean ∆ 
CI95%  
 Mean  ∆* 
CI95% 
p‡ 
HbA1c (%) -0.4 [-0.4;-0.3]  -0.4 [-0.4;-0.3] 0.660 
SBP (mm Hg) -4 [-5;-3]  -3 [-4;-1] 0.060 
DBP (mm Hg) -2 [-3;-2]  -2 [-3;-1] 0.718 
T-C   (mg / dl) -17 [-19;-15]  -14 [-17;-12] 0.204 
LDL-C (mg / dl) -14 [-15;-12]  -13 [-15;-11] 0.634 
HDL-C (mg / dl) +1 [0;2]  +1 [1;2] 0.254 
BMI (kg / m²) -0·4 [-0.5;-0.3]   -0.4 [-0.6;-0.3] 0.792 
 
Dichotomous 
outcomes 
∆  
(T1-T0) 
OR* 
[T1/T0] CI95% 
OR [T1/10] 
 ∆* OR* 
[T1/T0] CI95% 
OR [T1/10] 
p‡ 
Smoking (%) -2 0.85 [0.76; 0.97]  -4 0.69 [0.60;0.80] 0.051 
Physical Exercise (%) +8 1.46 [1.31; 1.63]  +1 1.08 [0.94; 1.24] 0.001 
Anti-platelet therapy 
(%) 
+21 2.32 [2.08; 2.59]  +12 1.64 [1.42; 1.89] <0.001 
Statin treatment (%) +14 1.80 [1.63; 1.99]  +11 1.61 [1.41; 1.83] 0.168 
 
*∆ = change in outcome after program intervention (T1-T0); evolution of proportions is shown as the 
absolute difference 
†
 OR = the odds ratio for obtaining vs. not obtaining the target before and after the intervention 
‡
 Significance level of p < 0.05 for outcome changes in CI vs. AQIP, determined by GEE model. The 
effects were adjusted for the clustering of patients within practices.  
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Table 3.  Improvement of HbA1c, SBP and LDL-C and therapy intensification 
* RC = relative chance of therapy change compared to the patient group reaching the ADA-target 
† for insulin: number of patients with insulin initiation divided by total patients without baseline insulin 
therapy 
‡ for BP lowering drugs:  number of patients with prescription of at least 1 new drug during the 
intervention divided by total  patients 
§ for statins: number of patients with statin initiation divided by total patients without baseline statin 
therapy 
║ significance level of p < 0.05, determined with logistic mixed models for the Relative Chance on 
changes in drug therapy, compared to the subgroup of patients at target.  
∏Significance level of p<0.05, determined with linear mixed models for change in HbA1c, SBP and 
LDL-C of various subgroups out of control compared to the subgroup that is at baseline in control. 
  
Range of initial 
values 
N Mean 
Baseline 
Value ± 
SD 
Mean  
change ± SD 
p∏ Therapy changes during 
intervention 
Proportion†‡§  RC* p║ 
HbA1c (%)      Initiation of insulin† 
< 7 1324 6.32 ± 0.4 0.0 ± 0.57 0.4027 1.5%  1  
7%-7.9 655 7.37 ± 
0.28 -0.4 ± 0.80 
<0.0001 6%  3.6 < 
0.0001 
≥ 8 464 9.17 ± 
1.30 -1.6 ± 1.28 
<0.0001 18%  10.9 < 
0.0001 
SBP (mm Hg)     BP lowering drug change‡ 
 ≤ 130 1230 124 ± 7 0.4 ± 12 0.1396 19%  1  
131 – 140   599 138 ± 3 -4 ± 13 <0.0001 22%  1.2 0.1061 
141 -160  509 152 ± 6 
-12 ± 15 
<0.0001 29%  1.5 < 
0.0001 
 > 160 146 175 ± 13 
-28 ± 19 
<0.0001 34%  1.8 < 
0.0001 
LDL-C (mg / dl)     Initiation of statins§ 
 < 100 900 78 ± 16 1 ± 25 0.9670 21%  1  
100 – 114 404 107 ± 4 -9 ± 24 0.0006 23%  1.1 0.5182 
115 -129 324 122 ± 4 -15 ± 28 <0.0001 25%  1.2 0.2209 
 ≥ 130  532 153 ± 21 
-49 ± 37 
<0.0001 40%  1.9 < 
0.0001 
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Figure 1.  Enrolment of physicians and patients in the study 
 
Assessed for eligibility (336 Primary care physicians) 
Randomized (142 physicians) 
90 practices 
 
Allocated to AQIP 
- 44 practices 
- 71 physicians 
 
Allocated to UQIP 
- 46 practices 
- 71 physicians 
 
Excluded : 194 physicians 
Reasons : refusal, too late for inscription 
 
Proceed to baseline registration & 
received Advanced Program 
42 practices, 67 physicians,  
1577 patients, median practice size 24 
Proceed to baseline registration & 
received Usual Program 
34 practices, 53 physicians,  
918 patients, median practice size 15 
Initial  drop out (4 
physicians) 
Reason : lack of time 
Initial drop out (18 
physicians) 
Reasons : lack of time, 
retired, maternity leave, 
moved out 
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Lost to follow up  
2  practices with 29 patients 
82 patients without practice loss 
Total patient loss: 111 
 
Reason for practice loss: 
lack of time, no electronic 
documents of patients, 
registration papers lost 
when moving to another 
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Figure 2.  Proportion of patients on target at T0 and T1  
  
Legend: Targets derived from the ADA guidelines: HbA1c < 7%; SBP ≤ 130 mm Hg; LDL-C < 100 
mg/dl. 
AQIP = Advanced Quality Improvement Program (67 GPs, 1577 patients);  UQIP = Usual Quality 
Improvement Program (53 GPs, 918 patients) ; T0 = baseline ; T1 = post intervention 
CI 95%  AQIP T0 HbA1c [54-57] ; SBP [49-52] ; LDL-C [41-43] ; T1 HbA1c [67-69] ; SBP [59-61] ; 
LDL-C [59-62] 
CI95%   UQIP T0 HbA1c [52-56] ; SBP [46-49] ; LDL-C [39-43] ; T1 HbA1c [64-67] ; SBP [52-55] ; 
LDL-C [53-57] 
p = significance level for the difference in change in AQIP vs. UQIP, determined by GEE.  Effects were 
adjusted for the clustering of patients within practices.  
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Addendum. Specific strategies to implement the LDP Quality Improvement Program, divided according to the analysed barriers and the level of action. 
Level Barrier Intervention 
Program Insufficient knowledge of the barriers and facilitators to quality 
improvement 
- Initial barrier analyses (stakeholders/GPs) 
- Analysis of the social and local context 
Guidelines  Too complex and not adapted to General Practice - Clear, scientific and attractive treatment protocol 
- Involvement of opinion leaders in the outline of the protocol 
- Involvement of the target audience (GPs) in the outline of the protocol 
GP-practice Routine in follow-up - Diabetes registries to picture the diabetes population 
- Clear protocol with follow-up schemes and reminders to follow the protocol 
- Reminders to change practice organization 
- Task arrangements and shared care protocol 
- Offer of multidisciplinary diabetes consultations in practice 
Lack of Time to accomplish EBM management - Task redistribution (IDCT) 
- Logistic support 
- Appeal to make changes in practice organization  
Lack of a protocol-based, standardized follow-up of type  
diabetes patients 
- Follow-up scheme 
- Reminders to register and thus to assure follow-up 
Lack of familiarity with shared care involvement - Shared care protocol 
- Reminders to actively encourage referral to IDCT 
Insufficient ‘reflexes’ to share care with other disciplines 
(‘colloque singulier’) 
- Shared care protocol 
- Reminders to share care 
Fear of government interference, control and sanctioning policy - Professional implementation program led by a multidisciplinary team 
- Special attention to careful communication 
- Phasing of the program according to the motivational stage of the GPs 
- Use of GPs with  moral authority (responsible of local professional organizations) 
- Revaluation of the GP role and positive motivation to participate 
- Reassurance on positive intentions (no control) 
Suboptimal organization: absence of logistic support (solo 
practices), absence of organized consults with an appointment 
system, absence of practice diabetes registries 
- Appeals to reorganize diabetes care at practice level 
- Creation of diabetes registries 
- Logistic  support at regional level 
Inadequate knowledge about treatment targets,  global 
treatment beyond glycemic control, insulin onset, motivational 
communication techniques and possibilities for shared care 
- CME on EBM, insulin,  communication and shared care 
Lack of ‘self knowledge’ by lack of data feedback - Benchmarking feedback 
Skepticism about the added value of unwell  known 
innovations (health psychologist, internal  medical doctor) 
- Extra reminders to stress the use of these disciplines 
Clinical inertia in diabetes treatment (glycemic and blood 
pressure control) 
- Emphasis on target driven treatment 
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Patient Lack of disease insight (‘a little touch of sugar ; no symptoms’) - Creation of IDCT 
- Group educational meetings 
- Structured written educational materials 
- Communication training for GPs 
- Patient centered feedback 
Fear of insulin therapy (‘end stage of the disease’ vs. no 
symptoms; injections ; weight gain, side effects) 
- IDCT with internal doctor and educator 
- GP education on insulin 
- Coherence in messages 
Lack of motivation to change lifestyle - Educator/dietary advisor for free 
- Communication training for GPs 
- Collaboration with community campaigns 
Problems with medical therapy compliance - Communication training for GPs 
- Shared Care 
- Patient centered feedback 
Insufficient involvement in its own treatment - Educator/dietary advisor for free 
- Communication training for GPs 
Objective age and morbidity related problems, difficulties to 
leave home 
- Educators at patients home 
Social context Competition with specialist care (“who’s in charge of Type 2 
Diabetes treatment?’) 
- Clear task arrangements (integrated care principles) 
o On patient related aspects (e.g. referral) 
o On coaching and communication 
- Facilitation of communication between GPs and specialists 
regional 
organization 
Absence of high skilled diabetes educators in the primary care - IDCT with trained educator 
Absence of a clear task description between GPs, specialists 
and paramedical disciplines (nurses, dietary advisors) 
- Shared care protocol 
Absence of the definition of one central responsible for the 
management of Type 2 Diabetes 
- Clear responsibilities for all involved disciplines 
- GP = central ‘patient manager’ 
Absence of specific diabetes teams supporting general 
practitioners 
- Creation of IDCT 
Absence of regional diabetes registries and quality monitoring 
systems 
- Creation of regional database register 
Absence of logistic support at regional level inducing the 
absence of organized communication between disciplines, 
absence of organized education programs, monitoring 
systems, quality evaluation. 
- Necessary role of the central ‘program manager’ or ‘promotor’ 
health care 
system 
Inadequate payment of providers (fee for service) - A fixed fee for each included patient 
health care 
system 
Important financial barriers for patient concerning auto test 
material and reimbursement of dietary advice and some insulin 
treatments 
- Educator/dietary advisor for free 
- Test material for free if insulin therapy 
 
93 
 
Chapter 3: The 2002 – 2007 Evolution of the Quality of Care 
for People with Type 2 Diabetes Receiving Glucose 
Lowering Medication: a Registry Based Study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Translated from the report for to the National Institute for Health and Disability Insurance 
(NIHDI, RIZIV): “De evolutie in de kwaliteit van zorg voor Type 2 Diabetespatiënten in de 
regio Leuven tussen 2002 en 2007.” Geert Goderis, Carine Van Den Broeke, Liesbeth 
Borgermans, Jan Heyrman, Anna Ivanova, An Carbonez Geert Verbeke, December 2009. 
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Background 
The use of insurance claims data to assess the evolution of disease related 
outcomes provides certain advantages in the evaluation of the quality of chronic 
diseases. It enables the possibility to evaluate a long period of follow-up since most 
data are stocked for at least five years. It is relatively cheap because it makes use of 
existing data and it assesses ‘real life’ situations without experimental interference. 
As such registry based studies have several advantages compared to experimental 
designs, like cross sectional or longitudinal studies of specific selected cohort of 
patients. Cohort studies with a selected study population need to be recruited and 
thus those trials always contain the risk to interfere with the spontaneous behaviour 
of professionals and patients. Moreover, they are always limited in the number of 
observed persons. However, claims data mostly only contain consumer data, i.e. 
data that refer to the use of certain medical services. Most of these data do contain 
neither disease diagnoses nor outcome data. As such, these data could only be used 
in the follow-up of certain process parameters, e.g. the frequency of HbA1c 
measurement. Yet, in the case of (Type 2) diabetes, two of the most important 
outcome parameters (HbA1c and LDL-C) are laboratory measurements stocked in 
laboratory databases. Moreover, we were particularly interested in the regional 
impact of a Quality Improvement Program that took place between 1/1/2005 and 
30/11/2006. In this project, 120 out of 336 active General Practitioners (GPs) in the 
region of Leuven (Belgium) volunteered to include 2495 Type 2 patients for 18 
months of follow-up. The program was associated with a siginificant improvement 
over time of HbA1c (from 7.1%±1.3% to 6.7%±1.0%), Total Cholesterol, LDL-C (from 
108mg/dl ± 34 mg/dl to) and HDL-C.  
The use of insurance claims data combined with laboratory data allows for 
interpreting the obtained results within a larger timeframe and within a regional 
context. It could also enable a comparison between the changes in the 
aforementioned parameters of patients clustered around GPs who were involved in 
the project versus the change in those clustered around GPs who were not involved 
in the project.  
The primary objective of this study was to evaluate the 5-year evolution of 
outcome and process parameters in the care for persons living in the region of 
Leuven before the start of the project (1/1/2005) and who have been treated by 
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glucose lowering medication since at least 2002. The primary outcome measure was 
the change in HbA1c and cholesterol values (Total cholesterol and LDL-cholesterol). 
The secondary outcome measure was the change in several process parameters 
such as the annual frequency of HbA1c measurement, total cholesterol 
measurement, fundoscopy (eye examination), microalbuminuria measurement and 
flu vaccination and the change in the proportion of patients on insulin and statin 
therapy. Additionally, we wanted to evaluate whether the change in those parameters 
in patients clustered around the ‘participating GPs’ was significantly different from the 
change in parameters of patients clustered around GPs who were not indicated as 
participating GPs.  
Methods 
Selection of the research population  
In Belgium each act or service from a health care professional towards a patient 
receives a different code.  A consult with a GP receives a specific code, a consult 
with a specialist receives another code, the laboratory test to determine the HbA1c 
level again another code, and the delivery of a specific drugs another one, and so on. 
Many hundreds or even thousands of codes exist and all these codes serve to 
reimburse the patients when they have paid for that act or to directly pay the health 
professional. The payment or reimbursement institute is the National Institute for 
Health and Disability Insurance, but the payment itself is done through specific health 
assurance companies, called ‘mutualiteiten’. These companies also collect and stock 
all those data (codes) and associated costs. Each person living in Belgium has a 
unique code, called the “INSZ”-code. The health care companies have the right to 
stock personal data with this code as identification key. As such, those data can 
serve to evaluate the health care consumption and related costs. However, the data 
are collected and stocked by 7 different companies. One agency, the ‘Inter 
Mutualistic Agency’ (IMA) serves as an interface between those companies to merge 
those different databases. In our case, the IMA served as an interface between our 
research group and the health insurance companies. The project has received 
written approval by the national privacy committee in May 2008. This approval 
elaborated a legal framework that enabled the analysis of the combined insurance 
claims data and laboratory data with respect to the privacy rules and without the 
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need of individual informed patient consent. All data had to be double coded implying 
the intervention of a Trusted Third Party (IBM).  
We were interested in consumer data concerning Type 2 Diabetes patients in 
the region surrounding the University Hospital of Leuven (and associated 
researchers were interested in the same data of patients living in the regions Aalst 
and St. Niklaas). Since the databases did not contain data about diagnoses, the 
selection of the diabetic population needed to be done by a two step selection 
procedure. First we selected a ‘too large sample’ using indirect “large selection 
criteria” that possibly could indicate the presence of Type 2 Diabetes (see table 1). 
Patients in this database could be labelled as “potential Type 2 Diabetes patients”. 
We asked the IMA to order data between 1/1/2002 and 01/01/2007 of all patients of 
the region Leuven who fulfilled these criteria. These data were delivered by the IMA 
in four different databases and are called “consumer data”, “population data”, 
“medication data” and “insurance costs”. More specifically, we asked the IMA to 
collect detailed data about the following parameters: year of birth, gender, year and 
month of death, contacts with GPs and other professionals (+ date of contacts), 
medication (glucose lowering, blood pressure lowering and lipid lowering medication, 
anti-platelet therapy and flu vaccination), hospital admissions, laboratory and 
technical acts (e.g. HbA1c measurement, eye examination).We also ordered to 
deliver the costs of each act. In the meanwhile, we asked all laboratories in the 
region to deliver data on patients with HbA1c tests during 2002 and 2006.  
Laboratories were asked to select patients (with INSZ codes) meeting following 
criteria: all patients older than 35 years at 1/1/2002, with at least 1 HbA1c-
measurement between 1/1/2002 and 01/01/2007 and living in the indicated regions 
(Leuven, Aalst, St.Niklaas). We asked laboratory to deliver following data (+ date of 
measurement): glycemia, Hba1c, total cholesterol, HDL-cholesterol, LDL-cholesterol, 
Triglycerides, serum creatinine, Microalbuminuria. There were 14 involved 
laboratories with 7 of them delivering data for the region of Leuven.  
Besides the data issue from the IMA and the laboratories, we were allowed to bring 
in ‘local data’ from the Leuven Diabetes Project. We brought several patients in who 
were coded as ‘participating patients’.  
All these data issue from three different sources were linked to one “merged 
database” through a process of double coding. In order to respect the privacy rules, 
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we had to use a complex methodology with coding of all data issue from the health 
insurance companies, the laboratories and the local database. Each patient in the 
databases of the health insurance companies was presented by a D-code, by a B-
code in the local database and by a C-code in the laboratory databases. In each 
database, the codes were linked with the INSZ number in so-called concordance 
tables. The health insurance companies sent all their data to the IMA who merged all 
databases in one “IMA database”. The IMA data, the local data and the laboratory 
data were sent to the data manager. The concordance tables were sent to IBM who 
served as ‘Trusted Third Party’. IBM changed the D-code into an E-code and 
ensured the concordance with the B-code and the C-code. Then IBM sent the unique 
concordance table containing the E-code linked to the B-code and C-code to the data 
manager who could now link the databases and merge the data by patients. As such, 
the “merged database” contained an enormous amount of consumer and laboratory 
data of ‘potential Type 2 Diabetes patients’ living in the region of Leuven, Aalst and 
St. Niklaas. In the region of Leuven, several patients were ‘tagged’ and thus could be 
identified as patients who really participated to the original LDP Quality Improvement 
Program. Unfortunately, it was not possible to bring in all participating patients 
because not all INSZ-codes could be collected. The flow chart that shows the data 
collection, coding and merging of the data is shown in figure 1.  
In a next step, we ‘tagged’ those GPs who participated to the LDP project. In 
Belgium, general practices do not have patient registries as patients have free 
access to medical services. However, each patient can choose a ‘preferred GP’ 
(code 102771) on a voluntary basis. Most of the diabetes patients do have a 
preferred GP because the NIHDI wants to stimulate patients to choose one preferred 
GP. It is also compulsory for diabetes patients to choose a preferred GP in order to 
have certain limited advantages as a certain access to reimbursement of dietary 
advice. We used this code to indicate the participating GPs as those GPs 
characterized by clusters of tagged participating patients in the merged database. In 
a next step, we used “refined inclusion criteria” to select a subset of “highly probable 
Type 2 Diabetes patients” out of the merged database. This was a necessary step 
because the merged database also contained type 1 diabetes patients and non 
diabetic patients taking metformin. Again, we had to use indirect criteria without 
possibility to control whether we really excluded non Type 2 Diabetes patients 
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without excluding Type 2 Diabetes patient. All selected patients had to meet the 
following inclusion criterion: to have received at least once a glucose lowering 
medication between 2002 and 2006. Were excluded from selection, those patients 
(1) who were coded as Type 1 Diabetes patients (this is a code in the diabetes 
convention 786 that only exists since 2006), (2) patients who were coded as adhering 
to a diabetes clinic and receiving 3 daily insulin injections or more, (3) patients who 
only take metformin and who did not have 2 succeeding HbA1c measurements within 
a timeframe of 1 year. We excluded patients with complex insulin schemes (≥ 3 daily 
insulin injections) because we assumed that most type 1 diabetes patients receive 
those more complex.  We excluded patients with only metformin and without two 
consecutive HbA1c measurements within 1 year in an attempt to exclude non 
diabetic patients taking metformin.  
The final step was to select the definitive research sample. We wanted to select a 
‘stable’ cohort of diabetes patients known since 2002. Therefore, to be included in 
the research sample, patients had to take glucose lowering drugs since 2002. No 
additional influx of new patients after 2002 was allowed. All patients also had to live 
in the region of Leuven before the start of the LDP project (1/1/2005). Furthermore 
patients who were clustered by a “preferred GP code” to a participating GP were 
indicated as ‘participating patients’. The ‘PICO’ design is shown in table 2. The 
scheme of the trial from research question to sample selection is shown in figure 2. 
Statistical analysis 
The change in patient outcomes between 01/01/2002 and 01/01/2007 was analyzed 
using a mixed model with broken line technique and with 01/01/05, the day LDP 
started as cut-off date. This technique allows for different evolutions before the start 
of the intervention (01/01/2002-01/01/2005) and after the start of the intervention 
(01/01/20005-01/01/2007). HbA1c, Total Cholesterol and LDL-Cholesterol were set 
as response variables but were log transformed because of the skewness. The time 
variable was split up in two variables (‘Time1’, before the start of the intervention and 
‘Time2’ after the start of the intervention). Time, the group variable (‘LDP’ vs. ‘non 
LDP’) and the interaction between the group variable and the time variables were set 
as fixed effects. The ‘LDP’ group included those patients clustered with a preferred 
GP code to a GP who participated to the project. The ‘Non LDP’ group included 
patients clustered with a preferred GP code to another GP.  Since all outcomes were 
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clustered within the patients, the patient was set as random effect. The change in 
parameters between the LDP and non-LDP group were compared before the start of 
the intervention and again after the start of the intervention. Additionally, within both 
groups, the real change after the start of the intervention was compared with the 
predicted evolution, i.e. the evolution of the parameter when the evolution before the 
start of the intervention was extrapolated until 31/12/2006.  Between group-analyses 
of discrete variables were performed using Mantel-Haenzel Chi-Square tests. 
Results 
As shown in table 3, the merged database contained data on 41547 “potential Type 2 
Diabetes patients” from whom 26 255 were living in the region of Leuven. After 
applying the refined selection criteria, we obtained a database with 8388 “probable 
Type 2 Diabetes patients receiving glucose lowering medication.” 4595 patients 
already lived in the region of Leuven before the start of the project and have received 
glucose lowering medication at least since 2002. 1569 of them were clustered around 
GPs who participated to the LDP project and were named ‘LDP-group’; 3026 patients 
were clustered around other GPs and were named ‘non-LDP-group’. Mean age in 
both groups was 71±11 years with 53% female patients, again in both groups. The 
results of the outcome parameters as presented in table 4 are not derived from 
descriptive statistics but are provided by the mixed model. The HbA1c-change was 
similar in both groups. Before the start of the LDP-intervention, we observed an 
increase from 6.9% to 7.1% at 1/1/2005 followed by a decrease after the intervention 
with a value of 6.8% at 1/1/2007.  This decrease was significantly different from the 
predicted change in both groups. Interestingly, both total cholesterol and LDL-C 
values decreased between 2002 and 2005 both in the LDP (-20 mg/dl) and non-LDP 
group (-19 mg/dl). Total cholesterol values decreased from 208 mg/dl at 1/1/02 in the 
LDP group to 188 mg/dl at 1/1/2005 (-20 mg/dl) and from 205 mg/dl at 1/1/02 to 186 
mg/dl at 1/1/05 in the non LDP group (-19 mg/dl). We observed a similar decrease in 
LDL-Cholesterol values with a decrease of 21 mg/dl in the LDP group and 20 mg/dl 
in the non LDP group. After the start of the intervention, lipid values decreased even 
more rapidly in both groups. The real change in respectively the Total Cholesterol 
and LDL-C was significantly different from the predicted evolution both in the LDP 
group (-22 mg/dl and – 20 mg/dl vs. -12 mg/dl and -13 mg/dl) and in the non-LDP 
group (-18 mg/dl and -16mg/dl vs. -12 m/dl and -11 mg/dl). The change in lipid values 
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before the start of the intervention was not significantly different between both 
groups. However, after the start of the intervention, both Total Cholesterol and LDL-C 
decreased significantly more in the LDP group vs. non LDP-group (Total cholesterol: 
- 22 mg/dl vs. – 18 mg/dl, p=0.0034; LDL-C – 20 mg/dl vs. -16 mg/dl, p=0.0314). As 
shown in figure 3, the proportion of patients reaching a HbA1c target of 7% 
decreased both in the LDP and non LDP group from 2002 (57% vs. 55%) to 2004 
(47% vs. 49%) and afterwards increased in 2005 (50% vs. 50%) and 2006 (54% vs. 
54%). The proportion of patients reaching a LDL-C target of 100 mg/dl increased in 
both groups from 25% (LDP) and 28% (non LDP) in 2002 to 57% (LDP) and 58% 
(non LDP). The most important increase in both groups was observed in the two 
years after 2004 (+ 25% in the LDP group and + 24% in the non LDP group). 
Analysis of process measures like the annual eye examination, annual micro-
albuminuria measurement, HbA1c and Cholesterol measurement showed several 
points of interest (figure 4 and 5). First, the proportion of patients with an annual 
micro-albuminuria screening and at least 1 Hba1c measurement has been 
significantly higher in the LDP group vs. non LDP group since 2002.  Second, the 
annual follow-up of HbA1c and cholesterol has been satisfactory (> 75%) in both 
groups since 2002. However, less than half of the patients receive an annual eye 
examination and less than 25% of the patients received an annual micro-albuminuria 
screening. Third, all process parameters improved in the LDP group after 2004 
(especially in 2005), but not or almost not in the non LDP group. As such, the 
proportion of patients with an annual eye examination became significantly higher in 
the LDP group in 2005  (p=0.0009) and the difference in the proportion of patients 
with at least 1 annual cholesterol measurement became significant in 2005 (LDP 
89% vs. Non LDP 79%, p<0.0001) and 2006 (LDP 88% vs. non LDP 79%, 
p<0.0001). The difference in the proportion of patients with at least one annual 
HbA1c measurement was also maximal in 2005 (LDP 91% vs. non LDP 80%, 
p<0.0001).  Finally, significantly more patients of the LDP group received statin 
therapy in 2005 (48% vs. 44%, p=0.0068) and 2006 (53% vs. 49%, p=0.0126) and 
insulin therapy in 2006 (29% vs. 26%, p=0.0134). 
  
  
102 
 
Discussion 
The present study describes the five year (2002-2007) evolution of HbA1c and 
cholesterol values of patients who have received glucose lowering medication at 
least since 2002 and who already lived in the region of Leuven before 1/1/2005.  The 
primary outcome measure was the change in HbA1c and LDL-cholesterol. The 
secondary outcome measure was the change in process parameters such as the 
annual frequency of HbA1c measurement, total cholesterol measurement, eye 
examination, microalbuminuria measurement and the change in the proportion of 
patients on insulin and statin therapy. The region of Leuven was the setting of a 
Quality Improvement Program (LDP) between 1/1/2005 and 30/11/2006. We have 
evaluated whether the change in HbA1c and cholesterol values in patients clustered 
around participating GPs in the LDP project was significantly different from the 
change in HbA1c and cholesterol values in patients clustered around GPs who were 
not indicated as participating GPs. We merged consumer data originated out of 
databases from health insurance companies with data issued from laboratory 
registries. This methodology was prone to several problems and possible biases. The 
process of data collection, coding and merging of databases, defining selection 
criteria and selecting the research sample nearly took one year. The problems, 
limitations and potential biases that we have encountered in this project are too 
numerous to mention all of them in this chapter. They are described in detail in the 
available NIHDI reports. Globally we can state that the results of this study have to 
be interpreted with a lot of care. In our opinion, the results cannot be generalized to 
the “diabetic population” in Belgium. Interpretation of the results must stick to those 
patients who are selected in the research sample. The main problem was that the 
diagnosis (of Type 2 Diabetes) was not present in the database. We had to select a 
subgroup of probable Type 2 Diabetes patients, those on glucose lowering drugs with 
some additional criteria to exclude probable Type 1 Diabetes patients and patients 
taking metformin without suffering from diabetes. We assumed that most type 1 
diabetes patients receive more complex insulin schemes (≥ 3 daily insulin injections) 
and thus, by excluding the group of intensively treated patients, we think we have 
excluded the majority of type 1 diabetes patients.  We are aware that we also 
excluded a number of intensively treated Type 2 Diabetes patients. We judged this 
loss acceptable because those patients are nearly exclusively treated in the diabetes 
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clinics and are supposed to have less benefit from the Quality Improvement Program 
(see chapter 1). We also lost all Type 2 Diabetes patients who did not take any 
glucose lowering medication, an estimated loss of 13% of all Type 2 Diabetes 
patients.  On the other hand, we cannot exclude that non diabetic patients taking 
metformin are really excluded from the research sample. Further on, we had to 
identify GPs who participated in the LDP in an indirect way by a process of clustering 
‘tagged LDP-patients’ patients. We succeeded this procedure but because of privacy 
matters, we could not control if the ‘participating GPs’ were really those who 
participated in the LDP. In a further stage, we had to find a method to cluster patients 
around the ‘tagged’ LDP GPs’.  Therefore, we used the code of ‘preferred GP’. 
However, as a consequence of this procedure, we could only select a group of 
patients who were clustered around GPs supposed to have participated in the 
original LDP project. We could not verify whether all these patients really were 
involved in the original LDP project. Moreover, not all patients who participated in the 
original project have a preferred GP and those patients were lost in this study. 
Another limitation of the study is due to the nature of the laboratory data. Data were 
collected from 9 different laboratories and some laboratories changed from machine 
or technique during this period.  Analysis may have been biased because new 
methods are likely to measure somewhat lower. It is however impossible to quantify 
this bias. 
Because of all these uncertainties and possible biases, we decided that the 
first objective of this study should be the  description of the 5-year evolution of the 
care for persons treated by glucose lowering medication in a region that was the 
setting of a Quality Improvement Program (LDP) for the last two years of this period. 
And thus, we had to create a ‘stable cohort’ of Type 2 Diabetes patients. Therefore 
we selected patients who have received glucose lowering medication since at least 
2002 and who already lived in the region before the start of the project. As a 
consequence, all patients who were diagnosed with Type 2 Diabetes patients after 
2002 and who participated to the LDP were also lost in the present study. As such, 
when interpreting the comparison between ‘participating’ patients and ‘reference 
patients’, one must know that in reality, it is a comparison between patients receiving 
glucose lowering medication at least since 2002 who are clustered by the ‘preferred 
GP code’ around GPs who probably participated in the LDP project between 
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1/1/2005 and 30/11/2006 versus the same type of patients, but who were clustered 
around another GP according to this ‘preferred GP code’. A last important limitation is 
the fact that DCCT standardization of the laboratory procedures for HbA1c 
determination was only available since 2003. The problem of different involved 
laboratories is not very important for the region of Leuven since the huge majority of 
data are collected by three laboratories using the same technique and 
standardization. However, the data concerning the year 2002 may be from a different 
nature of the data in the following years, although this assumption is refuted by the 
results themselves. We did not observe a ‘rupture’ in the HbA1c evolution between 
2002 and 2003. This might be the consequence of the fact that nearly all results 
(97%) are derived from three laboratories that used DCCT aligned techniques 
already before 2003. 
The results however remain interesting. The value of HbA1c increased and the 
proportion of patients reaching the target (< 7%) decreased before the start of the 
project until 2004. This evolution was unsurprisingly because Type 2 Diabetes is a 
disease that naturally deteriorates. However, since 2005, the proportion of patients 
reaching the targets has increased again and HbA1c values have decreased. This 
evolution was not only observed in the patients clustered around participating GPs, 
but also in patients of GPs who did not participate. These results are contradictory to 
the natural evolution of the disease and thus indicate that a change has occurred in 
the glucose treatment of diabetic patients in the region of Leuven. This change might 
have been induced by the LDP and the project may have ‘contaminated’ non 
participating practices and patients. However, other factors like published 
recommendations and other quality improvement initiatives that increased the 
attention to diabetes treatment may have played a role. The evolution of cholesterol 
values is even more interesting. We observed an important decrease in both Total 
and LDL-C values before the start of the project in both groups. These results 
indicate that the recommendation to treat cholesterol in patients with diabetes was 
already implemented before the start of the project. However, our results also 
indicate that the project boosted this implementation because the observed decrease 
in total cholesterol and LDL-C after 2005 is significantly different than the expected 
decrease. Moreover, we observed the highest increase in the proportion of patients 
reaching the LDL-Cholesterol in the years 2005 and 2006, especially in patients 
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clustered around participating GPs.  The analysis of the process parameters furthers 
allows gaining more insight in the diabetes care and the Quality Improvement 
Program. First, the results suggest that the selected cohort of participating GPs is 
different from non participating GPs since some crucial process parameters (HbA1c 
measurement and micro-albuminuria measurement) were significantly different far 
before the start of the project. Secondly, follow-up of the more ‘classical’ process 
parameters like Hba1c and cholesterol measurement has been satisfactory in the 
large majority of all included patients. However, there is a lot of room for 
improvement in the screening tests for eye and kidney complications. Thirdly, we 
observed a consistent improvement in all process parameters in the year 2005 in the 
LDP group, followed by a small decrease in the year 2006.  These results show that 
the cohort that was selected as “participating GPs” indeed corresponds with the 
original cohort of GPs who participated to the quality improvement project. Moreover, 
they indicate that the Quality Improvement Program has favourably influenced quality 
of the process of diabetes care of the participating GPs. Finally, significant 
differences were observed between the LDP and on LDP group in the evolution of 
the proportion of patients receiving statin and insulin therapy. These differences were 
too small or occurred too late to have an impact on patients’ outcome values. 
However, these results suggest that continued observation could have shown a 
difference at the outcome level between the LDP and non LDP group.  
In conclusion, studies based on patient registries can be useful to evaluate the long-
time evolution of diabetes related outcomes. They allow for evaluating results of a 
high number of patients all over the country without the necessity to set up specific 
trials. The results of these study designs should be interpreted with the necessary 
caution because of several sources of bias. The main problems were caused by the 
privacy legislation and the absence of coed diagnosis in the insurance claims 
databases. Taking into account these limitations, it is possible to state that a change 
in glucose treatment in patients with diabetes occurred in the region of Leuven in the 
period that the Leuven Diabetes Project started up. It is also possible to state that 
cholesterol treatment was implemented in the region far before the start of the 
project, but the project may have boosted this implementation. Finally, there is 
enough consistency in the evolution of the different process parameters to state that 
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the quality improvement project has favourably influenced the quality of process of 
diabetes care of the GPs who participated to this project. 
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Table 1: Different selection to compose the research sample.   
A. 1. “Large selection criteria” to select potential Type 2 Diabetes patients. Patients were 
selected out of the databases of health insurance companies. 
A patient is selected as potential Type 2 Diabetes patient if he/she meets criteria 1 AND 2 AND meets 
at least one of the criteria 3, 4, 5 OR  6 
1. Patients living in the region of Leuven (and Aalst and St. Niklaas, but these regions do not 
consider the LDP project) between 1/1/2004 en 31/12/2006 
2. Patients born in 1966 or before that year (minimum age 40 years at the start of the LDP) 
3. Patients with at least 1 Hba1c measurement (code 540750) between 1/1/2002 and 31/12/2006 
4. Patients who have received a ‘diabetes pass’. The diabetes pass was introduced at March 1° 
2003, but a code (102852) only exists since January 31° 2006 
5. Patients adhering to the convention 786. For those patients, one of the following codes has at 
least one time been introduced in a health Insurance company database between 1/1/2002 and 
31/12/2006: 773231, 773253, 773275, 771573 
6. Patients who bought at least one time diabetes specific medication between 1/1/2002 and 
31/12/2006: oral anti-diabetic medication (ATC code A10B) and/or insulin (ATC code A10A) 
A. 2. Laboratory selection criteria. 
1. patients must be older than 35 years at 1/1/2002,  
2. with at least 1 HbA1c result between 1/1/2002 and 31/12/2006  
3. living in the indicated regions (Leuven for LDP) 
B. “refined inclusion criteria” to select “highly probable Type 2 Diabetes patients”  
1. Inclusion criteria:  i. all patients are included who have received at least once a glucose 
lowering medication between 2002-2006. 
ii. and with presence in the database of the ‘preferred GP code’ (at least one 
since 1/1/05) 
2. Exclusion 
criteria: 
(and… and) 
i. Patients who were coded as Type 1 Diabetes patients (this is a code in the 
diabetes convention 786 that only exists since 2006),  
ii. Patients who were coded as receiving 3 daily insulin injections or more 
iii. patients who only take metformin and who have not had 2 succeeding 
HbA1c measurements within a timeframe of 1 year 
C. research sample criteria 
1. All patients who have received glucose lowering drugs since 2002. (No additional influx of new 
patients after 2002 was allowed.) 
2. And who already lived in the region of Leuven before the start of the LDP project (1/1/2005) 
D. Selection of the Intervention Population (participating patients) 
All patients who had a ‘preferred GP code’ with a participating GP. 
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Table 2. PICO design of the registry based “Leuven Diabetes Project” research project. 
P All patients living in the region before the start of the project (1/1/2005), older than 40 years, 
taking glucose lowering medication since 2002 with as exception those patients known as 
type 1 diabetes patients, with 3 or more daily insulin injections or patients only taking 
metformin without 2 succeeding HbA1c measurements in a timeframe of 1 year 
I Patients clustered with a ‘preferred GP code’ around GPs who participated to the Leuven 
Diabetes Project 
C Patients clustered with a ‘preferred GP code’ around GPs who did not participate to the 
Leuven Diabetes Project 
O • The change in HbA1c, Total Cholesterol, LDL-cholesterol between 2002 and 2007. 
• The proportion of patients reaching predefined targets of HbA1c (7%) and LDL-
cholesterol (100 mg/dl) 
• The change in the proportion of patients with annual HbA1c, Total Cholesterol, micro-
albuminuria measurements and annual fundoscopy. 
• The change in the proportion of patients with insulin therapy and statin therapy 
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Table 3. Results of the data collection, merging and applying the different selection criteria. 
Data delivered from different sources and with different contents 
Database Contents (timeframe 2002 – 2006) Number of records Number of identifiable 
patients according to the 
unique E-code 
IMA - “NCL” -
database” 
Consumer data: data concerning 
the use of medical and technical 
services 
8 440 264 41 747 
IMA - “GM” - 
database 
Medication data coded by 
international codification (CNK 
codes) 
2 585 822 36 372 
IMA- “POP” - 
database 
Population data (age, gender…)   38 709 41 767 
IMA- ZIV-costs Total Insurance costs per year 200 083 41 767 
Laboratory Outcomes 2002-2006 455 879 46 653 
Merging the databases into 1 database 
Merged database All data merged by patients  41547 
Refining the selection criteria 
Patients who Live in the region of Leuven 26 255 (from total 41547) 
And who have received at least once a glucose lowering medication 
between 2002 and 2006. 
12 545 
And with and with presence in the database of the ‘preferred GP 
code’ (at least one since 1/1/2005) 
9232 
Number of patients after exclusion of type 1 and intensively treated 
Type 2 Diabetes patients, i.e. patients adhering by convention to a 
diabetes clinic and coded as receiving 3 or more daily insulin 
injections.  
8474 
Number of patients after exclusion of patients who take only 
metformine and who have not been measured HbA1c twice within a 
timeframe of 365 days. 
8388 
Patients who took anti-diabetic medication in 2002 4700 
Patients who already lived in the region of Leuven before the start of 
the LDP project (1/1/2005) 
4595 
‘Intervention’ and ‘control’ population 
‘Intervention’ population: patients with a preferred GP code with a GP 
who participated to the LDP project 
1569 
‘Control’ population: patients with a preferred GP code with a GP who 
did not participate to the LDP project 
3026 
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Table 4: Change in HbA1c, Total Cholesterol, LDL-Cholesterol and HDL-cholesterol 
between 2002 and 2006. 
 Values at 
1/1/2002 
Values at 
1/1/2005 
∆1 P* Values at 
1/1/2007 
∆2 PΨ Predicted 
values at 
1/1/2007  
P° 
HbA1c (%) 
LDP 6.9 7.1 +0.2 NS 6.8 -0.3 NS 7.2 p<0.0001 Non-LDP 6.9 7.1 +0.2 6.8 -0.3 7.2 p<0.0001 
Total Cholesterol (mg/dl) 
LDP 208 188 -20 
NS 
166 -22 p=0.003
4 
176 p<0.0001 
Non-LDP 205 186 -19 168 -18 174 p<0.0001 
LDL-Cholesterol (mg/dl) 
LDP 125 104 -21 
NS 
84 -20 p=0.031
4 
91 p<0.0001 
Non-LDP 121 101 -20 85 -16 90 p<0.000
1 
 
∆1= change in values between 1/1/2002 and 1/1/2005; ∆2 = change in values between 1/1/2005 and 
1/1/2007. 
P*: testing whether the change in the parameter is significantly different in the LDP Group vs. Non 
LDP Group before the start of the intervention (1/1/2002 – 31/12/2004) 
PΨ: testing whether the change in the parameter is significantly different in the “LDP Group” vs. “non 
LDP Group” after the start of the intervention (1/1/2005-31/12/2006)  
P°: testing whether the ‘real within group’ change (1/1/2005-01/01/2007) of the parameter is 
significantly different from the predicted change (= extrapolation of the change between 1/1/2002 – 
31/12/2004 until 31/12/2006) 
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Figure 1: flow chart in the construction of the “merged database”. 
Codes A,B,C,D volgens 
machtiging
A= DPL; B= DPA.; C= labo; D=VI;  
E=IBM (TTP)
Datamanager (machtiging p7 art 1.9 par 3 en art 1.10 par 3)
DPL
IBM
DPA
VI’s
Labo
IMA
Code C + data
INSZ + Code C 
IMA
Code A + dataCode B + data
‘INSZ’ + Code A INSZ + Code B 
Code E = Code A = Code B = Code C 
Code E + data
INSZ = Code A = Code B = Code C 
Code D = Code C = Code B = Code A IMA
Code D + data
 
 
 
 
 
 
 
 
 
Legend of figure 2: 
Preferred GP code = 102771 = the code that indicates that this patient is linked to a preferred GP.  
 
Tagged patients = patients who surely participated to the LDP project and were made recognizable in 
the merged database as having participated (though anonymous) 
 
Participating GPs = GPs characterized by cluster of tagged patients who have a ‘preferred GP code 
with the concerned GP’. As such, there is a lot of chance that those GPs really participated to the LDP 
project and thus they were probably involved in a quality improvement project. 
 
Participating patients = patients clustered around a ‘participating GP’ according to the ‘preferred GP 
code’ 
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Research Questions 
Comparative analyses 
Type2 DM patients data 
Consumer data 
(IMA) 
Outcome data 
(laboratory) 
Large selection 
criteria 
5 databases with all 
data merged by 
patient through by the 
unique E-code 
Selection of « participating 
patients » 
Definition of feasible 
“refined inclusion 
criteria” to define 
“highly probable T2DM 
patients” 
« Participating 
patients » 
« Reference 
patients » 
Database with “highly probable 
T2DM patients” living in the 
region of Leuven” and with 
tagged ‘participating GPs’  
Tagging participating GPs  
Applying the criteria 
to the patients living in the region 
Leuven 
Tagging 
« participating GPs » 
Definition of the “sample 
cohort” criteria Applying the criteria 
 “preferred GP code” with a 
by clustering of tagged patients 
identifying patients who have a 
Figure 2: Methodologic scheme of the Leuven Diabetes Project - 
Analysis based on combined Insurance Claims Data & Laboratory Data 
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Figure 3.  Evolution in the proportion of patients reaching predefined targets for HbA1c (7%) 
and LDL-Cholesterol (100 mg/dl) 
 
* The difference in the proportion of patients reaching the LDL-C target was significant in 
2005 (Non LDP 52% vs. LDP 47%, p=0.0122) and faded away again in 2006. 
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Fig. 4: Evolution in the proportion of patients with at least 1 annual eye examination and 
least one annual measurement of micro
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Fig. 5. Evolution in the proportion of patients with at least one annual HbA1c measurement 
and with at least one annual cholesterol measurement. 
 
The proportion of patients with at least one annual Hba1c measurement was significantly 
higher in the LDP group in all years, but the difference between the LDP and non LDP group 
was maximal in 2005 (LDP 91% vs. Non LDP  80%). The difference in the proportion of 
patients with at least 1 annual cholesterol measurement was only significant in 2005 (LDP 
89% vs. Non LDP 79%) and 2006 (LDP 88% vs. Non LDP 79%). 
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Fig. 6. Evolution in the proportion of patients receiving statin therapy and insulin therapy. 
 
The proportion of patients receiving statin therapy was significantly higher in the LDP group 
in the years 2005 and 2006 and the proportion of patients receiving insulin therapy was 
significantly higher in the LDP group in 2006.  
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Abstract 
Objective: To evaluate the barriers and facilitators to high-quality diabetes care as 
experienced by general practitioners (GPs) who participated in an 18-month Quality 
Improvement Program (QIP). This QIP was implemented to promote compliance with 
international guidelines.  
 
Methods: Twenty out of the 120 participating GPs in the QIP underwent semi-structured 
interviews that focused on three questions: ‘Which changes did you implement or did you 
observe in the quality of diabetes care during your participation in the QIP?’ ‘According to 
your experience, what induced these changes?’ and ‘What difficulties did you experience in 
making the changes?’ 
 
Results: Most GPs reported that enhanced knowledge, improved motivation, and a 
greater sense of responsibility were the key factors that led to greater compliance 
with diabetes care guidelines and consequent improvements in diabetes care. Other 
factors were improved communication with patients and consulting specialists and 
reliance on diabetes nurse educators. Some GPs were reluctant to collaborate with 
specialists, and especially with diabetes educators and dieticians. Others blamed 
poor compliance with the guidelines on lack of time. Most interviewees reported that 
a considerable minority of patients were unwilling to change their lifestyles.  
 
Conclusions: Qualitative research nested in an experimental trial may clarify the 
improvements that a QIP may bring about in a general practice, provide insight into 
GPs' approach to diabetes care and reveal the program's limits. Implementation of a 
QIP encounters an array of cognitive, motivational, and relational obstacles that are 
embedded in a patient-healthcare provider relationship. 
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Introduction 
Landmark studies have demonstrated that intensive management of hyperglycemia, 
hyperlipidemia, and hypertension significantly reduces morbidity and mortality in 
patients with Type 2 Diabetes Mellitus (T2DM) (1-9). T2DM is a ‘silent disease’ until 
irreversible microvascular (e.g., nephropathy, retinopathy, diabetic foot) and/or 
macrovascular (e.g., myocardial infarction, stroke) complications become apparent. 
Prevention of these complications rests on timely institution of drug therapy by the 
prescribing physician, usually a general practitioner (GP), and the patient's 
compliance with the treatment regimen and willingness to make lifestyle changes. A 
proactive follow-up of diabetic patients is essential and should include foot 
examinations, blood and urine tests, and eye examination (10). In addition, patients 
should be counselled about the dangers of diabetes and the importance of a healthy 
lifestyle, and impressed with the need for compliance with doctor's orders. 
 
Unfortunately, many patients do not receive such level of care despite the availability 
of internationally-accepted treatment guidelines describing optimal management of 
patients with diabetes (11). Optimal use of guidelines in general practice demands 
specific implementation strategies aiming at the reduction of barriers to high-quality 
care (12). However, a clear understanding on how to overcome these barriers seems 
to be lacking (13-15), despite previous studies which outlined the obstacles that 
prevent GPs from following the guidelines (16-24). Our study reports on 20 GPs who 
participated in an 18-month Quality Improvement Program (QIP). The aim of this 
program was to improve diabetes-related patient outcomes through the 
implementation of evidence-based guideline recommendations. The different 
interventions of this QIP are described in the Appendix. The program resulted in 
significant improvements over time of HbA1c (-0.4%, CI 95% (-4;-3)), systolic blood 
pressure (-3 mmHg, CI 95% (-4;-1)) and LDL-C (-13 mg/dl, CI 95% (-15;-11)). 
However, results widely varied between participating GPs. Accordingly, we 
conducted a complementary, qualitative study (January to April 2008) nested in the 
controlled trial, to gain better insight into what changes the GPs had actually 
experienced. To fully understand these changes, we relied on an ‘implementation 
model’ based on the one described by Grol et al., 2004 (25-27).   
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Methods 
We conducted this qualitative research to acquire a better understanding of the 
barriers to high-quality diabetes care and into the mechanisms of change that 
eventually were induced by the QIP according to the experience of participating GPs. 
We opted for ‘one-on-one’ interviews in order to investigate the perceptions of the 
GPs about the QIP that essentially targeted the individual GP. We opted for semi-
structured interviews in order to let the interviewees talk freely, as well as to deepen 
the interviewees’ personal feelings about both the experienced barriers to high-
quality care and facilitators of change.  
 
To gain maximum information, the interviewees were randomly chosen from a 
stratified sample of participants according to clinical performance scores before and 
after the intervention. The clinical practices were divided in four strata relying on 
baseline performance (stronger versus weaker) and on the degree of improvement 
during the project (modest versus substantial). A researcher not involved in the 
interviews randomly chose five GPs within each stratum. If a selected GP refused to 
participate, the next GP on the list in that stratum was invited.  
 
Interviewees and interviewers were blinded to the practice stratum at the time of the 
interview. Our design called for 20 interviews with post-hoc analysis and evaluation 
of data saturation. Plans were made for additional interviews if the data saturation 
criterion was not met. Three main questions were asked in the semi structured 
interviews: ‘Which changes did you implement or did you observe in the quality of 
diabetes care during your participation in the QIP?’ ‘According to your experience, 
what induced these changes?’ and ‘What difficulties did you experience in making 
the changes?’ 
 
Subsequent discussions delved deeper into these topics by using an adaptation of 
‘reflective listening’, a counselling technique that elicits a thorough disclosure of the 
interviewees thoughts and feelings (28). It involves reflecting back to the interviewee 
what the interviewer believes was said in order to verify or clarify the interviewee's 
statements, and encourages interviewees to continue elaborating their views. In our 
121 
 
interviews, not only were the assertions reflected back, the interviewees were also 
actively confronted with eventual inconsistencies in their answers. Throughout, the 
interviewers provided reassurance by intonation and body language in order to 
disclose the very personal feelings and experiences of the interviewees. 
 
The interviews took 30 to 45 minutes and were conducted individually by two 
experienced researchers (GG and LBO), one a practicing GP and the other a 
community nurse specializing in health care consultancy. All interviews were taped 
and transcribed. 
 
Before analyzing the transcripts, we discussed the analytical method to use. We 
decided to categorize the items by theory-based deduction using the ‘implementation 
model’ (Grol et al., 2004). We chose this model because it is based on a 
comprehensive overview of theories on implementation and behavioural change. 
These theories relate to the individual's cognitive, educational, and motivational 
attributes, as well as social, organizational, and economic factors. This model also 
reflects the basic structure of the interviews: barriers and facilitators of guideline 
implementation are well-described. As such, this model allows for deductive coding 
and categorizing of the items according to the level of action. After a first discussion 
round, we reached consensus to categorize the items in three levels: individual GP, 
individual patient, and social interaction, context, and organization. Items were 
divided into ‘barriers to high-quality diabetes care’ and ‘factors facilitating change’. 
Barriers at the individual level were further categorized into subcategories of 
‘knowledge’, ‘awareness’, ‘attitude and motivation’, ‘routine’ and ‘others’. All 
transcripts were re-read when necessary and independently analyzed by GG and 
LBO to ensure reliability of the data. Transcripts were manually coded and the items 
were categorized using Microsoft Excel spreadsheets. Differences in coding were 
discussed and final decisions on items and categories were based on a consensus 
between the two interviewers.  
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Results 
Two GPs refused to participate in the interview and were replaced by the GP next in 
line. In a post-hoc analysis, we found that few new themes were emerging after 
about 17 interviews, making it unnecessary to continue the interviewing after the 20 
initially planned interviews. Table 1 shows the main characteristics of the 
interviewees that were felt to be typical of all 120 participants in the QIP. Table 2 
shows the results of itemization that was obtained in commons consensus by the two 
researchers. 
All but four of the GPs confirmed the importance of improved adherence to the 
evidence-based guidelines. The four GPs who did not experience improved 
adherence belonged to a stratum with a stronger baseline performance, and three of 
them also belonged to the stratum with weaker improvement during the project. 
Three of them revealed that they had previously followed an intensive course on 
diabetes management. The fourth GP is still collaborating with the medical faculty of 
the university. Most interviewees also reported improvements in follow-up 
procedures, evidence-based drug prescription practices, and referral rates. The more 
frequent follow-up visits included regular blood monitoring and general screening for 
complications. Several GPs mentioned better recordkeeping.  
Implementation of evidence-based treatment was evident in more timely adjustments 
in therapy if target criteria fell short, and in greater attention to cardiovascular risk 
factors, above and beyond conventional glycemic control. Finally, more patients were 
treated with insulin. 
Some interviewees reorganized their practices to better comply with the guidelines. 
Others instituted regularly scheduled office visits, and some split the visits into two 
parts: one part dedicated to routine follow-up and the other to discussions of 
treatment and lifestyle. The interviewees noted better medication compliance and 
improved adherence to follow-up schedules by the patients. 
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Barriers to high-quality diabetes care and factors facilitating change 
Our analysis showed that a first barrier to successful diabetes care was GPs 
inadequate knowledge how to manage insulin therapy and cardiovascular risk.  
‘My attitude about insulin therapy onset has changed. Before the start of the 
project, I tried too long oral anti diabetics, but the courses have changed my 
attitude. I became confident in starting insulin therapy, whereas before I would 
never initiate insulin therapy. (12-S3) 
A second barrier was the GPs’ lack of awareness of their own performance because 
of ‘blind spots’.  
‘Such a project with follow-up is important because it obliges you to question 
yourself. I thought my patients were reasonably well controlled, but the QIP—
especially the feedback—makes you confront your problems and weaknesses.’ 
(3, S1) 
Several interviewees also affirmed that before the start of the project they did not 
truly understand the importance of attaining clinical targets and regular follow-ups. 
‘The constant support and the organized courses made the difference. The 
protocol map, which has become a reference work, also contributed a lot. 
Because of the feedback, I became aware that my performance on lipid-lowering 
therapy was not good. This, together with information on vascular pathology as a 
major problem in diabetes, made me change my attitude. I have begun to 
prescribe more statins.’ (10-S3) 
A third barrier, expressed by several interviewees, was the presence of scepticism 
about evidence-based treatment and of collaborative care, and their concerns about 
losing control and sanctions that may result from diabetes care improvement plans.  
- ‘I do everything myself. I find it difficult to work in a team, and I am rather sceptical 
about the ‘soft sector’ (psychologists, educators…)’ (11-S3) 
- ‘Policymakers should use such programs for positive motivation. They should not 
connect results with negative implications (e.g., loss of accreditation).’ (15-S3) 
 
124 
 
Some GPs considered evidence-based medicine (EBM) only as background 
information describing the ideal situation to strive for, but not as a stringent, 
compulsory framework.  
‘Paper is no reality. EBM is only a support tool, but can never be an imposed 
framework.’ (3-S1) 
One GP admitted that he had worked according to a fundamentally different 
paradigm closer to alternative medicine. From this viewpoint he disagreed with the 
guideline on many aspects, such as the importance that was given to lipid control.  
‘Evidence-based medicine is a relative term…something might be evidence-
based, but I have in mind other parameters that are much more important. In my 
alternative point of view, I do not care a lot about cholesterol, for example.’ (7-S2) 
Some GPs admitted being lax and several indicated that lack of time—because of 
suboptimal practice management—prevented them from providing good quality care.  
- ‘I admit that I was lax before, but have changed during the project. Some patients 
were incredibly surprised that finally they were getting good care.’ (7-S2) 
- ‘I didn’t observe major behavioural changes in most patients, but this may be 
associated with my own passive attitude. I made no changes in my organization of 
care and I did not spend enough time at it.’ (16-S4) 
Several GPs also questioned the feasibility and desirability of implementing these 
guidelines in an older diabetes population. 
- ‘Many of my patients are older than 80. I will not forbid them to eat a piece of cake. 
Indeed, my own attitude towards elderly people is a little bit more loose.’ (4-S2) 
- ‘The recommendations on weight loss and physical activity are useless for a lot of 
elderly people who are too ill or immobile to follow them.’ (3-S1) 
Factors conducive to good care were also discussed. The consensus was that 
transparent treatment protocols and tailored post-graduate courses would go a long 
way in overcoming knowledge gaps. Benchmarking feedback confronted the GPs 
with their blind spots and weaknesses, and increased their awareness of 
shortcomings in their case management habits. Case coaching was identified as an 
important innovation in improving ‘knowledge on the spot’, especially in initiating and 
adapting insulin therapy.  
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‘The extra coaching was unique to this project and functioned like clockwork. You 
only had to make a phone call—that is very comforting to a GP.’ (12-S3) 
Several GPs confirmed that the three-month data collection exercise encouraged 
regular recordkeeping and a structured approach to patient follow-up. 
‘The imposed recordkeeping of patient data put me under some pressure. 
Imposing a structure helps you handle your job more systematically. Since the 
project has stopped, this disciplined approach is beginning to wane again.’ (1-S2) 
Many GPs also felt that care was compromised by the patients' insufficient 
understanding of diabetes, lack of awareness of serious complications, and of the 
importance lifestyle changes. Fear of insulin therapy (‘fear of the needle’) was also 
mentioned. However, these barriers were perceived as something that could be 
overcome by education, especially when provided by well-trained nurse educators.  
‘The big change is the availability of the nurse educator… She really took the time 
to explain the problem of diabetes. People have a better understanding of what 
HbA1c is…people are afraid of needle sticks and this fear has decreased 
because of the project, thanks to the nurse educator.’ (2-S2) 
GPs also described the synergistic effect of several healthcare workers delivering the 
same message in inducing a sudden change in attitude.  
‘If three professionals give the same message and if, moreover, patients receive 
the same message by television, and then a sudden change can occur.’ (8-S1) 
There was consensus that patients' attitudes and lack of motivation are major 
barriers to implementing evidence-based treatment, especially when it involved a 
change in lifestyle.  
‘Physical activity and weight control remain the main problems. The motivation to 
change lifestyle habits is often completely absent. Some patients deny the 
problem: ‘I don’t eat very much’. (9-S2) 
Finally, GPs felt that about one-third of the patients would be uncooperative no 
matter what changes were proposed, and most GPs agreed that changing 
entrenched lifestyle habits was difficult for most patients to achieve, whatever their 
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initial motivation. For the most part, any such changes would be small and 
temporary.  
‘A minority—about 30%—doesn’t want to hear anything. They won't even go to 
see the nurse educator. Another 30% are somewhat motivated, but not too much, 
and the remaining 30% really cooperate. The added value of the project, 
probably, applies only to patients who are motivated and who can get motivated.’ 
(2-S2) 
 
GPs also mentioned social, organizational, and legal barriers and facilitating factors. 
The interaction between a GP and his or her patients, especially when it concerns a 
long-term relationship, can itself hamper the transition to high-quality diabetes care. 
Several GPs described how patients were accustomed to certain situations and 
habits of their GPs, e.g., a limited use of drugs. They did not always understand or 
appreciate the sudden change in their GP’s attitude; this led to tensions in some 
cases and loss of contact in others.  
 
- I have started prescribing lipid-lowering drugs relatively recently. Before the 
project, I was rather reluctant to prescribe medications and my patients were 
not accustomed to my new attitude. So, I had to take a gradual approach.’ (10-
S3) 
- ‘Previously, some patients probably consulted me because I was easygoing. 
Since my participation in the project, I’ve pushed them more and so I lost two 
patients. They frankly told me ‘We’re leaving because you exaggerate things. 
What’s the matter with you?' But patients and physicians must evolve 
together, although at a moderate pace.’ (7-S2) 
 
However, the project mitigated such unfortunate instances through counselling 
sessions involving the GPs, patients and nurse educators. The net effect was a 
strengthening of the physician-patient relationship and a motivational boost to the 
latter.  
‘Diabetes patients themselves feel much more appreciated; because of that, the link 
between us and our patients has strengthened.’ (17-S4) 
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Most GPs held that a lack of a clear delineation of responsibilities leads to 
competition between the GP and the specialist, with the latter being perceived as 
holding the upper hand. This competition is reinforced by the skewed reimbursement 
schemes in Belgium in favour of the specialist concerning patient education and 
home blood glucose monitoring (HBGM) kits. This skewed situation was considered 
as an important factor that prevents many GPs from commencing timely insulin 
therapy.  
‘Specialists gain too much control of referred patients and often exclude GPs from 
direct patient care. This is especially true of patients on insulin who get free 
instructions and monitoring kits at the diabetes centres, unlike patients in primary 
care. So, it’s nearly impossible for GPs to hold on to patients on insulin.’ (1-S2) 
 
The QIP redefined the GP as a central ‘manager’ with explicit responsibilities for the 
care for patients with diabetes.  
‘To summarize this project: we started with a good protocol and established better 
channels of communication between primary and specialist care.…The 
delineation of responsibilities and degree of familiarity among the partners were 
very important in making it easier to me to refer more patients.’ (14-S1) 
This was much appreciated by the interviewees. It reinforced the GPs' feeling of 
recognition, boosted self-esteem, promoted a greater sense of responsibility, and 
improved their professional relationships with specialists.  
‘The project did not merely create the illusion that the GP was pivotal in diabetes 
care, he or she actually became the central figure and this fact increased their job 
satisfaction.…This only became possible because of an attitude change on the 
part of the endocrinologists. Now they say 'you GPs have to do the job, but call 
me when necessary.' This is a big change from the usual 'let us do our work; after 
all we are the specialists and you may help a little bit’. We collaborate as one 
team—there's mutual support! We’re on the same wavelength and feel we work 
together toward the same objectives.’ (13-S4) 
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Many GPs regarded the role of the nurse educator as complementary to their own 
and, feeling that they themselves lacked the requisite skills and time, were relieved to 
relinquish patient education to them. 
‘I prefer to have the nurse educator bring up insulin therapy before I get to 
it.…After 30 years in general practice, I'm somewhat hesitant to get into a 
protracted struggle with patients to try to convince them of the need for insulin. ’If 
you're not interested, so be it,’ I think by myself. The nurse educator is an 
invaluable asset in such cases.’ (8-S1) 
One GP felt that the Belgian fee-for-service scheme was an important impediment to 
the delivery of quality care, explaining that a pay-for-performance system would be a 
better motivator. In addition, direct payment by patients was also seen as a 
significant factor that discouraged patient referrals and HBGM necessary to evaluate 
insulin therapy.  
Discussion 
Previous studies have disclosed a significant gap between the quality of diabetes 
care commonly encountered and recommended evidence-based guidelines (14). To 
date, most research on barriers to and facilitators of high-quality care has been done 
before the start of improvement programs. Our study was based on interviews with 
GPs who actually participated in a project aimed at optimizing diabetes care. This 
approach, combined with the ‘reflective listening’ technique, elicited disclosure of 
very personal feelings and experiences related to changes in performance. As such, 
qualitative research nested in an experimental trial may clarify the improvements that 
a QIP brings about in a general practice.  
The primary finding was that the project accomplished more than merely improving 
the quality of care. It also impacted the emotional and motivational status of the GPs. 
Previous focus group-based research had revealed that GPs working in the ‘usual’ 
setting in our country felt frustrated, partly because they felt inferior to specialists 
(29). We showed that role-redesign and delineation of responsibilities vis-à-vis the 
specialists enhanced a GP’s self-esteem and sense of responsibility. All interviewees 
were unanimous that this project was very beneficial because it added value to their 
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jobs, even though some were concerned that QIPs could have manipulative ends or 
lead to sanctions.  
Second, most of the GPs reported a major improvement in their diabetes care. 
According to the theory of planned behaviour, decisions are made according to 
personal models and beliefs about the changes about to be made, and the perceived 
benefits and risks associated with them (30). Several GPs indicated that the changes 
resulted from a conscious decision based on interconnected key elements during the 
quality improvement process. Reported key elements were the need to keep up with 
knowledge, the increased awareness that their practice needs improvement, and that 
their attitude needs adjustment. The GPs also observed attitudinal changes in their 
patients, e.g., better adherence to drug regimens and follow-up visits.  
Third, a multifaceted QIP may evoke complex changes that go beyond individual 
physicians and patients, because they form an interconnected and interdependent 
social continuum. The GPs described cases in which joint and coherent actions of 
several health workers effected a change in a patient's attitude where a solitary GP 
failed. The QIP facilitated patient referrals to the nurse educator, despite certain 
resistance on the part of some patients or physicians. The nurse educator, in turn, 
contributed to patient care by ensuring follow-ups, providing information on insulin 
therapy and health lifestyles, and performing complementary examinations, i.e., 
carrying out functions for which the GP lacked time or did not possess adequate 
skills or motivation. This task delegation allowed the GPs both to sustain their 
ongoing relationship with the patients and to concentrate the efforts on their essential 
tasks, which are the medical management and follow-up of diabetes.  
Finally, the QIP also altered interpersonal relationships. Most GPs confirmed that the 
QIP strengthened their relationships with their patients and improved 
communications with specialists and other healthcare providers. They also perceived 
a change in attitude on the part of the endocrinologists toward them, which markedly 
enhanced the GPs' motivation and sense of responsibility. These findings 
substantiated various theories and research findings that a positive relationship 
among healthcare providers is an important component of high-quality patient care 
(31; 32).  
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Nevertheless, limitations of the QIP were also described. First, according to the 
interviewees, a significant minority of patients remained refractory to change, with 
many refusing to see a nurse educator. Most patients found it difficult to change their 
lifestyle, and even in the case of motivated individuals the changes were often 
minimal and temporary. These findings confirm previous findings that sustainable 
lifestyle changes are hard to implement in clinician-centred models of patient 
education (18;33-35). Moreover, these models are labour- and resource-intensive 
(36) and traditionally put the emphasis on imparting knowledge (37). Yet, in even the 
most successful trials of face-to-face education, many participants are not willing or 
able to attend the sessions (38;39). Therefore, ongoing research evaluates the effect 
of new models that are based on peer support. These models put the emphasis on 
coping with illness, rather than managing it (40). Peer support seeks to build on the 
strengths, knowledge and experience that peers can offer. Greenhalgh et al. has 
tested the effect of a narrative method (a person telling a story) versus conventional 
nurse-led education in a minority ethnic group of people with diabetes (40). The 
results show that unstructured storytelling is associated with improvement of patients’ 
enablement and comparable changes in biomedical markers. Other self-
management programs evaluate the effect of other peer support interventions, like 
telephone counselling or web-based peer support. Future QIPs may incorporate peer 
support interventions replacing or complementing the traditional clinician-centred 
patient education interventions.  
At GP-level, four interviewees affirmed not having experienced a major impact of the 
QIP on their quality of care. In fact, they experienced the QIP somehow as 
superfluous because they already paid special attention to evidence-based diabetes 
care before the start of the project. The study also revealed that some GPs were 
reluctant on to reorganize their practices to comply with the project's requirements, or 
even to find the time for efficient patient follow-up. Accordingly, future QIPs should 
specifically address such issues. Moreover, while the project was indeed able to 
induce a change in attitude with regard to medical diabetes treatment, some other 
deeply rooted attitudes were more difficult to change. For example, several GPs 
asserted that nurse educators and other personnel in the so-called ‘soft sector’ are of 
little value in good diabetes care. Collaborative shared care with specialists also 
remains a concern, despite the improvement that was observed during the project. 
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One GP reported persistent problems with one local endocrinologist who was blamed 
for his disdainful attitude to general practice. Other GPs described minor remaining 
difficulties with endocrinologists despite overall satisfaction with the arrangements. 
These findings complement previously reported difficulties in collaborative shared 
care. One of the major reported issues about shared care is the problem of 
suboptimal communication between the involved providers (41). This problem is 
associated with discontinuity in care and lower quality of care (42). Other problems 
are related to lack of clear division of tasks and responsibilities between the involved 
providers, eventually leading to overlap and competing interests (29;43). Despite 
these problems, we think that shared care is necessary to guarantee high-quality 
diabetes care because the management of this disease is too complex and too broad 
to have it provided by one person. However, the aforementioned problems are a real 
point of concern. Moreover, as our research shows, providers are not always willing 
to collaborate. Thus QIPs should pay special attention to eventual relational 
problems, to communication issues and to the distribution of rights, responsibilities 
and tasks between patients, GPs, nurse educators and specialists. 
The role of EBM in daily practice remains a point of controversy. While many GPs 
accepted the existing guidelines, some did not. Some GPs fundamentally disagreed 
with EBM. Others accepted EBM as background support, but were afraid that EBM 
would be used to impose coercive instructions for daily practice. Several GPs 
questioned the feasibility and desirability of the American Diabetes Association 
guideline-based recommendations in the elderly or immobile people. Indeed, elderly 
patients are particularly sensitive to the adverse effects of drugs and polypharmacy, 
putting constraints on the classic diabetes treatment. In particular, hypoglycemia is 
an important topic in the diabetes treatment of elderly people. Recent studies (44;45) 
clearly indicate that hypoglycemia may be a contributing factor to morbidity and 
mortality in older patients. As such, strict adherence to guidelines for younger 
patients could be deleterious for the frail elderly (46). Geriatric guidelines on the 
management of Type 2 Diabetes accentuate that treatment should be holistic, 
targeting all important aspects of the geriatric patients with priorities in the treatment 
scheme. Diabetes-related targets should be individually adapted to the frail patients 
with special attention to avoidance of side effects (47-49).  
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This qualitative research presents some limitations. A first possible bias concerns the 
researchers who conducted the interviews. They were previously involved in the QIP, 
and thus they are known by the interviewees as promoters of this program. As a 
consequence, GPs in disaccord with some issues of the QIP-process may have been 
discouraged to mention them. The GP cohort selected for the study represented an 
additional limitation. The participants were part of a larger sample of volunteer GPs 
who were particularly interested in the project. This selection bias may well be 
reflected in their answers. In order to generate a broad spectrum of answers 
regarding barriers to change, we employed a targeted sampling procedure that took 
into account the performance of the GP's practice. Only their subjective feelings and 
views are covered here, although a more balanced picture would have emerged if a 
joint patient-provider perspective had been offered. It remains for future research to 
include interviews with patients and, perhaps, employ mixed focus groups, and 
audio- or video-record observations of the clinician-patient encounters. However, 
despite the possible bias, we feel this qualitative study has provided a very balanced 
overview of the QIP's strengths and weaknesses, and validated the quantitative 
findings that had been obtained. 
Implications 
Previous research revealed numerous barriers to high-quality diabetes care at the 
level of provider, patient, and healthcare organization. However, most of this 
research was done outside the context of quality improvement. Our research reveals 
the viewpoints of physicians who experienced a quality improvement process and it 
allows for evaluating the complex interactions between barriers and facilitators during 
this process. It has become obvious that implementation of a QIP encounters an 
array of cognitive, motivational, and relational barriers that are embedded in a 
patient-healthcare provider relationship. As their success may depend on overcoming 
key barriers, QIPs should incorporate mechanisms to actively detect and overcome 
these barriers or to cope with them. Moreover, several barriers appear to be 
interdependent, developing several ‘chains of barriers’. This phenomenon may be a 
reason why multifaceted QIPs acting on different barriers in a chain are likely to be 
more effective than single interventions.  
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Our research particularly revealed the GPs feelings on collaborative shared care. 
While some of them disagree on the added value of diabetes educators, many GPs 
feel some uneasiness regarding the competition with specialist care. These feelings 
may be reinforced by the typical Belgian healthcare setting, but we believe that they 
are the expression of a very human nature and thus not unique to the Belgian 
situation. Literature on this issue, however, is very scarce. Our research also showed 
that these negative assumptions and feelings can be overcome by paying attention to 
them and by enhancing the personal contact and communication between the people 
involved.  
The interviews also revealed the limits of a clinician-centred model of patient 
education and self-management, and confirmed the quantitative results of the study 
on this issue. Future QIPs could incorporate and test innovative patient-centred 
methods, like different models on peer support for patients. 
Finally, several interviewees reported real concerns on the applicability of the 
‘traditional’ diabetes guidelines in a subset of the patient population, namely the 
elderly. These concerns have been joined by specific geriatric guidelines. These 
findings show that quality improvement is not a unidirectional process from guideline 
to practice. Often, several practitioners express the same difficulties with 
implementing a guideline. In that case, it might actually reveal a flaw in that guideline 
rather than a barrier related to the practitioners. And thus QIPs should also be used 
as instruments to test the feasibility of guidelines as well as to highlight any flaws.  
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Table 1. Principal characteristics of participating GPs. 
  S1 
(N = 5) 
S2 
(N = 5) 
S3 
(N = 5) 
S4 
(N = 5) 
All interviewees 
(N = 20) 
All participants (N 
= 120) 
Mean age (years) 46 45 48 36 44 44 
Females (N) 1 1 1 3 6 45% 
Workplace        
Solo practice (N) 3 3 0 1 7 38% 
Two man practice (N) 0 2 3 1 6 32% 
Group practice (N) 2 0 2 3 7 30% 
 
S1 = Stratum of GPs with weaker baseline performance and modest improvement during the QIP 
S2 = Stratum of GPs with weaker baseline performance and substantial improvement during the QIP. 
S3 = Stratum of GPs with stronger baseline performance and modest improvement during the QIP. 
S4 = Stratum of GPs with stronger baseline performance and substantial improvement during the QIP.
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Table 2. Coded categories and themes 
Perceived barriers to optimal diabetes care 
Level Factor Item 
Physician  Lack of knowledge on 
 
- global cardiovascular treatment beyond glycemic control 
- insulin therapy  
Lack of awareness 
regarding 
- personal practice performance (‘blind spots’) 
- need to reach treatment targets and regular follow-up 
Attitude and 
motivation 
- laxity regarding treatment targets and timely follow-up  
- attitude to polypharmacy 
- scepticism regarding evidence-based treatment, top-down quality 
improvement projects and shared care collaboration 
Practice organization - lack of scheduled visits, lack of planned follow-up, lack of support staff 
Patient Lack of knowledge  - insight regarding complications, significance of HbA1c 
Lack of awareness 
regarding 
- personal dietary patterns 
- personal health status (HbA1c, blood pressure, cholesterol) 
Attitude and 
motivation 
- fear of insulin treatment 
- lack of motivation for follow-up or to change lifestyle  
Routine behaviour  - maintaining lifestyle change very difficult 
- adhering to planned follow-up visits is difficult 
Age and co-morbidity - too strict control can be dangerous in older patients  
- immobility hampers physical exercise and shared care referral 
 
Context/or-
ganization 
Relationships  - between GPs and patients (inertia to change) 
- competition between specialists and GPs  
Lack of teamwork - Need for clear description of each provider’s duties and responsibilities  
- Need for identical messages to the patients from all health care 
providers 
Financial barriers - out-of-pocket payments for education, dietary advice and HBGM 
material 
- skewed reimbursement of HBGM material  
- fee for service: this system doesn’t motivate GPs to deliver high-quality 
care 
Perceived change facilitators 
Level of impact Item  
Physician Treatment protocol and post-graduate education; Benchmarking feedback 
Case coaching; Timely data collection 
Increased contact and communication with peers in other disciplines 
Participation in team meetings 
Attitude change on the part of specialists 
Patient Nurse educator and IDCT working as a team 
Free services and free materials 
Identical messages from different sources (GP, specialist, educator, 
television 
Attitude change on the part of the GP 
Context and organization Role redesign and reassignment of responsibilities 
Serial removal of barriers  
Task relief 
HBGM = Home Blood Glucose Monitoring; IDCT = Interdisciplinary Diabetes Care Team 
(endocrinologist, nurse educator, dietician) installed at the primary care level 
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Appendix: Interventions of the Quality Improvement Program 
Interventions in support of the GP 
- Diffusion of a Evidence-based treatment protocol with clear recommendations on:  
1. Timely follow-up (every three months), with attention to all important parameters (biological risk 
factors and early signs of complications). 
2. Global treatment with attention for: 
a. Glycemia control, blood pressure control and blood lipids control. 
b. Comprehensive treatment. 
i. Healthy lifestyle habits. 
ii. Comprehensive drugs treatment including anti-platelet therapy, BP treatment 
with ACE-inhibition, and statin therapy. 
3. Target-driven treatment (7% for HbA1c <7%, SBP ≤130 mm Hg, LDL-C <100 mg/dl) with 
treatment intensification whenever the targets are not reached. 
4. Task description: 
a. The GP receives the overall responsibility for the management of diabetes patients. If 
the GP does not succeed in reaching the targets, he or she can call for help by 
referring to partners in the diabetes care (interdisciplinary diabetes care team, or 
IDCT, or hospital-based diabetes clinics). 
b. The IDCT functions in support of the GP whenever treatment targets were not 
reached.  
c. The hospital-based diabetes clinic should treat patients with case of complications and 
with complex insulin therapy schemes. 
- Clinician education and coaching 
a. postgraduate educational sessions on: 
i. the evidence-based treatment of T2DM patients, according to the treatment 
protocol, with special attention to the principles of global cardiovascular 
treatment and the target driven approach. 
ii. the initiation and adjustment of insulin therapy in general practice. 
b. Case coaching by the endocrinologist: the GP can call for help by mail or by phone 
regarding treatment schemes of individual patients without referring them to the 
specialist. 
- Feedback: benchmarking feedback: each GP receives feedback on the treatment schemes and on 
the outcomes of patients of his or her practice in comparison with the results of the entire group. 
- Incentives: €60 for each included patient; involvement of opinion leaders (endocrinologist from the 
University Hospital) 
Interventions in support of the patient 
- Availability of patient education by a nurse educator, a dietician, or a general internist working 
together in one IDCT, upon referral by the GP 
- Availability of Home Blood Glucose Material for patients with insulin therapy initiated by the GP 
and the IDCT  
Organizational interventions 
- Team changes: the IDCT was newly created and acted on the interface between primary and 
specialist care. The team consisted of a general internist, a diabetes educator (this intervention is 
innovative in Belgian primary care) and a dietician. It could only be counselled upon referral by the 
GP and was supervised by the endocrinologist of the hospital-based diabetes clinic and her team 
trough bi-monthly joint team meetings. 
- Timely data collection: GPs are asked (by mail and by phone) to deliver diabetes related patient 
data every three months. 
- All interventions as well as all communication processes were implemented and guided by a 
‘program manager’. 
 
IDCT = Interdisciplinary Diabetes Care Team (endocrinologist, nurse educator, dietician) installed at 
the primary care level 
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Abstract 
 
Background: Since many patients in usual care reach the diabetes treatment goals, it may 
be more efficacious to focus quality improvement efforts on those general practice 
populations requiring additional support. We therefore developed a tool based on a 
composite endpoint considering blood pressure, lipids and glycemia.    
Methods: We created an aggregated zA-score, calculated as the average of three z-scores 
testing whether the mean practice values of HbA1c, LDL-C and Systolic Blood Pressure 
(SBP) are significantly higher than the corresponding ADA-target (respectively 7%, 100 mg/dl 
and 130 mm Hg).  This score was used with 100 general practices who participated in a 
Quality Improvement Program (QIP). We defined the cut-off value (COV) to determine 
‘Practices Requiring Support’ (zA < COV) using a Receiver’s Operating Characteristics curve 
with the mean practice CHD risk as gold standard. To further test the z-score validity, we 
calculated the correlation coefficient between the z-score and the mean practice CHD risk 
and the improvement in the z-score after the QIP.  
Results: The COV was -1.22 and was valid to discriminate between practices at higher risk 
from practices at lower CHD risk (24±4% vs. 19±4%). The correlation coefficient was -0.515 
(p=0.001). The average z-score increased from -1.21±0.97 at baseline to 0.49±1.01 after the 
intervention (p<0.001).  
Conclusion: This scoring system is useful to picture practice populations with diabetes who 
are at high cardiovascular risk due to modifiable risk factors. While the unadjusted z-score 
cannot be used to compare physicians, this technique can be used to evaluate improvement 
efforts over time.  
Key words: diabetes, quality measurement, cardiovascular disease, risk assessment, general 
practice 
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Introduction 
 Type 2 Diabetes Mellitus (T2DM) is a highly prevalent chronic disease that can 
lead to serious complications, including heart disease, stroke, blindness, lower limb 
amputation, kidney failure, disability and premature death (1). There is a sizable gap 
between the recommended care in general practices and the care patients actually 
receive (2). Quality Improvement Programs (QIP) are considered as essential to 
close this gap (3;4).  Yet many intervention programs do not succeed, or exert only 
small improvements (5;6).   Moreover, cross sectional studies of the usual care 
settings indicate that a large part of the patients still reaches the treatment targets (7-
13). These data could indicate that “blockbuster campaigns” involving QIP for all 
T2DM patients are expected to be less effective because an important number of 
patients already are on target. It may be more efficacious to focus the quality 
improvement efforts on those patients who still require additional support.  However, 
we are not aware of any monitoring system that prospectively enables focused 
quality improvement campaigns.   
On the other hand, a wide range of outcome and process indicators exist to 
evaluate both the quality of care and the physicians’ performances (14;15).  But the 
main objective of these indicator sets is to install a system that rewards “good clinical 
practice”. A well- known example of such a rewarding system is   the UK ‘Quality and 
Outcomes Framework’ (16). However, we think that such a system should at least be 
complemented by a system that supports practices lacking optimal performance.  
Practices may have objective problems in reaching high quality care. Some practices 
can concentrate patients whose diabetes may be difficult to control, others may work 
in a difficult context, e.g. in a region without the presence of specialized diabetes 
clinics... Therefore, we propose a monitoring tool that can picture diabetes practice 
populations who may be in need of additional support. In fact, we propose to monitor 
HbA1c, LDL-C and SBP at practice level using a z-score for each outcome. In 
addition, we propose to combine these z-scores into one aggregated score that is an 
indicator for the mean CHD risk of the practice population, associated with modifiable 
risk factors.  
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Methods 
Design, setting and statistical analysis 
 Study data were derived from the “Leuven Diabetes Project” (LDP), a 
prospective assessment of the quality of care for people with T2DM. The patients 
enrolled in the study were from the area surrounding the University Hospital 
Gasthuisberg Leuven in Belgium. Full information on the study design and subject 
recruitment is available elsewhere (17;18). Data on 2495 T2DM patients were 
submitted by 108 Family Medicine Practices before the start of a QIP between 
January and June 2005 (T0). Patient information was also obtained after the 
intervention between July and December 2006 (T1). The QIP tended to improve 
patient outcomes, especially HbA1c, blood lipids and blood pressure through support 
measures for general practitioners and patients.  All data were analyzed using SPSS 
17 software (SPSS Inc., Chicago, IL USA).
 
For all patients, we calculated the 
patients’ ten year risk of total coronary heart disease (CHD) using the UKPDS risk 
engine spreadsheet, a validated risk estimation model (19;20). We then calculated 
the mean practice CHD risk. In order to compute the individuals’ CHD risk, missing 
values were replaced by the average of two nearby points. 
Defining the outcomes for follow-up. 
In accordance with the recommendations for the development of quality indicators 
(4), the metric in this study was developed by a multidisciplinary, balanced 
consensus group who utilized literature searches and experimental testing. A 
literature search was performed for diabetes related intermediary patient outcome 
measures that are indicators of cardiovascular risk and that are sensitive to 
improvement by medical treatment. Three outcomes met the conditions necessary to 
be included in the scoring system  (HbA1c, LDL-C and Systolic Blood Pressure) 
because of the following reasons: i. A substantial part of morbidity and mortality in 
T2DM has a cardiovascular origin (65 to 80% of deaths) (21-23). The UKPDS (24) 
revealed that increased concentrations of LDL-C, decreased concentrations of HDL-
C, hypertension, increased HbA1c and smoking are the major independent risk 
factors for CHD once diabetes has developed. A Swedish prospective population-
based study of 400 patients concluded that inadequate glucose, lipid and 
hypertension control are predictors of mortality in T2DM patients (25). ii. Blood 
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pressure, glycemic and lipid levels are most likely to be positively influenced by 
medical treatment. A large body of clinical trials which evaluated improvements in 
HbA1c, blood pressure and LDL-C in T2DM patients has shown a reduction in 
cardiovascular morbidity and mortality (26-28). iii. The three outcomes are available 
in most electronic medical files and are easily extractable. iv.) HbA1c, Cholesterol 
and Systolic Blood Pressure are the only outcomes that have been validated as 
quality indicators for T2DM care (29). v. There is no conclusive evidence that other 
outcomes, such as body weight and triglycerides, are independent risk factors for 
cardiovascular disease in a diabetic population. vi. Despite conclusive evidence for 
other factors, such as smoking and HDL-C, we assumed that the impact that any 
provider controlled treatment recommended by the actual guidelines can have on 
these outcomes is not decisive enough to allow for practice monitoring (30). 
Construction of the z-scores 
Defining the concept 
Establishing a z-score is a standard procedure for normalizing aggregated data. This 
procedure is more useful for comparing practices than comparing the raw averages 
of HbA1, LDL-C and SBP because practices have different sample sizes and 
different standard deviations. Moreover, this procedure is necessary to aggregate 
different outcomes with different measurement  units into one combined indicator 
(31).  A z-score comparing a mean value iX
 
to a preset value µ0 is defined as follows: 
zi =
i
i
i
n
X
σ
µ −0
 where i is the index of practice i. σi denotes the standard deviation and ni 
the number of patients in practice i. The z-score functions as a one-tailed statistical 
test.  When iX  is significantly higher than µ0, with an alpha level of 0.05, then zi<-
1.64. As such, for each practice a z-score for the 3 outcomes Hba1c, LDL-C and 
SBP can be constructed. As values for µ0, we choose the targets defined by the 
American Diabetes Association (ADA) in 2003 (32): 7% for HbA1c, 100 mg/dl for 
LDL-C and 130 mm Hg for SBP. Further on, these outcome z-scores will be called zG 
for HbA1c (Glucose control), zC for LDL-Cholesterol, zB for systolic Blood pressure. 
The Aggregated practice z-score zA was then defined as the average of the three 
outcome z-scores.  The z-scores were calculated at the beginning and at the end of 
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the study for each of the 108 practices but data were only analyzed from practices 
with 5 or more patients at both time points.  To compute iX  and σi, case-wise 
deletion was used for missing variables.   
Validation of the aggregated z-score 
Valid indicators should show a strong correlation with what they intend to 
measure (‘content validity’). We hypothesized that the aggregated zA-score is an 
indicator of cardiovascular risk due to modifiable risk factors. Therefore, there should 
be a strong correlation between the zA-score and the mean practice CHD. Moreover, 
this correlation should be stronger than the correlation of each individual outcome z-
score with the practice CHD. We used a single linear regression model to calculate 
the Pearson’s correlation coefficient between the baseline z-scores and the mean 
practice CHD risk.  
Since the value of the z-scores mainly depends on their sensitivity to 
improvement over time, we also evaluated changes in zG, zC, zB and zA prior to and 
after the intervention with a paired t-test. We performed a McNemar test to evaluate 
whether the number of practices with zG, zC or zB-score< -1.64 significantly changed 
after the intervention. 
The aggregated zA-score should discriminate between practices with 
populations at higher cardiovascular risk from practices at lower cardiovascular risk. 
Therefore, we divided the practices into quintiles according to the zA-score and we 
compared the aggregated patient characteristics (mean CHD risk, mean HbA1c, 
LDL-C, SBP, age, diabetes duration and the proportion of female patients) using a 
one- way ANOVA technique with Bonferroni post hoc tests.   
We calculated the Intra Class Coefficient of the patients’ CHD risk for patient 
populations clustered around the practice using a one- way ANOVA. A large ICC 
(>0.5) indicates that the variability between the practices is higher than the variability 
between patients within those practices. As the ICC becomes larger (e.g., > .5), a 
practice level composite score is a more useful stand alone measure of the practice. 
Defining a cut-off point allowing for practice monitoring. 
The zA-score can be used to evaluate practices by ranking them. However, ranking 
only allows for a relative benchmark evaluation.  Yet practices can positively evolve, 
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even if their position in the ranking list remains status quo. Therefore we searched for 
a cut-off value (COV) of the zA-score that allowed us to label those practices with zA < 
COV as “Practices Requiring Support” (PRS). The COV was defined using a 
Receiver Operating Characteristic (ROC) curve. The mean practice CHD risk with 
cut-off point set at 25% was used as the Gold Standard.  The cut-off point of 25% 
was chosen because it presented the upper quartile limit of the CHD risk in the study 
sample. The COV of the z-score was defined as the closest point to (0, 1) on the 
ROC curve, i.e., false positive rate of zero and sensitivity of 100%. After practices 
had been labelled, they were divided in four groups according to the COV of the z-
score (-1.22) and according to the 25% cut-off point for CHD risk (table 3). We then 
compared the aggregated patient characteristics using a one- way ANOVA 
technique. We also evaluated changes over time in the number of PRS with a 
McNemar test.  
Results  
In the LDP, the mean age of the general practitioners (GP) was 45 years. 45% 
were female and 38% worked in solo practices, 33% in practices with one other and 
29% in group practices with three or more GPs. The number of T2DM patients 
registered per physician varied from 2 to 73 (with an average of 20 diabetic patients 
per physician and a median of 19).  Most of the GPs working in group practices 
registered patients individually, but 12 practices grouped all patients. Two practices 
were lost to follow-up and six others had a patient population < 5 and were excluded. 
Z-scores at baseline and follow-up were obtained for 100 practices and 2426 patients 
in total. The patients’ mean age at baseline was 68±12 years, the mean diabetes 
duration was 8±7 years and 51% the patients were female. 
Table 1 shows the results of the z-scores at T0 and T1 and the correlation 
coefficient between the baseline z-scores and the practice CHD.  This table shows 
that each outcome z-score significantly improved after the intervention. Moreover, all 
outcomes showed a large decrease in the number of practices with a mean value 
that is significantly higher than the ADA-target (z< -1.64). The correlation coefficient 
between the T0 zA and the T0 practice CHD risk was -0.515. This means that the 
correlation between zA and the CHD risk was stronger than the correlation of each 
outcome z-score with the CHD-risk (-0.271 for zG, -0.403for zC and -0.308 for zB). ZA 
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improved significantly over time, from -1.21±0.97 at T0 to 0.49±1.01 at T1 
(p<0.0001). 
Table 2 shows the baseline characteristics of the practice populations for all 
practices, divided according to the quintiles of the T0 zA-score. The practice CHD risk 
is calculated at 26%±4% for the first quintile, at 23%±4% for the second quintile, at 
22%±4% for the third quintile, at 20%±4% for the fourth quintile and at 19%±4% for 
the fifth quintile. Differences in CHD risk are significant between the first quintile on 
the one hand and the 3th, 4th and 5th quintile on the other hand. The Intra Class 
Coefficient for the CHD risk however is only 0.10, meaning that the variability of CHD 
risk between the patients in one practice is much higher than the variability between 
practices.  
The COV of zA used to label practices as PRS was defined at -1.22.  The Area 
Under the Curve was 0.780 (p<0.0001, the null hypothesis being that the true area = 
0.5). This resulted in a sensitivity of 82% and a specificity of 61%. However, as 
shown in table 3, ‘false positive’ practices (group B, N=28) still showed higher values 
of HbA1c (7.3±0.4%), LDL-C (109±8 mg/dl) and SBP (139±4 mm Hg) but lower 
values of unmodifiable risk factors, such as age (66±4 years) and diabetes duration 
(7±2 years). ‘False negative’ practices (Group C, N=5) on the other hand showed 
higher values of age (71±4 years) and diabetes duration (9±3 years) and contained 
more male patients (61%).  
PRS (group A and B) compared to other practices (group C and D) showed a 
significant difference in the mean CHD risk (24±4% vs. 19±4%, p<0.0001), mean 
HbA1c (7.4±0.5% vs. 7.0±0.4%,p<0.0001), mean LDL-C (112±8 mg/dl vs. 105±9 
mg/d), p<0.0001) and mean SBP (139±4 mm Hg vs. 134±5 mm Hg, p<0.0001). 
Almost all PRS (98%) presented with at least one outcome z-score < -1.64, in 
contrast with 56% of the other practices. 
The graphical representation of the zA-scores allows for the evaluation of the 
change over time within each individual practice (Figure 1). Only 4 of the 50 practices 
that were initially labelled as PRS kept this label at T1 (p<0.0001). The zA-score of all 
but 3 practices improved after the intervention.  
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Discussion 
This paper proposes a tool for the monitoring of patient populations with T2DM 
in General Practice. The tool is based on HbA1c, LDL-C and SBP, the three principal 
diabetes related outcomes, all of which are associated with cardiovascular risk and 
are modifiable via medical treatment. Firstly, we composed a z-score for each 
outcome. We then aggregated the outcome z-scores into one zA-score. Each 
outcome z-score is a statistical test comparing the average of each practice with the 
corresponding ADA-target. These Z-scores can be used to determine whether the 
practice mean of HbA1c, LDL-C and SBP is significantly higher than the ADA-target.  
The z-scores take into account the number of patients in each practice. High volume 
practices with a high mean HbA1c, LDL-C or SBP are considered a bigger problem 
than smaller volume practices with similar mean values. The z-score also takes the 
practice variability into consideration, which means that with equal mean values, a 
better z-score indicates that more patients are closer to the ADA-target.  
 The choice of HbA1c, LDL-C and SBP was not arbitrary. Previous research 
has validated HbA1c, SBP and LDL-C as reliable outcome quality indicators for 
diabetes care (29). The three proposed patient outcomes are easily extracted from 
the electronic medical files. Moreover, standardization of the laboratory results 
enables the possibility that LDL-C and HbA1c measures are free of intra- or inter-
observer variability. The recent consensus on the standardization of HbA1c supports 
the reliability of national and international comparisons of HbA1c measurements (33). 
The reliability of the SBP value depends on the physician even though recommended 
procedures exist to reduce variability (34). We decided not to incorporate other 
outcomes such as HDL or smoking status because these outcomes have not yet 
been validated as quality indicators. However, when necessary, the concept of the 
aggregated z-score is flexible and is fit for extension to other outcomes. 
The aggregated z-score (zA) offers some supplementary advantages.  The 
score has shown to discriminate practice populations at higher cardiovascular risk 
from practice populations at lower cardiovascular risk. Using a COV of -1.22 the zA-
score allows for highlighting practices that may require supplementary support 
(“Practices Requiring Support”). As such, practices labelled as PRS contain patients 
at high cardiovascular risk due to modifiable risk factors. It is of utmost importance to 
improve those risk factors in these highlighted populations. Such practices could 
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benefit from special quality improvement interventions or from a more profound audit, 
because they can uncover eventual barriers preventing optimal quality of diabetes 
care. The individual outcome z-scores (zG, zC and zB) and the aggregated zA-score 
are complementary tools. For all practices, each outcome z-score is a monitoring and 
feedback tool for respectively HbA1c, LDL-C and SBP. For those practices that are 
labelled as “PRS”, the individual outcome z-scores can further detail the nature and 
extent of the diagnosed problem. The set of z-scores however cannot simply replace 
the monitoring of individual patients. The small ICC of the CHD risk indicates that 
patient variability is much higher than practice variability. Thus, besides the z-scores, 
a second system monitoring the individual patient values of HbA1c, LDL-C and SBP 
should exist in order to designate patients at high risk, even in those practices not 
labelled as PRS.   
As z-scores standardize ‘raw’ average values, they are often used in medical 
literature for biometric measures (like length, weight and BMI (35)), for scale-tests 
(36) and for technical procedures, such as bone density measurement (37). 
However, although the z-score procedure is mentioned as a standard procedure in 
the construction of composite quality indicators (31), it is hard to find examples of 
such a use in the medical literature.  When used for quality purposes, z-scores are 
applied to control the quality of laboratory or other technical measurements (38;39). 
We found one article referring to the use of a z-score to measure the quality of ECG 
reading (40) and we found none on its use for quality assessment in General 
Practice. 
In the recent past other composite quality indicators for diabetes care in 
General Practice have been proposed. De Berardis et al. investigated whether a 
composite quality score was able to predict the development of cardiovascular 
events in patients with Type 2 T2DM (41). The score was calculated using process 
and intermediate outcome indicators (HbA1c, blood pressure, low-density lipoprotein 
cholesterol, micro-albuminuria) and was associated with long-term outcomes. 
However, in our opinion, micro-albuminuria should not be used as an outcome 
indicator. The test is prone to false positives and needs to be repeated to confirm the 
diagnosis. Additionally, micro-albuminuria cannot necessarily be removed by medical 
treatment.   
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Kaplan et al. recently proposed an aggregate process and outcome indicator 
to measure the physicians’ performance (15). This composite indicator aims to 
evaluate practices and to assess the physicians’ performances, whereas the z-score 
should be used to monitor the practices. Even if the z-score allows for the ranking of 
individual practices, it cannot be used to evaluate the performance of individual 
physicians due to the fact that it has not been adjusted for case-mix factors. No 
judgment can be made on the provider’s performance, since factors such as 
geographic region, patients’ ethnicities, (8;42-44) duration of diagnosis, (45) 
readiness to change (46), personality traits (45) and psychological co-morbidities (47) 
may also explain why target levels were not achieved. Given these facts, the z-score 
is an indicator of the performance of the “practice (patient-physician)” entity, but not 
of a single physician’s performance. It should be noted that an indicator which takes 
into account patient’s case-mix factors would lose its validity as an indicator of 
patients’ cardiovascular risks. Such an indicator would not support our aim of 
monitoring practice populations with a high but modifiable risk of cardiovascular 
events. 
It is possible to construct alternative z-scores. Initially, we constructed a 
composite z-score that was based on the number of patients who had reached 
predefined targets for each outcome. However, the correlation of this target- based z-
score with the mean practice CHD risk was only -0.314. It is also possible to define 
other values for µ0 for HbA1c, LDL-C and for SBP. Again, these exercises resulted in 
weaker correlations with the mean practice CHD. Finally, it is possible to construct a 
weighted z-score. The weighting coefficients can be determined by a linear 
regression model with CHD as a dependent variable and HbA1c, LDL-C and SBP as 
independent variables. However, the correlation coefficient between the weighted z-
score and the mean practice CHD risk was only slightly higher (-5.33).  The weighting 
was based on the specific cohort of the LDP which could eventually lead to problems 
of generalizability. Therefore, we decided to present the unweighted score. 
One limitation of this study is that the z-score was constructed and validated 
using a data cohort that was collected in an experimental setting. Further validation 
should be achieved by applying the z-score to other cohorts in several countries. A 
longitudinal follow-up of practices and patients could also validate the z-score for 
hard endpoints, not just by calculating the risk of cardiovascular events.   
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In conclusion, we hereby propose a rather innovative concept in the quality 
approach of diabetes care. We propose a monitoring system that proactively allows 
for highlighting practices with patient populations who are at high cardiovascular risk 
due to modifiable risk factors. This tool can be complemented by a system monitoring 
the individual patient data. Such a combined system would be a powerful tool to 
assess those patient populations requiring additional support in order to improve their 
health status. As such, it would enable the implementation of Quality Improvement 
Programs that are focused on those patients who require improvement. In addition, 
the z-score system can be used to assess progress over time, to evaluate the impact 
of quality improvement efforts, to facilitate communication with the general public and 
to improve the transparency in diabetes care (31).   
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Table 1. This table indicates the values of the mean z-scores for glucose control (zG), 
cholesterol control (zC), Blood Pressure control as well as the mean values of the average z-
score (zA) at baseline (T0) and after the intervention (T1); the correlation coefficients between 
the baseline outcome z-scores and the baseline practice CHD risk and the number of 
practices with z-score < -1.64 at the T0 and T1. 
N=100 zG zC zB zA 
Average value at baseline (T0) -0.48±1.39 -1.33±1.53 -1.81±1.63 -1.21±0.97 
Pearson’s correlation coefficient between 
baseline z-score and baseline CHD risk 
-0.271 -0.403 -0.308 -0.515 
Average value at the end of the study (T1) 1.19±1.96* 0.95±1.69* -0.72±1.61* 0.49±1.01 
Number of practices with a z-score <-1.64 at 
T0 
24 41 51 NA 
Number of practices with a z-score <-1.64 at 
T1 
3† 4† 21† NA 
* The mean difference between the z-score before (T0) and after (T1) the intervention is significant at 
the 0.001 level using a paired t-test. 
†
 The difference between the number of practices with z<-1.64 before the start of the intervention and 
after the end of the intervention is significant at the 0.001 level, using a McNemar test for paired 
samples. 
NA = Not Applicable 
 
Table 2. Descriptive data aggregated at practice level for all practices and divided according 
to the quintiles of the aggregated z-score at baseline (ZAT0) 
 All Q1 Q2 Q3 Q4 Q5 
N 100 20 20 20 20 20 
Mean z-score -1.21±0.97 -2.60±0.53 -1.64±0.12 -1.22±0.16 -0.69±0.15 0.13±0.38 
Range of z-score -3.59 ; 0.83 -3.59 ;-1.87 -1.84 ;-1.49 -1.45 ;-0.94 -0.89 ;-
0.38 
-0.33 ;0.83 
Mean CHD risk ± SD (%) 22.0±4.8 25.9±3.7 23.1±4.4 21.7±3.8* 20.4±4.9* 18.6±4.2† 
Mean age±SD (years) 67±4 69±3 66±4 67±4 67±5 65±4 
Mean diabetes 
duration±SD (years) 
8±2 8±2 9±2 9±3 7±2 8±2 
Female patients (%) 48 49 42 50 53 47 
Mean HbA1c±SD (%) 7.2±0.5 7.4±0.3 7.5±0.7 7.2±0.4 7.1±0.3* 6.8±0.2† 
Mean LDL-C±SD (mg/dl) 109±9 116±9 110±7 108±8* 108±7* 100±9† 
Mean SBP±SD (mm Hg) 136±5 140±4 139±5 137±4 134±5† 132±5† 
* The mean difference compared to Q1 is statistically significant at the 0.05 level using One-way 
Anova with Bonferroni post-hoc tests. 
†
 The mean difference compared to Q1 is statistically significant at the 0.01 level using One-way 
Anova with Bonferroni post-hoc tests. 
SD= Standard deviation 
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Table 3: Descriptive data aggregated at practice level and divided according to the COV of 
the z-score (-1.22) and according to the cut-off point for the CHD risk (25%).  
 PRS 
(Group 
A+B) 
Group A Group B No PRS 
(Group C 
+D) 
Group C Group D 
N 50 22 28 50 5 45 
Mean z-score -1.97±0.63 -2.16±0.67 -
1.81±0.57 
-0.44±0.55 -
0.69±0.30 
-
0.42±0.57 
Mean CHD risk ± SD (%) 24.4±4.0 27.8±2.3 21.7±2.8† 19.4±4.3 27.4±2.4 18.6±3.6† 
Mean age ± SD (years) 67±4 69±3 66±4* 66±4 71±4 65±4† 
Mean diabetes duration ± 
SD (years) 
8±2 9±3* 7±2 7±2 9±3 7±3* 
Female patients (%) 46% 48% 44% 51% 39% 52% 
Mean HbA1c ± SD (%) 7,4±0,5 7.5±0.6 7.3±0.4 7,0±0,4 7.1±0.3 7.0±0.3† 
Mean LDL-C ± SD (mg/dl) 112±8 116±7 109±8* 105±9 108±7 105±9† 
Mean SBP ± SD (mm Hg) 139±4 140±5 139±4 134±5 135±5 133±5† 
% (N) of practices with zG < 
-1.64 
40% (20) 41% (9) 39% (11) 8% (4) 20% (1) 7% (3) 
% (N) of practices with ZC < 
-1.64 
56% (28) 68% (15) 46% (13) 26% (13) 20% (1) 27% (12) 
% (N) of practices with zB < 
-1.64 
82% (41) 82% (18) 82% (23) 20% (10) 20% (1) 20% (9) 
% (N) of practices with at 
least one  parameter score 
< -1.64 
98% (49) 100% (22) 96% (27) 56% (28) 60% (3) 56% (25) 
Legend:  
Group A= Practices Requiring Support at ‘higher risk’ (zA≤-1.22 AND CHD risk ≥ 25%( 
Group B: Practices Requiring Support at ‘lower risk’ (zA≤-1.22) AND CHD risk <25%) 
Group C: Practices not requiring support at ‘higher risk’ (zA > -1.22 AND CHD risk ≥ 25%) 
Group D :Practices not requiring support at ‘lower risk’ ( zA>-1.22 AND CHD RISK < 25%)  
N = Number 
* The mean difference compared to Group A is statistically significant at the 0.05 level, using One-way 
Anova with Bonferroni post-hoc tests. 
†
 The mean difference compared to Group A is statistically significant at the 0.01 level, using One-way 
Anova with Bonferroni post-hoc tests. 
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Figure 1: Z-score of each practice at baseline (T0) and at the end of the study (T1). Each 
block represents the z-score of one practice, ♦ before the start of the intervention (T0) and  
after the intervention (T1). Each practice is therefore represented by two blocks. 
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Chapter 6: Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“He that will not apply new remedies must expect new evils; for time is the greatest 
innovator.”   
 
Francis Bacon (1561-1626)  
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The ‘care-trajectory’ Type 2 Diabetes Mellitus 
In September 2009, the “care-trajectory” Type 2 Diabetes Mellitus has been 
initiated as a new initiative for chronic care delivery in the Belgian health care 
system.   A care-trajectory is based on the cooperation between 3 contracting 
partners: the patient, the General Practitioner (GP) and the specialist 
(endocrinologist). The individual care-trajectory gets started when all 3 parties have 
signed the contract of the care-trajectory that signs the involvement in optimal 
chronic care, and lines up the 3 partners in working to individually set targets. The 
general aim of a care-trajectory is to improve the cooperation between the GP and 
the specialist in the treatment of chronic diseases in order to optimize the patients’ 
treatment. The patients will also be actively involved in the treatment of their disease. 
The criterion to start up with a care-trajectory is a clinical one: all Type 2 Diabetes 
patients who are treated or who should be treated by 1 or 2 daily insulin injections or 
incretin mimetic drugs are candidates for a care-trajectory. Patients who should be 
treated by insulin or incretin mimetic drugs are those who are uncontrolled (HbA1c 
target not reached) despite maximal oral treatment. The number of patients who are 
candidate for a care-trajectory in Belgium is estimated at 72.500.  
The GP is considered as the ‘central coordinator of the care-trajectory. The GP, 
together with the patient elaborates a treatment plan for the patient’s management of 
Type 2 Diabetes including quantified individual goals (targets) for the control of 
glucose (HbA1c), blood pressure, blood lipids and a few other parameters. This plan 
also needs the approval of the endocrinologist and the 2 involved physicians are 
encouraged to confer on the plan, and on the specific treatment plan for insulin. 
Afterwards, the patient is sent to the educator who will teach the patient specific 
guidelines on the personal management of insulin injections and glucose monitoring. 
The GP will also be asked to deliver some data: BMI, HbA1c, LDL-C, systolic and 
diastolic blood pressure. Data will be extracted out of the electronic medical file and 
will serve to evaluate the quality of care. 
The endocrinologist is responsible for the necessary continuing medical 
education of the GPs in the region where they work. The individual specialist should 
also be available for individual coaching of the GP by means of the modern 
communication channels (email, telephone, web-based...).  
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 A necessary paradigm shift. 
The care-trajectories can be considered as the Belgian adaptation of the 
Chronic Care Model. In 2007, the KCE (Belgian Health Care Knowledge Centrum) 
published a report that urged to implement this model in the Belgian Health Care 
system (1). Belgian GPs just like in several neighbouring countries, have a tradition 
to work in a ‘Retro-Active’ demand oriented way. This means that GPs come to 
action when patients ask to help them with their complaints and symptoms. The 
treatment process mainly occurs between the individual practitioner and the 
individual patient during the consultation. This is called the “Colloque Singulier”.  
Many GPs feel responsible as a doctor in the frame of this individual care process, 
but not beyond. The GP sometimes refers to a specialist, but in our country, there is 
no tradition of teamwork cooperation between GPs and specialists. Indeed, in a lot of 
cases, the treatment is relatively simple and is within the competency scope of the 
broad trained GP. The treatment can be based on existing directives, but busy GPs 
often rely on their experience to administer the right treatment to their patients. As 
such, many doctors still consider that they have a “Therapeutic freedom” to treat 
the patients according to their own medical judgment. This way of working is deeply 
anchored in the Belgian general practice, but is also strongly present in specialist 
care. It has well functioned for over 60 years in a system that was both mentally and 
organizationally oriented to cure acute diseases, especially infectious diseases.  
The clinical epidemiology however is changing. The ageing population, the 
changed life style habits and the better survival rates of patients after acute disease 
events (e.g. a heart attack) are associated with an increased prevalence of chronic 
diseases, such as Type 2 Diabetes. These diseases slowly evolve towards serious 
complications. For the moment most doctors treat chronic diseases in the same way 
as they treat acute diseases.  Nearly the entire process of care for patients takes 
place during the consultation or home visit.  
This approach is considered as a barrier to quality diabetes care. When a 
patient with diabetes spontaneously consults a GP, he or she often consults because 
of other reasons than his or her diabetes. Diabetes is treated in the second or third 
place during the consultation. Patients and GPs often only have a few minutes to 
spend to diabetes, far too little time to evaluate essential objectives of the disease. In 
a lot of cases, there is no organized plan to follow-up the treatment and to screen for 
early signs of complications. The time for detailed discussions on life style is lacking 
163 
 
and teamwork with a dietician or educator is often absent in primary care. Moreover, 
there is no tradition to work with patient registries. As such, patients who do not 
consult spontaneously can get lost for years until complications occur. 
Chronic diseases are supposed to require a totally different approach than 
acute diseases (2-4). The Chronic Care Model represents a structured and 
scheduled follow-up of chronic diseases. In this model, health professionals and 
patients anticipate eventual problems and complications (“pro-active approach”). 
This requires a mentality change with the physicians and a change in organizational 
approach. Good diabetes care is considered to require planning and preparation. In 
this model, GP practices should have a registry of all their diabetic patients. This 
registry can be used and checked beyond the individual GP-patient consultation, e.g. 
to enable a call/recall system. In the Chronic Care Model, a great deal of the 
attention is spent on informing and motivating patients (patient empowerment).  
Moreover, in chronic care, there is a need for a multidisciplinary approach, shared 
care. In this system, each professional is aware of his own tasks and responsibilities. 
The professionals share information and knowledge and work together as a team in 
mutual agreements, according to a specific protocol that is based on scientific 
guidelines (‘evidence -based medicine ’).  In this system, several tools are used to 
evaluate and to optimize the care for patients, such as patient registries, feedback 
systems, specific CME, coaching...  
 
Care-trajectories and the Leuven Diabetes Project 
The care-trajectories want to encourage General Practitioners and specialists 
to adopt new paradigms and working styles in the routine care for patients with 
chronic diseases. The National Institute for Health and Disability Insurance (NIHDI) 
has chosen two pathologies to start with: Chronic Kidney Disease and Type 2 
Diabetes. In the case of Type 2 Diabetes, a subgroup of patients has been chosen, 
those who are out of control on oral treatment and need insulin treatment and thus 
who are more in need of a multi-disciplinary approach. This approach could be 
criticized because the NIHDI chose to take in charge end stage patients, whereas 
most benefit could be drawn when newly diagnosed patients are maintained in good 
control. However, uncontrolled patients are difficult to treat and GPs mostly feel the 
urgency to consider shared care in this category of patients. As such, this subgroup 
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of patients can be considered as a leverage to change GPs mentality and to 
introduce the new working paradigms. Moreover, the NIHDI-report on care-
trajectories explicitly mentions the option to extend the care-trajectories to all patients 
with Type 2 Diabetes. 
The support measures in the care-trajectory (CME, benchmarking feedback, 
coaching of GPs and diabetes educators, patient education) are very similar to the 
interventions that were elaborated in the Usual Quality Improvement Program (UQIP) 
of the Leuven Diabetes Project. Indeed, the Leuven Diabetes Project and its sister 
project the “Diabetes Project Aalst” were set up as pilot projects to prepare a nation-
wide implementation of a disease management program. The scientific conclusions 
of these projects can be used to guide the further implementation of the care-
trajectories. 
Therefore, we will critically evaluate the findings of this project in the light of the 
national implementation of the care trajectories. In this discussion, we will evaluate 
the results of the Leuven Diabetes Project with regards to the research questions that 
were described in the introduction of this thesis. The main objective of this PhD 
project was to assess the quality of care for patients with Type 2 Diabetes and to 
evaluate the effectiveness of quality improvement measures in the Belgian health 
care setting. 
Room for improvement  
We first answered the question “Is there room for improvement in the care for 
Type 2 diabetic patients in Belgium?” in a cross sectional study conducted in a region 
of 357,000 inhabitants that surrounds the medical university hospital of Leuven. The 
aim of this study was to picture the profile of patients with Type 2 Diabetes in 
Belgium and to study the quality of care in the primary care setting. Quality of care 
was evaluated by the achievement of three major treatment targets: HbA1c <7%; 
Systolic Blood Pressure ≤130 mmHg; LDL-Cholesterol <100mg/dl.  The HbA1c target 
was reached in 54% of the patients, the Systolic Blood Pressure target in 50% of the 
patients and the LDL-C target in 42% of the patients. Statin use was present in only 
39% of the patients. Patients treated by insulin therapy and with follow-up in diabetes 
centres obtained significant lower values for HbA1c (7.5±1.2% vs. 7.8±1.5%, 
p=0.038) and for LDL-C (90±34 vs. 111±37, p<0.001) compared to insulin-treated 
patients only followed up in primary care. We obtained some indications that clinical 
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inertia was present in the critical transition from oral anti-diabetic treatment to insulin 
treatment. Our results suggest that quality of Type 2 Diabetes care can be improved 
in those patients primarily treated by the GPs. Patients, exposed to shared care 
between GPs and specialized care obtain better results in glycemia, blood pressure, 
lipid and pharmacological treatment targets. Moreover, the data presented in this 
manuscript could even be more favourable compared to data of the overall 
population because of possible biases in the study.  Taking into account this 
consideration, we have good arguments to state that indeed it is necessary to try to 
improve diabetes care in Belgium in the primary care setting. The results of this study 
also argue for a better integration of the different care levels and the introduction in 
the GP setting of the more structured, consensus and guideline-based approach 
characteristic to the diabetes clinics.   
The results of a quality improvement trial  
 “Is it possible to improve the quality of diabetes care?”  To answer this question, 
we conducted a “Quality Improvement Effectiveness Study” implementing a two-arm 
Quality Improvement Program (QIP). The precise research question of the trial was 
whether improved patient outcomes could be achieved with a basic support program 
for GPs and patients (Usual QIP), and whether intensified support of GPs and 
patients in the advanced (Advanced QIP) arm which paid special attention to shared 
care, patient compliance and adherence to lifestyle changes would further improve 
outcomes in T2DM patients achieved by the UQIP. In cluster randomized trial with 
mean follow-up of 18 months, UQIP (53 GPs, 918 patients) merged standard 
interventions including evidence-based treatment protocol, annual benchmarking, 
postgraduate education, case-coaching for GPs and patient education.  AQIP (67 
GPs, 1577 patients) introduced additional interventions focusing on intensified follow-
up, shared care and patient behavioural changes.  The results showed that in UQIP, 
endpoints improved significantly after the intervention: HbA1c -0.4%, CI95%[-0.4;-0. 
3]; SBP -3 mmHg, CI95%[-4; -1]; LDL-C -13 mg/dl, CI95%[-15; -11].  In AQIP 
however, there were no significant better improvements in outcomes. The overall 
proportion of patients reaching the HbA1c, SBP and LDL-C target respectively 
increased with 13% 8% and18%. After the intervention, 53% of the patients were on 
statin therapy (+14%).  
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As a conclusion it was made clear that a multifaceted program, including different 
interventions used to support General Practice in its care for diabetes Type 2 patients 
was associated with important improvement over time of the major diabetes related 
cardiovascular risk factors. Intensified follow-up with interventions that focused on 
more intensified shared care and more intensified training on patient behaviour 
changes did not yield additional benefit. 
Methodological issues  
Yet, in the absence of a randomized control group, there is no hard, univocal 
evidence that the UQIP really "caused" better outcomes.  During the preparation 
period, we decided we would not assign a ‘real’ control group because we deemed it 
impossible to conduct a randomized controlled trial (RCT) without biasing the control 
group. The RCT is the ‘archetype’ of clinical research design. This design is the only 
one that allows for causal interpretation of the study results because in an RCT, all 
possible confounders with potential bias on the results should equally be divided in 
the two randomized arms. However, the conventional parallel group randomized trial 
presents some limitations regarding population-based health interventions (5;14). 
Randomization - even at the cluster level - might not remove all origins of bias, even 
if it eliminates all observable differences between groups (15). Designing a correct 
control group can be problematic in population based interventions.  All studies need 
data. In our case these data had to be delivered by the GPs who were also the 
subject of the study. The GPs need to be motivated and reminded to deliver data. 
Yet, reminding the GPs to deliver data and the process of delivering data (especially 
when they write it down on paper) is a powerful intervention that raises the 
awareness of the physician on his/her own quality of care. All these actions can be 
considered as interventions with an effect (potential bias) on the control group. So, 
we were aware that we could not assign a real control group, i.e. a group of GPs who 
did not receive any stimulation to change behaviour.  A second problem is the 
problem of contamination. Randomization of practices in one region gives the 
problem that neighbouring practices adhering to the same quality circles, working in 
the same region and appealing on the same services are divided in either a control 
group or an intervention group. Yet, in reality it is possible that practices of the 
‘control group’ make appeal on interventions dedicated to the intervention groups. 
Finally, lack of blinding of the randomized arms can stimulate the ‘control group’ to 
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perform as well as the intervention group or could eventually cause the opposite 
effect. In the case of UQIP, several GPs affirmed to be extra motivated to deliver 
good quality of care. This lack of blinding probably resulted in the bias that the most 
motivated GPs in the UQIP-arm completed the trial while the less motivated dropped 
out at the beginning of the trial.  
If QI researchers want to use a real control group in a RCT design, then they 
should pay special attention to avoid these matters of bias. A potential solution is the 
complete blinding of the randomized control group, i.e. that the control group ignores 
taking part to a study. Therefore, privacy rules should be changed and data should 
automatically be extracted from the electronic medical file. Contamination could be 
avoided by randomizing quality circles or communities rather than practices. An 
alternative is the “Latin square” or “incomplete block design”. In this design, both 
arms receive a different intervention, e.g. one arm receives an intervention to 
improve the care for asthma, the other for diabetes. Each arm serves as a control 
group for the other group. In our study, it was not possible to design a balanced block 
design because the trial was widely announced as a trial to improve diabetes care, 
long before the start of the field phase. Thus it was not possible to blind the GPs in a 
balanced block design. Moreover, in such a design both groups still know that they 
are part of an experimental trial and still have to deliver data for both diseases. As 
such, awareness about the quality of care for the ‘opposite’ disease can still occur in 
the ‘control group’. This is what happened in the MIKSTRA-study in Finland. Three 
groups received each an intervention to improve adherence on two guidelines. Yet, 
some health care centres preferred to work on adherence to other guidelines than 
those they were supposed to work on. This study neither did show any difference in 
quality improvement between the three groups (6). The “delayed intervention” RCT / 
stepped wedge design are other alternatives. In these designs both randomized arms 
receive an intervention, but in one arm, the intervention is postponed. In such a 
design, the pre-intervention data of the delayed intervention group serve as control 
data for the post-intervention data of the immediate intervention group. Other 
possibilities are the preference trials, randomized consent designs and the N of 1 
design (14). 
When it is actually not possible to assign a real control group within the RCT-
design, then an alternative or a hybrid design (with an external control group) should 
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be taken in consideration. In all cases, there should be a written consensus in the 
form of a trial protocol about the design before the start of the field phase. This 
consensus was not complete in the case of our trial. We reached consensus about 
the necessity to have two randomized arms, but we underestimated the problems 
related to the absence of a randomized control group. Moreover, we could not reach 
consensus on the means how to include an external control group. Finally, we 
decided to compare the change of the primary outcomes between a random sample 
of the intervention population and a ‘reference group’, a matched subgroup of 
patients with T2DM from the «INTEGO» Registry Network.  
The value of insurance claims data  
In June 2006 we also obtained the approval and the necessary budget to 
construct a controlled design, based on insurance claims data combined with 
laboratory data from people in the intervention region.  We used the opportunity to 
start the data collection three years before the intervention. So, we evaluated the five 
year (2002-2007) evolution of outcome and process parameters in the care for Type 
2 Diabetes patients taking glucose lowering medication and living in the region of 
Leuven. The measured outcomes were HbA1, LDL-C, Triglycerides and related 
process parameters. Additionally, we have evaluated whether the evolution of those 
parameters in patients clustered around GPs’ who participated to the Leuven 
Diabetes Project from 2005 till the end of 2006 was significantly different from the 
evolution of parameters of patients clustered around GPs who did not participate.  
This study was not only important with regards to the results. The entire set-up of this 
study was important because it was the first time in Belgium that consumer data 
routinely registered by health insurance companies were combined with laboratory 
data in order to evaluate the evolution of quality of care. As such it was a pilot project 
to study the feasibility of such exercises.  The study showed that claims data can 
effectively be used to evaluate the long-time evolution of some essential diabetes 
related outcomes. They allow for evaluating results of a large number of patients all 
over the country without the necessity to set up specific trials with a selected cohort. 
These results should however be interpreted with the necessary caution because of 
several sources of bias. Taking into account the limitations of this study, it is probably 
possible to state that a change in glucose treatment in patients with diabetes 
occurred in the region of Leuven in the period that the Leuven Diabetes Project was 
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starting up. It is also possible to state that cholesterol treatment was implemented in 
the region far before the start of the project, but the project may have boosted this 
implementation, especially by GPs who participated to the project. 
Evidence on the effectiveness of the Quality Improvement Program 
In the absence of a control group, the design of the randomized trial did not allow 
to draw a formal causal relationship between the Quality Improvement Program 
(UQIP) and the improved patient outcomes.  However, the overall results of the 
randomized trial and the results of the study based on the insurance claims data 
provided good arguments that strengthen the evidence of effectiveness.  
First, the improvement over time of Hba1c, LDL-C and SBP in the UQIP-arm of 
the randomized trial lies in the same range or is even better than the improvement 
over time of the intervention group of other, similar intervention studies. Some of 
these intervention groups showed significant differences with the respective control 
group. Secondly, higher baseline values were significantly associated with better 
improvement of HbA1c, SBP and LDL-C. The intensification of blood pressure 
treatment and the initiation of statin and insulin treatment were both in AQIP and 
UQIP significantly higher in patients who were not in good control at baseline. 
Thirdly, compared to a matched group issued from the national (Flemish) INTEGO 
registry network, the positive evolution of HbA1c and LDL-C in the UQIP-arm was 
significantly better. This registry based network of GPs is used as a trend watcher, 
clearly spread all over the Flemish region. It collects also HbA1c and LDL-C. These 
are laboratory data that are automatically incorporated in the Electronic Medical 
Record and thus can be considered as reasonably reliable. 
The analysis of the insurance claims data strengthened the evidence. In this 
study, we looked for differences in the evolution of outcome and process parameters 
in patients clustered around participating GPs versus patients clustered around non-
participating GP’s. When comparing the primary outcome parameters in those 2 
groups, we could only observe a significant difference in the evolution of LDL-C. The 
real important differences were noticed in the process parameters, like the proportion 
of patients receiving an annual eye examination and a micro-albuminuria screening 
test. These process parameters are considered as important because early detection 
and treatment of diabetes symptoms and complications may reduce morbidity and 
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mortality (16; 17). Moreover, we also observed a significant difference in 2005 and in 
2006 in the proportion of patients taking statin treatment. This difference can explain 
the difference in LDL-C evolution.  Finally, there was a significant difference in insulin 
treatment in 2006 between ‘participants’ and ‘non participants’. This difference has 
probably occurred too late so that we did not observe significant differences in the 
HbA1c evolution. 
The annual investment costs of UQIP amounted to €164 per patient (vs. AQIP 
€207/patient/year), a rather modest amount compared to the total annual diabetes-
related medical costs estimated at €1207 (12). A cost-effectiveness analysis 
alongside the insurance claims data analysis showed an acceptable cost-
effectiveness-ratio of the program with – in the worst case scenario – a calculated 
amount of 10398€ per saved quality adjusted life-year (7).   
Care coordination: toward new partnerships in health care 
 In a qualitative study, nested in the controlled trial, we tried to get more insight how a 
Quality Improvement Program interacted with the existent individual and social 
patterns in health care. The primary finding was that the project accomplished more 
than merely improving the quality of care. All interviewees were unanimous that this 
project was beneficial because it added value to their jobs. Most of the GPs reported 
also a major improvement in their diabetes care and indicated that changes resulted 
from a conscious decision based on interconnected key elements during the quality 
improvement process: enhanced knowledge, improved motivation and awareness, 
and a greater sense of responsibility. Most GPs confirmed improved relationships 
and communication with specialists. They also perceived a change in attitude on the 
part of the endocrinologists toward them, which markedly enhanced the GPs' 
motivation and sense of responsibility. This is a very important finding since patients 
with chronic conditions mostly interact with more than one provider. Treatment of 
complex conditions often requires consultation with multiple specialists. Logically, 
high quality chronic care demands concerted action, collaboration and coordination 
of care. The Leuven Diabetes Project has shown that general practitioners and 
specialists can collaborate in partnerships and team spirit instead of competing with 
each other. In the international literature, ‘teams’ are often understood as either 
hospital-based (an endocrinologist in a hospital, with paramedics) or primary care 
based. We expanded the contents of this term in our project to a partnership above 
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all layers of care. In our opinion, this is a prerequisite to high quality chronic care: we 
need to focus on the full population and not on what either primary care or hospitals 
should do.  
The project also strengthened some views on the development of good partnerships: 
- If one provider should be considered as the main responsible of care delivery, 
for most patients with a chronic condition, the GP is the appropriate 
professional to play this role. 
- However, the GP should rely on partners in healthcare and consider his role 
as part of a real teamwork. Therefore, there should be a written and 
consensus based protocol that is supported by all partners in healthcare. This 
protocol should describe the rights, responsibilities and tasks of all involved 
professional disciplines.  It should not only develop a stratified task division 
regarding the individual patient follow-up. It should also develop a framework 
regarding the follow-up of groups of patients and matters of coaching and 
medical education. 
- In this teamwork, specialists do not only have the task to directly treat the most 
difficult and complex patients, but they also have to form and coach the GPs 
enabling them to fully play their role as central coordinator. 
- In order to stimulate partnerships and team spirit, the communication, the 
interaction and the personal contact between the professionals should be 
guided by a health care ‘coordinator’ or ‘manager’ with special attention to 
eventual relational problems. This local process coach, called the “promoter” 
or “manager”, was considered indispensable by the participating GPs. 
Changing a complex system: need for well-designed implementation strategies 
Our qualitative research also highlighted the complexity of quality 
improvement. Over the last years, the health care system has increasingly been 
considered as a Complex Adaptive System, a view that is opposed to the 
mechanistic view considering the health care system as a predictable ‘machine’ (8).  
The theory has been adopted in the landmark report of the Institute of Medicine 
“Closing the Quality Chasm” (9) but its implications on quality improvement and 
quality improvement research have yet to be explored (10). According to this theory, 
patients, general practitioners and other involved providers can be considered as 
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‘agents’, individual elements with freedom to act in ways that are not always totally 
predictable. All ‘agents’ compose a system with several subsystems. Agents and 
subsystems interact with each other.  As such, a system is an integral whole in which 
things are interdependent, rather than a mixture of things isolated from each other. 
Moreover, the whole system and all its components are in a constant state of 
movement and change. In such a system, changes emerge from the interaction 
between agents and subsystems. The effect of whatever intervention in such a 
system is not determined in a linear, predictive, ‘mechanistic’ way. Each intervention 
induces reactions within the system and the final outcome partially depends on the 
nature, intensity and interaction of the internal ‘forces’ that are present in that system.   
Our health care system, that behaves as a Complex Adaptive System is increasingly 
being challenged by the ‘epidemic’ of chronic diseases. As a consequence, the 
system must be revised in its structure and financing, in the care delivery to patients, 
in the organization of practices and hospitals and in the organization between 
practices, hospitals and regions.  In relation to chronic care delivery, this change will 
demand a change in mentality of the health care providers who will have to adopt 
new concepts such as team spirit and partnership, organized care of groups of 
patients, pro-active planning of the care and protocol-based practice with quality 
evaluation.  In our opinion it is not possible that such important changes can pass in 
a spontaneous way. Changing the system and the mentalities from an acute care 
delivery system into a system that is also fitted for chronic care delivery demands 
active implementation strategies brought together in a well designed plan. This plan 
must be tailored to the national and local context and must be preceded by a detailed 
“diagnostic analysis” of the local context (13;14). A rigorous “diagnostic analysis” of 
the setting is of utmost importance for all those who want to change the field 
situation. This analysis should not only evaluate the barriers to high quality care, but 
should also picture the target group of the intervention and the potential strengths of 
the particular setting. As a consequence, the implementation interventions should be 
tailored to the particular setting and target group. Indeed, some theoretical important 
interventions may not be applicable because of insurmountable barriers. On the other 
hand, the specific setting can also induce some facilities that are not available 
elsewhere. As such, every setting is characterized by both barriers and facilitating 
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factors to successful guideline implementation. These factors should be carefully 
analyzed, using several complementary methods.  
 
Future directions in quality improvement 
Should our health care system change the basics of the financial allocation 
routines? This PhD-project does not deal with changing the financial allocation 
systems and reimbursement methods. Yet the current fee-for-service payment 
system has increasingly been criticized (11). Fee-for-service is unlikely to promote 
quality improvement and tends to reward excessive use of services, high-cost and 
complex procedures.  Care coordination and other global services which contribute to 
high-quality care but that rely less on technical resources tend to be undervalued. 
Providers often miss occasions for collaboration since the payment system rewards 
neither team management nor the integration of services across care settings.  
The introduction of pay-for-performance systems or elements of it certainly could 
stimulate a quality culture and teamwork in our health care system. Care trajectories 
on chronic conditions, like the program we evaluated, could be considered, planned 
and implemented as a Pay for Quality program.   
 It should however be noticed that P4P is no magic bullet. Until now research did 
not find one ‘magic bullet’ intervention or program that spectacularly improved the 
quality of care. On the other hand, the insurance claims data analysis showed that 
some outcome parameters have progressively improved in the whole region of 
Leuven since 2002, thus before the introduction of well organized Quality 
Improvement Programs.  Other, international studies have shown a similar evolution 
(18). This improvement might be due to an increased attention for diabetes care with 
publication of landmark studies and guidelines, the combination of different national, 
local or regional quality improvement initiatives and the introduction of new, more 
powerful drugs. Quality improvement as a continuity process probably needs multiple 
initiatives and sustainment.   
Our study also confirmed that in the usual care, as measured at the beginning 
of our study, about half of the patients already do reach the target. For those 
patients, a clinical significant improvement over time is not possible. Therefore, it 
may be reasonable to concentrate the resources and efforts of Quality Improvement 
Interventions on those practices and patient populations that are out of control.  For 
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this purpose, we constructed a composite Z-score that is weighted based on the 
number of patients per practice. This scoring system evaluates whether the mean 
practice values of parameters that are of vital importance are significantly different 
from a preset target.  This indicator can be used in a nation-wide monitoring system 
of general practices to highlight practice populations at mortality or morbidity risk due 
to modifiable risk factors. Those practice populations may be in need of extra support 
to decrease this risk. Moreover, the ability of this indicator to detect change makes it 
an important metric to evaluate the efficacy of a Quality Improvement Program. 
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Chapter 7: Conclusions 
 
 
 
 
 
 
 
 
The Leuven Diabetes Project, serving as a pilot project for the nation-wide 
introduction and implementation of a Chronic Care Model has provided substantial 
evidence for the need of a comprehensive plan. This plan should combine a 
reinforcement of the structure and organization in primary care with improved 
coordination of care between General Practitioners and Specialists, increased 
evidence-based guidance of General Practitioners and patient education by a nurse 
educator as a new collaborator in the primary care setting.  
The LDP showed that such a plan is associated with an improvement in the 
quality of diabetes care, both in terms of essential outcome and process indicators 
that are related to protocol based working and to early awareness for complications.  
A basic program was associated with significant improvement over time. 
Enhancing the frequency or intensity of the interventions of the program and/or 
adding supplementary interventions to a basic program do not necessarily induce 
better improvement of the patient outcomes.  
The program also showed other benefits. The LDP program has led to a better 
understanding and better relationships between the different health care 
professionals and to more satisfaction and more work pleasure as appreciated by the 
General Practitioners. The positive perception of the program as a support initiative is 
a precondition for success.   
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Diabetes care in the Belgian primary care setting 
o General practice can be considered as the pivotal level in the care of 
people with Type 2 Diabetes since GPs take care for the majority of Type 2 
Diabetes patients. 
o  ‘Spontaneous’ implementation of certain diabetes recommendations, 
notably with regards to cholesterol treatment, has been observed several 
years before the start of whatever Quality Improvement Program.   
o Nevertheless, room for improvement exists.  
 About half of the primary outcome targets are reached in usual 
primary care. 
 Clinical inertia, especially regarding insulin therapy onset is present. 
 Patient lifestyle habits and motivation to comply with the complex 
diabetes treatment are a matter of concern. 
o Variability between patients and between practices is rather high 
 
• Effective measures to improve the quality of diabetes care in the Belgian 
health care system  
o A comprehensive program that 
 reinforces the structure and organization in primary care through the 
introduction of a management function  
  introduces a better coordination of and task division between 
specialist and generalist care  
 provides a more guideline-based approach in general practice  
 introduces patient education by a nurse educator in the primary care 
setting  
        is associated with significant improvement in the quality of care:  
 Improved clinical outcomes of diabetes patients  
 Improved follow-up (e.g. screening on complications) 
 Improved prescription of ‘guardian drugs’ (e.g. statins) and 
increased prescription of insulin therapy 
 Improved communication and relationships between specialists and 
generalists 
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 Improved job satisfaction as experienced by the General 
Practitioners  
 
o This program was composed of following basic interventions: diffusion of a 
treatment protocol, tailored CME for GPs, benchmarking feedback, task 
description of the involved professionals, case coaching by a specialist, 
organization of a multidisciplinary diabetes team in primary care and 
possibility to refer patients for patient education. 
o These measures are essentially ‘generic’ measures that are transposable, 
i.e. they could eventually be introduced to better manage other chronic 
conditions.  
o Additional interventions in the AQIP-arm involving three areas - a more 
intense, three monthly follow-up of GPs, actively stimulated shared care 
with an interdisciplinary diabetes care team care and additional facilitation 
of patient behaviour changes - did not add substantial benefit.  
 
• Issues about future nation-wide implementation 
o The improvement over time at the end of the intervention was clinically 
significant in patients that were at baseline out of control and not in 
patients who were already on target before the start of the project. 
Therefore, it could be reasonable to focus or to limit nation-wide Quality 
Improvement Programs to specific target groups: newly diagnosed 
patients, patients and patient populations who are out of control as well as 
practices with a lot of uncontrolled patients.  
o It is recommended to organize a system for monitoring practices in relation 
to the relevant diabetes outcomes. A composite z-score could be a useful 
tool for nation-wide monitoring of general practices. 
 
• Conclusions about Quality Improvement and Implementation Programs 
o Quality improvement cannot be considered as a linear predictive process. 
Up to now, there is no ‘magic bullet’ that spectacularly improves quality of 
diabetes care. 
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o Successful implementation of Quality Improvement Programs should 
always be preceded by a ‘diagnostic’ analysis of the setting, including the 
barriers and the facilitators to change.  
o Successful implementation should target all important, removable barriers 
at all levels in a system and not reduce to one single level. 
o Implementation programs must be well planned, structured and organized, 
based on different available theories on change management and 
behaviour change.  
o Quality improvement is not only a ‘rational’, ‘technical’ matter. The 
preponderant importance of positive motivational attitudes has clearly been 
shown. Therefore, implementation programs should take into account the 
motivational and perceptive reaction of the target audience and should be 
considered as “campaigns to win the hearts of the target audience”. 
o Quality improvement programs should spend attention to the quality of the 
relationships between the different involved partners since this element has 
been described as essentially for the participants’ motivation. 
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Executive summary 
 
As explained in the introduction of this PhD-thesis, the prevalence of Type 2 
Diabetes has dramatically been growing for about 20 years. The disease has recently 
been labelled as the first world-wide non infectious epidemic (UN December 2006).  
Suboptimal treated Type 2 Diabetes Mellitus provokes major long-term complications 
with essentially a vascular origin, either micro-vascular (kidney failure, neuropathy, 
retinopathy) or macro-vascular (heart attack, stroke, peripheral arterial disease).  
Clinical evidence suggests that aggressive, timely, and multi-factorial 
interventions aimed at controlling risk factors such as high blood pressure, blood 
lipids and glycemia can reduce diabetes related complications.  Treatment should 
aim at changes in lifestyle habits and daily use of multiple drugs, once Type 2 
Diabetes has been diagnosed. Treatment should be long-term and target-driven with 
intensified interventions aimed at all validated targets. Lifestyle approach (stop 
smoking, regular physical exercise, healthy diet and weight loss in case of obesity) is 
of primary importance. Important biomedical targets are the reduction of HbA1C 
(target 7%), blood pressure (target 130/80 mm Hg), blood lipids (LDL-cholesterol < 
100 mg/dl).  
However, international studies have shown a gap between the optimal 
recommended treatment of Type 2 Diabetes and the actual treatment. Therefore, we 
examined in this PhD project the Belgian situation. More concretely, we evaluated 
whether it is necessary and possible to improve the quality of Type 2 Diabetes 
primary care in Belgium at the outcome level.  
In the first chapter we answer the question “What is the quality of care as 
measured by patients’ cardiovascular intermediate outcomes in a Belgian health care 
setting?” The chapter relates to a cross-sectional study conducted in 2495 diabetes 
patients living in a region of 357,000 inhabitants that surrounds the medical university 
hospital of Leuven.  Overall metabolic control was found to be comparable with the 
results of studies in primary care settings in other countries. Nevertheless there is 
ample room for improvement since the HbA1c target was reached in 54% of the 
patients, the Systolic Blood Pressure target in 50% of the patients and the LDL-C 
target in 42% of the patients. Patients, exposed to shared care between GPs and 
specialist care obtained better results in glycemia, LDL-C and pharmacological 
treatment targets (aspirin and statin prescription). Finally, indications on clinical 
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inertia were shown, especially concerning insulin treatment onset. These results 
suggest that also in Belgium quality of Type 2 Diabetes care could be improved in 
those patients primarily treated by the GPs.  
The second chapter deals a “Quality Improvement Effectiveness Study” and 
examined the effectiveness of a two-arm Quality Improvement Program (QIP) that 
mainly focused on supporting General Practitioners in the care for patients with 
T2DM.  Improvement from a basic support program for GPs and patients (Usual-QIP) 
was compared to the results from an intensified support program for GPs and 
patients (Advanced-QIP).  The Usual-QIP (53 GPs, 918 patients) included the 
availability of a clear evidence-based treatment protocol, annual benchmarking, 
postgraduate education and individual case-coaching if judged necessary by the GP. 
GPs had the availability to refer patients for patient education and follow-up to a 
Diabetes Support Team. Advanced-QIP (67 GPs, 1577 patients) added an intensified 
follow-up, active stimulation to shared care and supplementary training on patient 
behavioural changes.  Endpoints improved significantly over time both in UQIP and 
AQIP.  No significantly better outcomes could be proved in AQIP as compared to 
UQIP.  The overall proportion of patients reaching the HbA1C, SBP and LDL-C target 
respectively increased with 13%, 8% and 18%.  
This improvement over time of HbA1C, Cholesterol and Systolic Blood Pressure 
values in the Leuven Diabetes Project was comparable to the results of other similar 
studies with comparable baseline values.  However, in the absence of a randomized 
control group (a group of GPs and patients without any support intervention), there is 
no hard, univocal evidence that the UQIP really "caused" better outcomes.  
Therefore, we searched for additional arguments that can strengthen the evidence 
about the effectiveness of the program.  
In chapter three we describe the evaluation of the five year (1/12002-1/1/2007) 
evolution of outcome and process parameters in the care for (probable) Type 2 
Diabetes patients taking glucose lowering medication and living in the region of 
Leuven. Therefore, a new database was created, It combined consumer data that are 
routinely collected by health insurance companies and laboratory data. In order to 
respect the privacy rules, a complex methodology with double coding of all data had 
to be used. The primary objective of this study was to describe the 5-year evolution 
(2002-2007) in the care for persons treated by glucose lowering medication in a 
region that was the setting of a Quality Improvement Program (Leuven - LDP) for the 
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last two years of this period. Additionally, we have evaluated whether the evolution of 
those parameters in patients clustered around the GPs who had participated to the 
LDP was significantly different from the evolution of parameters of patients clustered 
around GPs who had not participated. This study was not only important with regards 
to the results. The entire set-up of this study was important because it was the first 
time in Belgium that consumer data routinely registered by health insurance 
companies were combined with laboratory data in order to evaluate the evolution of 
quality of care. As such it was a pilot project to study the feasibility of such exercises.  
The results of this study show that studies based on insurance claims data can be 
useful to evaluate the long-time evolution of some essential diabetes related 
outcomes. Yet those results should be interpreted with the necessary caution 
because of several sources of bias. Taking into account the limitations of this study, it 
is however possible to state that a positive change in glucose treatment in patients 
with diabetes occurred in the region of Leuven in the period that the Leuven Diabetes 
Project was starting up. It is also possible to state that cholesterol treatment was 
implemented in the region far before the start of the project, but the project may have 
boosted this implementation, especially by GPs who participated to the project. 
Moreover, essential process parameters like screening on eye and kidney 
complications improved significantly after the start of the intervention program (2005) 
in patients clustered around participating GPs but not in patients clustered around 
GPs who did not participate to the LDP. 
Chapter four deals with an analysis of the barriers and facilitators to high-
quality diabetes care as experienced by GPs who participated in the Quality 
Improvement Program.  In a qualitative study design, twenty out of the 120 
participating GPs were interviewed.  The Leuven Diabetes Project seems to have 
accomplished more than merely improving the quality of care outcomes. Most GPs 
confirmed improved relationships and communication with specialists. They also 
perceived a change in attitude on the part of the endocrinologists toward them, which 
markedly enhanced the GPs' motivation and sense of responsibility. This is a very 
important finding since patients with chronic conditions mostly interact with more than 
one provider. Treatment of complex conditions often requires consultation with 
multiple specialists. Logically, high quality chronic care demands collaboration and 
coordination of care. The Leuven Diabetes Project has shown that general 
practitioners and specialist can collaborate in partnerships and team spirit instead of 
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competing with each other.  Precondition to this success is the perception of the 
program as a support program for the daily care by healthcare professionals and 
their patients.  
This qualitative research also highlighted the complexity of quality 
improvement.  The program influenced interpersonal relationships and evoked 
complex changes that go beyond individual physicians and patients. GPs were 
confronted with their limitations to change patients’ lifestyle habits, and their own 
hesitations in changing their habits and beliefs. Several GPs mentioned scepticism 
about the added value of collaborative shared care, notably with the 
diabeteseducator, a newly introduced function in primary care. Implementing some 
necessary practice changes to better care for chronic conditions was another major 
problem. 
Finally, the study supported the message that Quality Improvement Programs 
should pay special attention to systematic and individual relational- and 
communication issues, and should explicitly discuss rights, responsibilities and tasks 
between patients, GPs, nurse educators and specialists. 
Chapter five reflects on some issues in relation to possible nation-wide 
implementation of a diabetes disease management program in general practices that 
show a large variety in populations, intervention styles, and disease outcomes. In this 
chapter, we propose a practice based monitoring tool. It is conceived as a composite 
Z-score that evaluates whether on the total practice population the mean practice 
values of HbA1c, LDL-C and Systolic Blood Pressure (SBP) are significantly higher 
than the commonly set targets for optimal diabetes care.  We tested its validity, 
reliability and sensitivity to change on the group results of the practices that 
participated in the Leuven Diabetes Project. There was good correlation between the 
practice z-score and the average risk on CHD. Moreover, the results indicated that 
the z-score was able to discriminate between practices with populations at higher risk 
from practice populations at lower CHD risk. Most practices showed a considerable 
improvement in the z-score during the course of the intervention.  This scoring 
system could be used in a nation-wide monitoring system of general practices to 
highlight those practice populations at increased cardiovascular risk due to 
modifiable risk factors. Those practice populations may be in need of extra support to 
decrease their cardiovascular risk. The ability of this indicator to detect change 
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makes it an important metric to evaluate the efficacy of Quality Improvement 
Programs. 
General conclusion: The Leuven Diabetes Project serving as a pilot project for 
the nationwide introduction  of a Chronic Care Model has provided substantial 
evidence that the implementation of a comprehensive plan that combines a 
reinforcement of the structure and organization in primary care with coordination of 
care between General Practitioners and specialists, increased evidence-based 
guidance of General Practitioners and patient education by a nurse educator in the 
primary care setting is associated with an improvement in the quality of diabetes 
care, both in terms of essential outcome and process indicators.  
Enhancing the frequency or intensity of the interventions of the program and/or 
adding supplementary interventions to a basic program do not necessarily induce 
better improvement of the patient outcomes.  
In addition to the outcome improvement, the program has led to a better 
understanding and better relationships between the different health care 
professionals and to more satisfaction and more work pleasure as appreciated by the 
General Practitioners. The positive perception of the program as a support initiative is 
a precondition for success. 
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Samenvatting: Doeltreffende Antwoorden op de Klinische 
Uitdagingen in de Chronische Zorg: Bevindingen van het 
Diabetes Project Leuven. 
 
De laatste 20 jaar werd een dramatisch sterke stijging van de prevalentie van 
Diabetes Mellitus Type 2 waargenomen. De ziekte werd onlangs bestempeld als de 
eerste epidemie op wereldvlak van niet besmettelijke oorsprong (Verenigde Naties, 
december 2006). Suboptimaal behandelde Type 2 Diabetes Mellitus leidt op termijn 
tot ernstige, zelfs levensbedreigende verwikkelingen van microvasculaire oorsprong 
(nierfalen, neuropathie, retinopathie) of macrovasculaire oorsprong (hartaanval, 
Cerebro Vasculair Accident, perifeer arterieel vaatlijden). Vroegtijdige, agressieve en 
multifactoriële behandeling met als doel het controleren van de belangrijkste 
risicofactoren zoals hoge bloeddruk, verhoogde cholesterolwaarden en een 
verhoogde bloedsuikerspiegel (weergegeven door de parameter HbA1c) vermindert 
op een significante wijze het risico op verwikkelingen. De behandeling moet ingesteld 
worden zodra de diagnose gesteld wordt en moet zowel gericht zijn op het wijzigen 
van de levensgewoontes als op het dagelijks innemen van meerdere soorten 
medicatie. De behandeling dient levenslang gevolgd te worden en is gericht op het 
behalen van gevalideerde doelstellingen. Aanpassingen van de levensgewoontes 
zoals rookstop, regelmatige lichaamsbeweging, gezonde voeding en gewichtsverlies 
indien nodig, zijn van primordiaal belang. De belangrijkste biomedische 
doelstellingen hebben betrekking op HbA1C (7%), de systolische bloeddruk (130 mm 
Hg) en de LDL-cholesterol (100 mg/dl).  
Internationale studies hebben echter aangetoond dat er een kloof bestaat 
tussen de optimale, aanbevolen behandeling van Diabetes Mellitus Type 2 en de 
werkelijke behandeling in de dagelijkse praktijk. We hebben dan ook onderzocht wat 
de situatie in België is. We gingen na of het noodzakelijk en mogelijk is om de 
kwaliteit van de diabeteszorg in België te verbeteren. Kwaliteit werd in de eerste 
plaats gemeten aan de hand van patiëntenuitkomsten.  
In het eerste hoofdstuk beantwoorden we de vraag "Wat is de kwaliteit van 
de diabeteszorg in de België? In dit hoofdstuk worden de resultaten beschreven van 
een transversale studie waarin 2495 diabetespatiënten in de regio Groot-Leuven zijn 
opgenomen. Uit die studie bleek dat de metabole controle van deze patiënten 
vergelijkbaar was met de resultaten van studies in andere landen in vergelijkbare 
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settings. Er was echter ruimte voor verbetering want slechts 54% van de patiënten 
bereikte de doelstelling voor HbA1c terwijl respectievelijk slechts 50% en 42% van de 
patiënten de doelstellingen voor systolische bloeddruk en LDL-cholesterol bereikte. 
Patiënten die in gedeelde zorg (shared care) behandeld werden in een 
gespecialiseerd diabetescentrum (opgenomen in de zogenaamde conventie 786) 
behaalden betere resultaten voor HbA1 en LDL-C en namen meer noodzakelijk 
medicatie zoals plaatjesremmers en statines in. Tot slot hebben we aanwijzingen 
gevonden voor het bestaan van klinische traagheid – het té traag aanpassen van de 
medische behandeling als de doelstellingen niet bereikt worden – vooral wat betreft 
het opstarten van insuline. Daar we bovendien aanwijzingen hebben dat de 
resultaten in deze studie wellicht beter zijn dan de globale Belgische situatie, mogen 
we besluiten dat de kwaliteit van de diabeteszorg in België vatbaar is voor 
verbetering. 
Het tweede hoofdstuk beschrijft de resultaten van een gerandomiseerde 
studie waarin de doeltreffendheid van een kwaliteitsverbeteringsprogramma 
bestudeerd werd. Dit programma werd opgevat als een set van 
ondersteuningsmaatregelen voor huisartsen en hun patiënten. In feite was er niet 
één, maar waren er twee programma’s. De huisartsen en hun patiënten werden 
willekeurig onderverdeeld in twee groepen. De eerste groep kreeg een 
basisondersteuningsprogramma. De veranderingen in HbA1c, systolische bloeddruk 
en LDL-cholesterol in de groep van patiënten die dit programma aangeboden kregen, 
werden vergeleken met de resultaten van de groep van patiënten die een intensief 
ondersteuningsprogramma aangeboden kregen. Het basisprogramma dat 
aangeboden werd aan 53 huisartsen en 918 patiënten stelde een ‘evidence based’ 
behandelingsprotocol ter beschikking, leverde een jaarlijkse benchmarking feedback 
en voorzag bijscholingen voor de huisartsen. Huisartsen konden ook beroep doen op 
een diabetoloog voor individuele case-coaching. Bovendien konden patiënten die 
onvoldoende onder controle waren doorsverwezen worden naar een gespecialiseerd 
diabetes steunteam voor educatie en follow-up. Het intensieve 
ondersteuningsprogramma werd ter beschikking gesteld aan 67 huisartsen en 1577 
patiënten. Bovenop het pakket maatregelen van het basisondersteuningsprogramma 
voorzag het intensieve programma een driemaandelijkse follow-up van de huisartsen 
met bijkomende herinneringen, benchmarking feedback én feedback over elke 
individuele ingebrachte patiënt. De huisartsen werden ook actief aangespoord om 
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patiënten die onvoldoende onder controle waren door te verwijzen naar het 
steunteam. Tenslotte voorzag het programma ook in bijkomende lespakketten die de 
huisartsen moesten toelaten om patiënten aan te sporen hun levensgewoontes te 
veranderen. De bovenvermelde patiëntenuitkomsten verbeterden tijdens de 
interventie aanzienlijk zowel in de groep van het basisprogramma als in de groep van 
het intensieve programma. De resultaten verbeterden echter niet significant méér in 
de intensieve groep in vergelijking met de basisgroep. Globaal genomen steeg het 
percentage patiënten dat de doelstellingen bereikte voor HbA1C, Systolische 
Bloeddruk en LDL-C respectievelijk met 13%, 8 % en 18 %. Deze resultaten zijn 
vergelijkbaar met de resultaten van andere studies met vergelijkbare beginwaarden. 
De meeste studies tonen net zoals het Diabetes Project Leuven een bescheiden 
verbetering aan van de patiëntenuitkomsten.  
 
In afwezigheid van een gerandomiseerde controlegroep (dit is een groep van 
artsen en patiënten die geen enkele ondersteuning gekregen hebben) konden we 
echter geen sluitende evidentie vinden dat het basisondersteuningsprogramma de 
verbetering in patiëntenuitkomsten ook echt veroorzaakt heeft. Daarom hebben we 
bijkomende argumenten verzameld die de doeltreffendheid van het 
ondersteuningsprogramma aangetoond hebben.  
In hoofdstuk drie wordt de evolutie van de diabeteszorg gedurende een 
periode van vijf jaar (2002-2007) beschreven. De evolutie wordt beschreven aan de 
hand van verschillende patiëntenuitkomsten (onder andere HbA1c en LDL-C) en 
procesparameters die essentiële indicatoren zijn voor de kwaliteit van de 
diabeteszorg. De onderzochte cohorte betreft Type 2 Diabetespatiënten die 
suikerverlagende medicatie (orale antidiabetica en/of insuline) innamen en die 
woonachtig waren in de regio Groot-Leuven. De gegevens werden verzameld in een 
nieuw ontwikkelde databank waarin consumptiegegevens gecombineerd  werden 
met laboratoriumgegevens. De consumptiegegevens zijn gegevens die routinematig 
verzameld worden door de verzekeringsinstellingen (mutualiteiten). De 
laboratoriumgegevens (HbA1c, glycemie, bloedvetten…) werden rechtstreeks 
opgevraagd aan de klinische laboratoria in de regio. Om te voldoen aan de 
privacyregels hebben we een complexe methode van gegevensverzameling, 
cleaning, extractie en codering moeten uitvoeren. De belangrijkste doelstelling van 
deze studie was het beschrijven van de evolutie van de zorg in de jaren tussen 
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1/1/002 en 1/1/2007 in een regio (Groot-Leuven) waarin tijdens de laatste twee jaar 
van die periode een kwaliteitsverbeteringsprogramma liep, het Diabetes Project 
Leuven. Vervolgens gingen we na of de evolutie in patiëntenuitkomsten en 
procesparameters van patiënten die verbonden waren aan huisartsen die 
deelgenomen hebben aan het diabetesproject significant anders was dan de evolutie 
van de patiëntenuitkomsten en procesparameters van patiënten die verbonden 
waren aan huisartsen die niet hadden deelgenomen aan dit project. Dit onderzoek 
was niet enkel belangrijk met betrekking tot de resultaten. De hele opzet van dit 
onderzoek was belangrijk omdat het de eerste keer in België was dat 
consumptiegegevens en laboratoriumgegevens samengebracht werden met de 
bedoeling de kwaliteit van zorg te evalueren. Het was met andere woorden een 
pilootproject dat ook als doel had de haalbaarheid van dergelijke studies na te gaan. 
Deze studie laat toe om te stellen dat consumptiegegevens afkomstig van de 
verzekeringsinstellingen effectief gekoppeld kunnen worden aan laboratoriagegevens 
en als dusdanig een belangrijke bron van informatie kunnen zijn, zeer nuttig in de 
evaluatie van de kwaliteit van zorg. Het is in het bijzonder mogelijk om lange 
termijnevoluties te bestuderen, iets wat met experimenteel opgezette designs veel 
moeilijker en veel duurder uitvalt. De resultaten van dergelijke studies moeten echter 
met de nodige voorzichtigheid geïnterpreteerd worden vanwege de verschillende 
bronnen van potentiële bias. Rekening houdend met de beperkingen van deze studie 
is het toch mogelijk te stellen dat er zich tijdens de periode dat het Diabetes Project 
Leuven opgestart werd (2005) een positieve kentering voorgedaan heeft in de 
evolutie van de HbA1c-waarden bij diabetespatiënten in de regio Groot-Leuven. De 
cholesterolwaarden daarentegen daalden reeds jaren voor het opstarten van het 
project, maar het project heeft deze evolutie waarschijnlijk gestimuleerd, met name 
bij de patiënten van huisartsen die aan het project deelgenomen hebben. Bovendien 
zijn na de start van het project bij de patiënten van deelnemende huisartsen een 
aantal essentiële procesparameters zoals het screenen op oog- en 
nierverwikkelingen significant verbeterd, terwijl dit niet het geval was bij patiënten van 
niet-deelnemende huisartsen.  
In hoofdstuk vier worden de knelpunten en faciliterende factoren van kwalitatief 
hoogstaande diabeteszorg zoals deze ervaren werden door huisartsen die aan een 
kwaliteitsverbeteringsprogramma deelgenomen hebben, geëvalueerd. In een 
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kwalitatieve studie werden twintig van de 120 deelnemende huisartsen geïnterviewd. 
De eerste vaststelling is dat het Diabetes Project Leuven méér lijkt te hebben 
bewerkstelligd dan alleen maar de verbetering van de kwaliteit van zorg. Het heeft 
ook een beter begrip en betere relaties tussen de diverse disciplines bewerkstelligd 
en het verhoogde het gevoel van eigenwaarde en de arbeidsvreugde bij de 
huisartsen. De geïnterviewde artsen vermeldden inderdaad een veranderde houding 
van de diabetologen ten opzichte van hen, gebaseerd op vertrouwen en respect. 
Deze verandering verhoogde aanzienlijk de motivatie en het 
verantwoordelijkheidsgevoel van de huisartsen. Dit is een zeer belangrijke bevinding 
omdat patiënten met chronische ziektes meestal méér dan één arts consulteren. 
Behandeling van complexe ziektes vereist vaak het advies en de opvolging van 
meerdere specialisten. Logischerwijze vereist een optimale chronische zorgverlening 
samenwerking tussen de artsen in een gezamenlijke, gecoördineerde aanpak. Het 
Diabetes Project Leuven heeft aangetoond dat huisartsen en specialisten inderdaad 
vlot kunnen samenwerken in een partnerschap en teamspirit in plaats van met elkaar 
in concurrentie te treden. De voorwaarde voor het succes van dit verbeterprogramma 
was dat het gepercipieerd werd als een ondersteuniningsinitiatief in de dagelijkse 
zorg voor patiënten.  
Dit kwalitatieve onderzoek bracht ook de complexiteit van kwaliteitsverbetering 
aan het licht. Het programma beïnvloedde immers ook de inter-persoonlijk relaties en 
veroorzaakte complexe sociale veranderingen die de individuele artsen en patiënten 
te boven gaan. De huisartsen werden ook geconfronteerd met hun beperkingen, 
zoals de moeizaamheid om duurzame veranderingen te bewerkstelligen in de 
levensgewoontes van hun patiënten en hun eigen aarzelingen tegenover het 
doorvoeren van de gevraagde veranderingen in de zorg voor hun diabetespatiënten. 
Vooral samenwerken met diabetes-educatoren, als nieuw ingevoerde zorgverleners 
in de eerste lijn, en het doorvoeren van veranderingen in de praktijkorganisatie 
bleken soms problemen te geven.  
Tot slot toonde de studie ook het belang aan om in 
kwaliteitsverbeteringsprojecten speciale aandacht te hebben voor relationele 
patronen en communicatiekanalen tussen de hulpverleners. Daarbij is het belangrijk 
om expliciet de rechten, de verantwoordelijkheden en de taken van de patiënten, de 
huisartsen, de educatoren en de specialisten te definiëren.  
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Hoofdstuk vijf gaat dieper in op een indicator om de diabeteszorg in 
huisartsenpraktijken te monitoren. Er bestaat immers een grote variabiliteit tussen de 
praktijken onderling wat betreft de gemiddelde patiëntenuitkomsten. Het instrument is 
ontworpen als een samengestelde z-score dat op praktijkniveau nagaat of de 
waarden van HbA1c, systolische bloeddruk en LDL-C van de patiëntenpopulatie 
significant hoger zijn dan de gangbare doelstellingen. We hebben de validiteit, de 
betrouwbaarheid en de gevoeligheid voor verandering van dit instrument getest op 
de praktijken die deelgenomen hebben aan het Diabetes Project Leuven. We stelden 
vast dat er een goede relatie bestond tussen de z-score van een praktijk en het 
gemiddeld berekende cardiovasculaire risico van die praktijkpopulatie. Bovendien 
toonden de resultaten aan dat z-score het vermogen heeft om patiënten met een 
hoger cardiovasculair risico te onderscheiden van patiëntenpopulaties met een lager 
cardiovasculair risico. De z-score verbeterde aanzienlijk gedurende het project bij de 
grote meerderheid van de praktijken. Dit scoresysteem kan op landelijk niveau 
gebruikt worden als om huisartsenpraktijken te monitoren. Praktijken met een lage z-
score bevatten patiëntenpopulaties met een verhoogd cardiovasculair risico te wijten 
aan behandelbare risicofactoren. Deze praktijkpopulaties hebben wellicht baat aan 
extra onderststeuning om als dusdanig het risico op hart- en vaatziektes bij hun 
diabetespatiënten te verminderen. De gevoeligheid aan verandering van de z-score 
zorgt er bovendien voor dat het een goed instrument is om de impact van een 
kwaliteitsverbeteringsprogramma te evalueren. 
 
Algemene conclusie: het Diabetes Project Leuven diende als proefproject 
voor het breed invoeren van een Chronisch Zorgmodel in de Belgische 
gezondheidszorg. Het project heeft de nood en het nut aangetoond van een globaal 
programma voor de verbetering van de kwaliteit van de diabeteszorg in België. In het 
Diabetes Project Leuven bestond dit programma uit een structurele versterking van 
de eerste lijn door het invoeren van een zorgmanager (‘promotor’) gecombineerd met 
een verbeterde samenwerking en coördinatie van zorg tussen huisartsen en 
specialisten, het stimuleren van een protocollaire aanpak van diabeteszorg door 
huisartsen en het faciliteren van patiënteneducatie door een eerste-lijns-
diabeteseducator. In het pilootproject ging de implementatie van dit programma 
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gepaard met een substantiële verbetering van de kwaliteit van zorg, zowel wat betreft 
de belangrijkste patiëntenuitkomsten als wat betreft essentiële procesparameters 
Het verhogen van de frequentie of intensiteit van onderdelen van de 
interventie evenals het toevoegen van interventies aan een basisprogramma leidt 
echter niet noodzakelijk tot een sterkere verbetering van de patiëntenuitkomsten. 
Naast de verbetering van de patiëntenuitkomsten heeft het programma geleid 
tot een beter begrip en betere relaties tussen de verschillende professionals in de 
gezondheidszorg en meer tevredenheid en meer arbeidsvreugde bij de huisartsen. 
De positieve perceptie van het programma door de huisartsen en patiënten als een 
initiatief ter ondersteuning van de zorg is een noodzakelijke voorwaarde voor succes. 
  
196 
 
  
Professional career of Geert Goderis 
 
 
Certificates 
Medical Doctor (General Practitioner, KUL)
Masters in Medical Sciences (UCL, Department of Public 
Health) 
 
List of publications in peer reviewed and indexed 
• Goderis G, Boland B. Cardiovascular prevention in 
treatments. Acta Clin Belg. 2004;59:329
• Goderis,G, Borgermans,L, Heyrman,J, 
Diabetes in primary care in belgium: need for structured shared care. 
Exp.Clin.Endocrinol.Diabetes 117:367
• Goderis G, Borgermans L, Mathieu C, Van Den B
and facilitators to evidence based care of 
practitioners participating to a Quality
• Goderis G, Borgermans L, Grol R, Van Den B
the quality of care for people with 
cluster randomized trial. Diabetes Res Clin Pract 2010; 88(1):56
• Goderis G, Borgermans L, Heyrman
Grol R. Monitoring Modifiable Cardiov
the Use of an Aggregated z-score
• Boland B, De Muylder R, Goderis G, Degryse J, Gueuning Y, Paulus D et al. Cardiovascular 
prevention in general practice: dev
2004;59:598-605. 
• Boland B, Goderis G. Statins in patients at high risk of cardiovascular disease presenting with 
peripheral artery disease. Eur Heart J 2004;25:712
• Borgermans L, Goderis G, Van Den B
randomized trial to improve adherence to evidence
clinical inertia in primary care physicians in Belgium: study protocol (NTR 1369). Implement.Sci. 
2008;3:42. 
• Borgermans L, Goderis G, Ouwens M, Wens J, Heyrman J, Grol R. 
programmes and views on high quality diabetes care: are we in need of a standardized 
framework? Int.J.Integr.Care 2008;8:e07.
• Borgermans L, Goderis G, Van Den B
Aertgeerts B, Heyrman J, Grol R: Interdisciplinary diabetes care teams operating on the interface 
between primary and specialty care are associated with improved outcomes of care: findings from the 
Leuven Diabetes Project. BMC.Health Serv.Res. 9:179, 2009
 
Clinical work as GP
‘La Chenevière’ (Marcinelle)
197 
- °12/9/1968 - married, father of two sons.
 
 
 29/6/1993
1/9/2005
journals 
Type 2 diabetic patients: review of efficacious 
-39. 
Van Den Broeke C, Grol,R, Boland,B, Mathieu,C: 
-372, 2009 
roeke C, Hannes K, Heyrman J et al. 
Type 2 Diabetes patients: experiences of general 
 Improvement Program. Implement.Sci. 2009;4:41.
roeke C, Boland B, Verbeke G et al. Start improving 
Type 2 Diabetes through a general practice support program: a 
-64. 
 J, Van Den Broeke C, Carbonez A, Mathieu C, Verbeke
ascular Risk in Type 2 Diabetes Care in General Practice: 
. Medical Care (accepted for publication) 
elopment and validation of an algorithm. Acta Cardiol. 
-3. 
roeke C, Mathieu C, Aertgeerts B, Verbeke G et al. 
-based guidelines on diabetes and reduce 
Diversity in diabetes care 
 
roeke C, Verbeke G, Carbonez A, Ivanova A, Mathieu C, 
 
 in the healthcare centre 
 
 
 
 
Type 2 
Barriers 
 
 G, 
A cluster 
